[{"Element":"<div class=\"WordSection1\"> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\r I<\/span><\/b><\/p> <p class=\"TitleA\"><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">1.       NAME OF <\/span><\/b><b><span lang=\"EN-GB\">THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR<\/span><span lang=\"EN-GB\"> 100 units\/mL solution for\r injection in a cartridge<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each mL\r contains 100 units insulin glargine* (equivalent to 3.64 mg). <\/span><\/p> <p style=\"margin:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Each cartridge contains 3 mL of solution for injection,\r equivalent to 300 units. <\/span><\/p> <p style=\"margin:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">*produced by recombinant DNA technology in <i>Escherichia coli<\/i>. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For the full list of excipients, see section 6.1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Solution for\r injection (injection).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Clear,\r colourless solution.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><\/b><b><span lang=\"EN-GB\">CLINICAL PARTICULARS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Treatment of diabetes mellitus in adults, adolescents and children\r aged 2 years and above.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">4.2     Posology\r and method of administration<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR contains insulin glargine, an insulin analogue and has a\r prolonged duration of action. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR should be administered once daily at any time but at the\r same time each day. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The dose regimen (dose and timing) should be individually adjusted.\r In patients with type 2 diabetes mellitus, ABASAGLAR can also be given\r together with orally active antidiabetic medicinal products. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The potency of this medicinal product is stated in units. These\r units are exclusive to insulin glargine and are not the same as IU or the units\r used to express the potency of other insulin analogues (see section 5.1). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Elderly population (\u226565 years old)<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In the elderly, progressive deterioration of renal function may lead\r to a steady decrease in insulin requirements.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">In patients with renal impairment, insulin requirements\r may be diminished due to reduced insulin metabolism.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In patients with hepatic impairment, insulin requirements may be\r diminished due to reduced capacity for gluconeogenesis and reduced insulin\r metabolism.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Adolescents and children aged 2 years and older<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The safety and efficacy of insulin glargine have been established in\r adolescents and children aged 2 years and older (see section 5.1). The\r dose regimen (dose and timing) should be individually adjusted. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Children below 2 years of age<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The safety and efficacy of insulin glargine have not been\r established No data are available. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Switch from other insulins to ABASAGLAR<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">When switching from\r a treatment regimen with an intermediate or long-acting insulin to a regimen\r with ABASAGLAR, a change of the dose of the basal insulin may be required and\r the concomitant antidiabetic treatment may need to be adjusted (dose and timing\r of additional regular insulins or fast-acting insulin analogues or the dose of\r oral antidiabetic medicinal products). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Switch from twice daily NPH insulin to ABASAGLAR<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">To reduce the risk of nocturnal and early morning hypoglycaemia,\r patients who are changing their basal insulin regimen from a twice daily NPH\r insulin to a once daily regimen with ABASAGLAR should reduce their daily dose\r of basal insulin by 20-30 % during the first weeks of treatment. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Switch\r from insulin glargine 300 units\/ml to ABASAGLAR<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR and\r Toujeo (insulin glargine 300 units\/ml) are not bioequivalent and are not directly\r interchangeable. To reduce the risk of hypoglycemia, patients who are changing\r their basal insulin regimen from an insulin regimen with once daily insulin\r glargine 300 units\/ml to a once daily regimen with ABASAGLAR should reduce\r their dose by approximately 20%.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">During the first weeks the reduction should, at least partially, be\r compensated by an increase in mealtime insulin, after this period the regimen\r should be adjusted individually. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Close metabolic monitoring is recommended during the switch and in\r the initial weeks thereafter. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">With improved metabolic control and resulting increase in insulin\r sensitivity a further adjustment in dose regimen may become necessary. Dose\r adjustment may also be required, for example, if the patient's weight or\r life-style changes, change of timing of insulin dose or other circumstances\r arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see\r section 4.4). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients with high insulin doses because of antibodies to human\r insulin may experience an improved insulin response with ABASAGLAR.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Method of administration<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is administered subcutaneously.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR should not be administered intravenously. The prolonged\r duration of action of insulin glargine is dependent on its injection into\r subcutaneous tissue. Intravenous administration of the usual subcutaneous dose\r could result in severe hypoglycaemia.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">There are no clinically relevant differences in serum insulin or\r glucose levels after abdominal, deltoid or thigh administration of insulin\r glargine. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Injection sites should always be rotated within the same region in\r order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see\r section 4.4 and 4.8).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR must not be mixed with any other insulin or diluted.\r Mixing or diluting can change its time\/action profile and mixing can cause\r precipitation. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For further details on handling, see section 6.6.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Hypersensitivity to the active substance or to any of the excipients\r listed in section 6.1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.4     Special warnings and precautions for use<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Traceability<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered product should be clearly recorded.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Diabetic ketoacidosis<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is not the insulin of choice for the treatment of diabetic\r ketoacidosis. Instead, regular insulin administered intravenously is\r recommended in such cases. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><a name=\"_Hlk38983853\"><u><span lang=\"EN-GB\">Insulin requirements and dose\r adjustments<\/span><\/u><\/a><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In case of insufficient glucose control or a tendency to hyperglycaemic\r or hypoglycaemic episodes, the patient's adherence to the prescribed treatment\r regimen, injection sites and proper injection technique and all other relevant\r factors must be reviewed before dose adjustment is considered.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Transferring a patient to another type or brand of insulin should be\r done under strict medical supervision. Changes in strength, brand\r (manufacturer), type (regular, NPH, lente, long\u2011acting, etc.), origin\r (animal, human, human insulin analogue) and\/or method of manufacture may result\r in the need for a change in dose.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The time of occurrence of hypoglycaemia depends on the action\r profile of the insulins used and may, therefore, change when the treatment\r regimen is changed. Due to more sustained basal insulin supply with insulin\r glargine, less nocturnal but more early morning hypoglycaemia can be expected.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Particular caution should be exercised, and intensified blood\r glucose monitoring is advisable in patients in whom hypoglycaemic episodes\r might be of particular clinical relevance, such as in patients with significant\r stenoses of the coronary arteries or of the blood vessels supplying the brain\r (risk of cardiac or cerebral complications of hypoglycaemia) as well as in\r patients with proliferative retinopathy, particularly if not treated with\r photocoagulation (risk of transient amaurosis following hypoglycaemia). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients should be aware of circumstances where warning symptoms of\r hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be\r changed, be less pronounced or be absent in certain risk groups. These include\r patients:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom glycaemic control\r is markedly improved,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom hypoglycaemia\r develops gradually,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        who are elderly,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        after transfer from\r animal insulin to human insulin,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom an autonomic\r neuropathy is present,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        with a long history of\r diabetes,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        suffering from a\r psychiatric illness,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        receiving concurrent\r treatment with certain other medicinal products (see section 4.5).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Such situations may result in severe hypoglycaemia (and possibly\r loss of consciousness) prior to the patient's awareness of hypoglycaemia.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The prolonged effect of subcutaneous insulin glargine may delay\r recovery from hypoglycaemia.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If normal or decreased values for glycated haemoglobin are noted,\r the possibility of recurrent, unrecognised (especially nocturnal) episodes of\r hypoglycaemia must be considered. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Adherence of the patient to the dose and dietary regimen, correct\r insulin administration and awareness of hypoglycaemia symptoms are essential to\r reduce the risk of hypoglycaemia. Factors increasing the susceptibility to\r hypoglycaemia require particularly close monitoring and may necessitate dose\r adjustment. These include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        change in the injection\r area,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        improved insulin\r sensitivity (e.g., by removal of stress factors),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        unaccustomed, increased\r or prolonged physical activity,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        intercurrent illness\r (e.g. vomiting, diarrhoea),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        inadequate food intake,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        missed meals,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        alcohol consumption,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        certain uncompensated\r endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or\r adrenocortical insufficiency),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        concomitant treatment\r with certain other medicinal products.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Injection\r technique<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients must be instructed to perform\r continuous rotation of the injection site to reduce the risk of developing\r lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed\r insulin absorption and worsened glycaemic control following insulin injections\r at sites with these reactions. A sudden change in the injection site to an\r unaffected area has been reported to result in hypoglycaemia. Blood glucose\r monitoring is recommended after the change in the injection site, and dose\r adjustment of antidiabetic medications may be considered.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Intercurrent illness<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Intercurrent illness requires intensified metabolic monitoring. In\r many cases urine tests for ketones are indicated, and often it is necessary to\r adjust the insulin dose. The insulin requirement is often increased. Patients\r with type 1 diabetes must continue to consume at least a small amount of\r carbohydrates on a regular basis, even if they are able to eat only little or\r no food, or are vomiting etc. and they must never omit insulin entirely. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Insulin antibodies<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin administration may cause insulin antibodies to form. In rare\r cases, the presence of such insulin antibodies may necessitate adjustment of\r the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see\r section 5.1).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Pens to be used with ABASAGLAR cartridges <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The cartridges should only be used in conjunction with a Lilly reusable\r insulin pen and should not be used with any other reusable pen as the dosing\r accuracy has not been established with other pens. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Medication errors<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Medication\r errors have been reported in which other insulins, particularly short\u2011acting\r insulins, have been accidentally administered instead of insulin glargine.\r Insulin label must always be checked before each injection to avoid medication\r errors between ABASAGLAR and other insulins.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Combination of ABASAGLAR with pioglitazone<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Cases of cardiac\r failure have been reported when pioglitazone was used in combination with\r insulin, especially in patients with risk factors for development of cardiac\r heart failure. This should be kept in mind if treatment with the combination of\r pioglitazone and ABASAGLAR is considered. If the combination is used, patients\r should be observed for signs and symptoms of heart failure, weight gain and\r oedema. Pioglitazone should be discontinued if any deterioration in cardiac\r symptoms occurs.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Sodium\r content<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">This medicinal product contains less than 1 mmol sodium\r (23 mg) per dose, i.e., essentially \u201csodium\u2011free\u201d.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.5     Interaction with other medicinal products\r and other forms of interaction<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A number of substances affect glucose metabolism and may require\r dose adjustment of insulin glargine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Substances that may enhance the blood-glucose\u2011lowering effect\r and increase susceptibility to hypoglycaemia include oral antidiabetic\r medicinal products, angiotensin converting enzyme (ACE) inhibitors,\r disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,\r pentoxifylline, propoxyphene, salicylates, somatostatin anologues and sulphonamide\r antibiotics. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Substances that may reduce the blood-glucose-lowering effect include\r corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid,\r oestrogens, progestogens, phenothiazine derivatives, somatropin,\r sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,\r terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g.\r clozapine and olanzapine) and protease inhibitors. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Beta-blockers, clonidine, lithium salts or alcohol may either\r potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine\r may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In addition, under the influence of sympatholytic medicinal products\r such as beta-blockers, clonidine, guanethidine and reserpine, the signs of\r adrenergic counter-regulation may be reduced or absent.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.6     <\/span><\/b><b><span lang=\"EN-GB\">Fertility, p<\/span><\/b><b><span lang=\"EN-GB\">regnancy and lactation<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For insulin glargine no clinical data on exposed pregnancies from\r controlled clinical studies are available. A large amount of data on pregnant\r women (more than 1,000 pregnancy outcomes) indicate no specific adverse\r effects of insulin glargine on pregnancy and no specific malformative nor\r feto\/neonatal toxicity of insulin glargine. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Animal data do not indicate reproductive toxicity. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The use of ABASAGLAR may be considered during pregnancy, if clinically\r needed. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">It is essential for patients with pre-existing or gestational\r diabetes to maintain good metabolic control throughout pregnancy to prevent\r adverse outcomes associated with hyperglycaemia. Insulin requirements may\r decrease during the first trimester and generally increase during the second\r and third trimesters. Immediately after delivery, insulin requirements decline\r rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose\r control is essential. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">It is unknown whether insulin glargine is excreted in human milk. No\r metabolic effects of ingested insulin glargine on the breast\u2011fed\r newborn\/infant are anticipated since insulin glargine as a peptide is digested\r into amino acids in the human gastrointestinal tract. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Breast-feeding women may require adjustments in insulin dose and\r diet. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Animal studies do not indicate direct harmful effects with respect\r to fertility.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7     Effects on ability\r to drive and use machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">The patient's ability to concentrate and react may be\r impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a\r result of visual impairment. This may constitute a risk in situations where\r these abilities are of special importance (e.g. driving a car or using machines).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients should be advised to take precautions to avoid\r hypoglycaemia whilst driving. This is particularly important in those who have\r reduced or absent awareness of the warning symptoms of hypoglycaemia or have\r frequent episodes of hypoglycaemia. It should be considered whether it is\r advisable to drive or operate machines in these circumstances.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">4.8     Undesirable\r effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Summary of safety profile<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Hypoglycaemia (very common), in general the most frequent adverse\r reaction of insulin therapy, may occur if the insulin dose is too high in\r relation to the insulin requirement (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Tabulated list of adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">The following related adverse reactions from clinical trials\r are listed below as MedDRA preferred term by system organ class and in order of\r decreasing incidence (very common: \u22651\/10; common: \u22651\/100 to\r &lt;1\/10; uncommon: \u22651\/1,000 to &lt;1\/100; rare: \u22651\/10,000 to\r &lt;1\/1,000; very rare: &lt;1\/10,000<span style=\"color:black\"> and not known\r (cannot be estimated from the available data<\/span>).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Within each frequency grouping, adverse reactions are presented in\r order of decreasing seriousness.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:12.5pt;border-collapse:collapse;border:none\" width=\"99%\"> <tr style=\"height:16.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">MedDRA system organ classes<\/span><\/b><\/p> <\/td> <td style=\"width:15.4%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Very common<\/span><\/b><\/p> <\/td> <td style=\"width:12.32%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Common<\/span><\/b><\/p> <\/td> <td style=\"width:13.84%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Uncommon<\/span><\/b><\/p> <\/td> <td style=\"width:10.76%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Rare<\/span><\/b><\/p> <\/td> <td style=\"width:11.66%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Very rare<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Not known<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Immune system disorders <\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Allergic reactions<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:16.75pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Nervous system disorders<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:11.0pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Dysgeusia<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:11.0pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Eyes disorders<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Visual impairment <\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Retinopathy<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Lipohypertrophy<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Lipoatrophy<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Cutaneous amyloidosis<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"6\" style=\"width:87.04%;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Myalgia<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">General disorders and administration site conditions<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Injection site reactions<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Oedema<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><u><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">Severe hypoglycaemic attacks, especially if recurrent,\r may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may\r be life-threatening. In many patients, the signs and symptoms of\r neuroglycopenia are preceded by signs of adrenergic counter-regulation.\r Generally, the greater and more rapid the decline in blood glucose, the more\r marked is the phenomenon of counter-regulation and its symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Immune system disorders<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Immediate-type allergic reactions to insulin are rare. Such\r reactions to insulin (including insulin glargine) or the excipients may, for\r example, be associated with generalised skin reactions, angio-oedema,\r bronchospasm, hypotension and shock, and may be life-threatening.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Eyes disorders<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A marked change in glycaemic control may cause temporary visual\r impairment, due to temporary alteration in the turgidity and refractive index\r of the lens.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Long-term improved glycaemic control decreases the risk of\r progression of diabetic retinopathy. However, intensification of insulin\r therapy with abrupt improvement in glycaemic control may be associated with\r temporary worsening of diabetic retinopathy. In patients with proliferative\r retinopathy, particularly if not treated with photocoagulation, severe\r hypoglycaemic episodes may result in transient amaurosis.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Lipodystrophy and cutaneous amyloidosis may occur at the injection\r site and delay local insulin absorption. Continuous rotation of the injection\r site within the given injection area may help to reduce or prevent these reactions\r (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">General disorders and administration site conditions<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Injection site reactions include redness, pain, itching, hives,\r swelling, or inflammation. Most minor reactions to insulins at the injection\r site usually resolve in a few days to a few weeks. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Rarely, insulin may cause sodium retention and oedema particularly\r if previously poor metabolic control is improved by intensified insulin\r therapy.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In general, the safety profile for children and adolescents (\u2264 18 years\r of age) is similar to the safety profile for adults. The adverse reaction\r reports received from post marketing surveillance included relatively more\r frequent injection site reactions (injection site pain, injection site\r reaction) and skin reactions (rash, urticaria) in children and adolescents\r (\u2264 18 years of age) than in adults. Clinical study safety data\r are not available for children under 2 years.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\r medicinal product is important. It allows continued monitoring of the\r benefit\/risk balance of the medicinal product. Healthcare professionals are\r asked to report any suspected adverse reactions via <span style=\"background:\r lightgrey\">the national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.9     Overdose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Symptoms<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin overdose may lead to severe and sometimes long-term and\r life-threatening hypoglycaemia. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Management<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">Mild episodes of hypoglycaemia can usually be treated\r with oral carbohydrates. Adjustments in dose of the medicinal product, meal\r patterns, or physical activity may be needed. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">More severe episodes with coma, seizure, or neurologic impairment\r may be treated with intramuscular\/subcutaneous glucagon or concentrated\r intravenous glucose. Sustained carbohydrate intake and observation may be\r necessary because hypoglycaemia may recur after apparent clinical recovery.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">5.1     Pharmacodynamic\r properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pharmacotherapeutic\r group: Drugs used in diabetes, insulins and analogues for injection,\r long-acting. ATC Code: A10AE04.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR is a\r biosimilar medicinal product. Detailed information is available on the website\r of the European Medicines Agency <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext\">http:\/\/www.ema.europa.eu<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Mechanism of\r action<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r is a human insulin analogue designed to have a low solubility at neutral pH. It\r is completely soluble at the acidic pH of the ABASAGLAR injection solution (pH 4).\r After injection into the subcutaneous tissue, the acidic solution is\r neutralised leading to formation of micro-precipitates from which small amounts\r of insulin glargine are continuously released, providing a smooth, peakless,\r predictable concentration\/time profile with a prolonged duration of action.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r is metabolised into 2 active metabolites M1 and M2 (see section 5.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Insulin\r receptor binding<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">In vitro<\/span><\/i><span lang=\"EN-GB\"> studies indicate that the affinity of insulin glargine and its\r metabolites M1 and M2 for the human insulin receptor is similar to the one of\r human insulin.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">IGF-1 receptor\r binding: The affinity of insulin glargine for the human IGF-1 receptor is\r approximately 5 to 8-fold greater than that of human insulin (but approximately\r 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1\r receptor with slightly lower affinity compared to human insulin.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The total therapeutic insulin concentration (insulin glargine and\r its metabolites) found in type 1 diabetic patients was markedly lower than\r what would be required for a half maximal occupation of the IGF-1 receptor and\r the subsequent activation of the mitogenic-proliferative pathway initiated by the\r IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may activate\r the mitogenic-proliferative pathway; however, the therapeutic concentrations\r found in insulin therapy, including in ABASAGLAR therapy, are considerably\r lower than the pharmacological concentrations required to activate the IGF-1\r pathway. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Pharmacodynamic\r effects<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The primary\r activity of insulin, including insulin glargine, is regulation of glucose\r metabolism. Insulin and its analogues lower blood glucose levels by stimulating\r peripheral glucose uptake, especially by skeletal muscle and fat, and by\r inhibiting hepatic glucose production. Insulin inhibits lipolysis in the\r adipocyte, inhibits proteolysis and enhances protein synthesis.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In clinical\r pharmacology studies, intravenous insulin glargine and human insulin have been\r shown to be equipotent when given at the same doses. As with all insulins, the\r time course of action of insulin glargine may be affected by physical activity\r and other variables.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In euglycaemic\r clamp studies in healthy subjects or in patients with type 1 diabetes, the\r onset of action of subcutaneous insulin glargine was slower than with human NPH\r insulin, its effect profile was smooth and peakless, and the duration of its\r effect was prolonged.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The following\r graph shows the results from a study in patients:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Figure 1: <\/span><\/b><b>Activity profile in patients with type<\/b><b>1 diabetes<\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;line-height:normal;\r page-break-after:avoid\"><span style=\"position:absolute;z-index:251682816;\r left:0px;margin-left:-6px;margin-top:15px;width:652px;height:274px\"><img height=\"274\" src=\"data:image\/png;base64,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\" width=\"652\"\/><\/span><span style=\"position:absolute;z-index:251680768;left:0px;margin-left:161px;\r margin-top:233px;width:159px;height:39px\"><img alt=\"Time (h) after s.c injection\" height=\"39\" src=\"data:image\/png;base64,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\" width=\"159\"\/><\/span><span lang=\"EN-GB\"><img border=\"0\" height=\"286\" src=\"data:image\/jpg;base64,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\" width=\"590\"\/><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">* Determined as\r amount of glucose infused to maintain constant plasma glucose levels (hourly\r mean values)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The longer\r duration of action of subcutaneous insulin glargine is directly related to its\r slower rate of absorption and supports once daily administration. The time\r course of action of insulin and insulin analogues such as insulin glargine may\r vary considerably in different individuals or within the same individual<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a clinical\r study, symptoms of hypoglycaemia or counter-regulatory hormone responses were\r similar after intravenous insulin glargine and human insulin both in healthy\r volunteers and patients with type 1 diabetes.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Clinical safety and efficacy<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In clinical\r studies, antibodies that cross-react with human insulin and insulin glargine\r were observed with the same frequency in both NPH-insulin and insulin glargine\r treatment groups.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Effects of\r insulin glargine (once daily) on diabetic retinopathy were evaluated in an\r open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2\r diabetic patients in which progression of retinopathy by 3 or more steps on the\r Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by\r fundus photography. No significant difference was seen in the progression of\r diabetic retinopathy when insulin glargine was compared to NPH insulin.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The ORIGIN\r (Outcome Reduction with Initial Glargine INtervention) study was a multicenter,\r randomised, 2x2 factorial design study conducted in 12,537 participants at high\r cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired\r glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus\r treated with \u22641 antidiabetic oral agent (88% of participants).\r Participants were randomised (1:1) to receive insulin glargine (n=6,264),\r titrated to reach FPG \u226495 mg\/dL (5.3 mM), or standard care (n=6,273).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The first\r co-primary efficacy outcome was the time to the first occurrence of CV death,\r nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary\r efficacy outcome was the time to the first occurrence of any of the first\r co-primary events, or revascularisation procedure (coronary, carotid, or\r peripheral), or hospitalisation for heart failure.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Secondary\r endpoints included all-cause mortality and a composite microvascular outcome.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r did not alter the relative risk for CV disease and CV mortality when compared\r to standard of care. There were no differences between insulin glargine and\r standard care for the two co-primary outcomes; for any component endpoint\r comprising these outcomes; for all-cause mortality; or for the composite\r microvascular outcome.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Mean dose of\r insulin glargine by study end was 0.42 U\/kg. At baseline, participants had a\r median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9\r to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care\r group throughout the duration of follow-up. The rates of severe hypoglycaemia\r (affected participants per 100 participant years of exposure) were 1.05 for\r insulin glargine and 0.30 for standard care group and the rates of confirmed\r non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard\r care group. Over the course of this 6-year study, 42% of the insulin glargine\r group did not experience any hypoglycaemia. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At the last\r on-treatment visit, there was a mean increase in body weight from baseline of\r 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the\r standard care group.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a randomised,\r controlled clinical study, paediatric patients (age range 6 to 15 years)\r with type 1 diabetes (n=349) were treated for 28 weeks with a\r basal-bolus insulin regimen where regular human insulin was used before each\r meal. Insulin glargine was administered once daily at bedtime and NPH human\r insulin was administered once or twice daily. Similar effects on\r glycohaemoglobin and the incidence of symptomatic hypoglycaemia were observed\r in both treatment groups, however fasting plasma glucose decreased more from\r baseline in the insulin glargine group than in the NPH group. There was less\r severe hypoglycaemia in the insulin glargine group as well. One hundred forty\r three of the patients treated with insulin glargine in this study continued\r treatment with insulin glargine in an uncontrolled extension study with mean\r duration of follow-up of 2 years. No new safety signals were seen during\r this extended treatment with insulin glargine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A crossover\r study comparing insulin glargine plus lispro insulin to NPH plus regular human\r insulin (each treatment administered for 16 weeks in random order) in 26\r adolescent type 1 diabetic patients aged 12 to 18 years was also\r performed. As in the paediatric study described above, fasting plasma glucose\r reduction from baseline was greater in the insulin glargine group than in the\r NPH group. HbA<sub>1c<\/sub> changes from baseline were similar between treatment\r groups; however blood glucose values recorded overnight were significantly\r higher in the insulin glargine\/ lispro group than the NPH\/regular group, with a\r mean nadir of 5.4 mM vs. 4.1 mM. Correspondingly, the incidences of\r nocturnal hypoglycaemia were 32 % in the insulin glargine \/ lispro group\r vs. 52 % in the NPH \/ regular group.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A 24-week\r parallel group study was conducted in 125 children with type 1 diabetes\r mellitus aged 2 to 6 years, comparing insulin glargine given once daily in\r the morning to NPH insulin given once or twice daily as basal insulin. Both\r groups received bolus insulin before meals. The primary aim of demonstrating\r non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and\r there was a trend to an increase of hypoglycaemic events with insulin glargine\r [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. Glycohaemoglobin\r and glucose variabilities were comparable in both treatment groups. No new\r safety signals were observed in this trial.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.2     Pharmacokinetic\r properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In healthy subjects and diabetic patients, insulin serum\r concentrations indicated a slower and much more prolonged absorption and showed\r a lack of a peak after subcutaneous injection of insulin glargine in comparison\r to human NPH insulin. Concentrations were thus consistent with the time profile\r of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the\r activity profiles over time of insulin glargine and NPH insulin. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin glargine injected once daily will reach steady state levels\r in 2-4 days after the first dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">After subcutaneous injection in diabetic patients, insulin glargine\r is rapidly metabolised at the carboxyl terminus of the Beta chain with\r formation of two active metabolites M1 (21A-Gly-insulin) and M2\r (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is\r the metabolite M1. The exposure to M1 increases with the administered dose of insulin\r glargine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pharmacokinetic and pharmacodynamic findings indicate that the\r effect of the subcutaneous injection with insulin glargine is principally based\r on exposure to M1. Insulin glargine and the metabolite M2 were not detectable\r in the vast majority of subjects and, when they were detectable their\r concentration was independent of the administered dose of insulin glargine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">When given intravenously the elimination half-life of insulin\r glargine and human insulin were comparable. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"> <\/p> <p style=\"margin:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Special populations<\/span><\/u><\/p> <p style=\"margin:0in\"><\/p> <p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In clinical\r studies, subgroup analyses based on age and gender did not indicate any\r difference in safety and efficacy in insulin glargine-treated patients compared\r to the entire study population.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Pharmacokinetics in children aged 2 to less than 6 years with type 1\r diabetes mellitus was assessed in one clinical study (see section 5.1). Plasma\r trough levels of insulin glargine and its main M1 and M2 metabolites were\r measured in children treated with insulin glargine, revealing plasma\r concentration patterns similar to adults, and providing no evidence for\r accumulation of insulin glargine or its metabolites with chronic dosing.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.3     Preclinical safety data<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Non-clinical data reveal no special hazard for humans based on\r conventional studies of safety pharmacology, repeated dose toxicity,\r genotoxicity, carcinogenic potential, toxicity to reproduction.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Zinc oxide<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Metacresol<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Glycerol<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Hydrochloric acid (for pH adjustment)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Sodium hydroxide (for pH adjustment)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Water for injections<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">This medicinal product must not be mixed with other medicinal\r products. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">2 years.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Shelf life after first use <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The medicinal product may be stored for a maximum of 28 days up\r to 30\u00b0C and away from direct heat or direct light. Pens in use must not be\r stored in the refrigerator. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pen cap must be put back on the pen after each injection in\r order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Before use<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C - 8\u00b0C).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not store ABASAGLAR next to the freezer compartment or a freezer\r pack.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Keep the cartridge in the outer carton in order to protect from\r light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">In use <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For storage conditions after first opening of this medicinal\r product, see section 6.3.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.5     Nature and contents of container<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><s><span lang=\"EN-GB\"><\/span><\/s><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">3 mL solution in a cartridge (type 1 colourless glass) with a\r plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl\r rubber) with aluminium seal.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Packs of 5 and 10 cartridges. Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.6     Special precautions for disposal and other handling<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR must not be mixed with any other insulin or medicinal\r products or diluted. Mixing or diluting can change its time\/action profile and\r mixing can cause precipitation.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Insulin pen<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The ABASAGLAR cartridges are to be used only in conjunction with a\r Lilly reusable insulin pen (see section 4.4). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pen should be used as recommended in the information provided with\r the device. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The instructions for using the pen must be followed carefully for\r loading the cartridge, attaching the needle, and administering the insulin\r injection. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If the insulin pen is damaged or not working properly (due to\r mechanical defects) it has to be discarded, and a new insulin pen has to be\r used. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Cartridge<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Inspect the cartridge before use. It must only be used if the\r solution is clear, colourless, with no solid particles visible, and if it is of\r water-like consistency. Since ABASAGLAR is a solution, it does not require\r re-suspension before use. Air bubbles must be removed from the cartridge before\r injection (see instructions for using the pen).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">To prevent the possible transmission of disease, each pen must be\r used by one patient only. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Empty cartridges must not be refilled and must be properly\r discarded. Insulin label must always be checked before each injection to avoid\r medication errors between insulin glargine and other insulins (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><b><span lang=\"EN-GB\">7.       MARKETING\r AUTHORISATION HOLDER<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The\r Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">8.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/14\/944\/003<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/14\/944\/009<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Date of first authorisation: 9 September 2014<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Date of latest renewal: 25 July 2019<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Detailed\r information on this medicinal product is available on the website of the\r European Medicines Agency http:\/\/www.ema.europa.eu <br clear=\"all\" style=\"page-break-before:always\"\/> <b>1.       NAME OF <\/b><b>THE MEDICINAL PRODUCT<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR<\/span><span lang=\"EN-GB\"> 100 units\/mL KwikPen solution\r for injection in a pre-filled pen<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR<\/span><span lang=\"EN-GB\"> 100 units\/mL Tempo Pen solution\r for injection in a pre-filled pen<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each mL\r contains 100 units insulin glargine* (equivalent to 3.64 mg). <\/span><\/p> <p style=\"margin:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Each pen contains 3 mL of solution for injection, equivalent to\r 300 units. <\/span><\/p> <p style=\"margin:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">* produced by recombinant DNA technology in <i>Escherichia coli<\/i>.\r <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For the full list of excipients, see section 6.1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Solution for\r injection (injection) <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Clear,\r colourless solution.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><\/b><b><span lang=\"EN-GB\">CLINICAL PARTICULARS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Treatment of diabetes mellitus in adults, adolescents and children\r aged 2 years and above.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">4.2     Posology\r and method of administration<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR contains insulin glargine, an insulin analogue and has a\r prolonged duration of action. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR should be administered once daily at any time but at the\r same time each day. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The dose regimen (dose and timing) should be individually adjusted.\r In patients with type 2 diabetes mellitus, ABASAGLAR can also be given\r together with orally active antidiabetic medicinal products. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The potency of this medicinal product is stated in units. These\r units are exclusive to insulin glargine and are not the same as IU or the units\r used to express the potency of other insulin analogues (see section 5.1). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Elderly population (\u226565 years old)<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In the elderly, progressive deterioration of renal function may lead\r to a steady decrease in insulin requirements.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">In patients with renal impairment, insulin requirements\r may be diminished due to reduced insulin metabolism.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">In patients with hepatic impairment, insulin\r requirements may be diminished due to reduced capacity for gluconeogenesis and\r reduced insulin metabolism.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Adolescents and children aged 2 years and older<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The safety and efficacy of insulin glargine have been established in\r adolescents and children aged 2 years and older (see section 5.1). The\r dose regimen (dose and timing) should be individually adjusted.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Children below 2 years of age<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The safety and efficacy of insulin glargine have not been\r established. No data are available. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Switch from other insulins to ABASAGLAR<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">When switching from\r a treatment regimen with an intermediate or long-acting insulin to a regimen\r with ABASAGLAR, a change of the dose of the basal insulin may be required and\r the concomitant antidiabetic treatment may need to be adjusted (dose and timing\r of additional regular insulins or fast-acting insulin analogues or the dose of\r oral antidiabetic medicinal products). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Switch from twice daily NPH insulin to ABASAGLAR<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">To reduce the risk of nocturnal and early morning hypoglycaemia,\r patients who are changing their basal insulin regimen from a twice daily NPH\r insulin to a once daily regimen with ABASAGLAR should reduce their daily dose\r of basal insulin by 20-30 % during the first weeks of treatment.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Switch\r from insulin glargine 300 units\/ml to ABASAGLAR<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR and Toujeo\r (insulin glargine 300 units\/ml) are not bioequivalent and are not directly\r interchangeable. To reduce the risk of hypoglycemia, patients who are changing\r their basal insulin regimen from an insulin regimen with once daily insulin\r glargine 300 units\/ml to a once daily regimen with ABASAGLAR should reduce\r their dose by approximately 20%.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">During the first weeks the reduction should, at least partially, be\r compensated by an increase in mealtime insulin, after this period the regimen\r should be adjusted individually. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Close metabolic monitoring is recommended during the switch and in\r the initial weeks thereafter. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">With improved metabolic control and resulting increase in insulin\r sensitivity a further adjustment in dose regimen may become necessary. Dose\r adjustment may also be required, for example, if the patient's weight or\r life-style changes, change of timing of insulin dose or other circumstances\r arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see\r section 4.4). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients with high insulin doses because of antibodies to human\r insulin may experience an improved insulin response with ABASAGLAR.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Method of administration<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is administered subcutaneously.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR should not be administered intravenously. The prolonged\r duration of action of insulin glargine is dependent on its injection into\r subcutaneous tissue. Intravenous administration of the usual subcutaneous dose\r could result in severe hypoglycaemia.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">There are no clinically relevant differences in serum insulin or\r glucose levels after abdominal, deltoid or thigh administration of insulin\r glargine. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Injection sites should always be rotated within the same region in\r order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see\r section 4.4 and 4.8).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR must not be mixed with any other insulin or diluted.\r Mixing or diluting can change its time\/action profile and mixing can cause\r precipitation. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For further details on handling, see section 6.6.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Before using ABASAGLAR solution for injection in pre\u2011filled\r pen, the instructions for use included in the package leaflet must be read\r carefully (see section 6.6).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"Default\"><i><u><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>KwikPen<\/span><\/u><\/i><\/p> <p class=\"Default\"><i><u><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><\/span><\/u><\/i><\/p> <p class=\"Default\"><a name=\"_Hlk46321788\"><span style='font-size:11.0pt;\r font-family:\"Times New Roman\",serif'>The<\/span><\/a><span style='font-size:11.0pt;\r font-family:\"Times New Roman\",serif'>K<\/span><span lang=\"BG\" style='font-size:\r 11.0pt;font-family:\"Times New Roman\",serif'>wik<\/span><span style='font-size:\r 11.0pt;font-family:\"Times New Roman\",serif'>P<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>en is <\/span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>registered<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> in two\r presentations. One <a name=\"_Hlk46321308\">delivers 1 \u201360 units<\/a> in\r steps of<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1 unit\r in a single injection<\/span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\r and the other<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\r delivers 1 \u2013 <\/span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>8<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0 units\r in steps of 1 unit in a single injection. The needed dose is dialled in\r units. The number of units is shown in the dose window of the pen<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Tempo Pen<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"_Hlk38964026\"><span lang=\"EN-GB\">The Tempo Pen delivers 1 \u2013 80 units in steps of 1 unit\r in a single injection. The needed dose is dialled in units. The number of units\r is shown in the dose window of the pen.<\/span><\/a><\/p> <p class=\"mdTblEntry\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The Tempo Pen can be used with the optional transfer\r module Tempo Smart Button (see section 6.6).<\/span><\/p> <p class=\"mdTblEntry\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><a name=\"_Hlk32916492\"><span lang=\"EN-GB\">As with any insulin injection,\r when using the Tempo Pen, Smart Button and the mobile application,<\/span><\/a><span lang=\"EN-GB\">the\r patient should be instructed to check their blood sugar levels when considering\r or making decisions about another injection if they are unsure how much they\r have injected.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">Hypersensitivity to the active substance or to any of\r the excipients listed in section 6.1.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.4     Special warnings and precautions for use<\/span><\/b><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Traceability<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered medicinal product should be clearly recorded.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Diabetic ketoacidosis<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is not the insulin of choice for the treatment of diabetic\r ketoacidosis. Instead, regular insulin administered intravenously is\r recommended in such cases. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Insulin requirements and dose adjustments<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In case of insufficient glucose control or a tendency to\r hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the\r prescribed treatment regimen, injection sites and proper injection technique\r and all other relevant factors must be reviewed before dose adjustment is\r considered.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Transferring a patient to another type or brand of insulin should be\r done under strict medical supervision. Changes in strength, brand\r (manufacturer), type (regular, NPH, lente, long\u2011acting, etc.), origin\r (animal, human, human insulin analogue) and\/or method of manufacture may result\r in the need for a change in dose.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The time of occurrence of hypoglycaemia depends on the action\r profile of the insulins used and may, therefore, change when the treatment\r regimen is changed. Due to more sustained basal insulin supply with insulin\r glargine, less nocturnal but more early morning hypoglycaemia can be expected.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Particular caution should be exercised, and intensified blood\r glucose monitoring is advisable in patients in whom hypoglycaemic episodes\r might be of particular clinical relevance, such as in patients with significant\r stenoses of the coronary arteries or of the blood vessels supplying the brain\r (risk of cardiac or cerebral complications of hypoglycaemia) as well as in\r patients with proliferative retinopathy, particularly if not treated with\r photocoagulation (risk of transient amaurosis following hypoglycaemia). <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients should be aware of circumstances where warning symptoms of\r hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be\r changed, be less pronounced or be absent in certain risk groups. These include\r patients:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom glycaemic control\r is markedly improved,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom hypoglycaemia\r develops gradually,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        who are elderly,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        after transfer from\r animal insulin to human insulin,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom an autonomic\r neuropathy is present,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        with a long history of\r diabetes,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        suffering from a\r psychiatric illness,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        receiving concurrent\r treatment with certain other medicinal products (see section 4.5).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Such situations may result in severe hypoglycaemia (and possibly\r loss of consciousness) prior to the patient's awareness of hypoglycaemia.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The prolonged effect of subcutaneous insulin glargine may delay\r recovery from hypoglycaemia.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If normal or decreased values for glycated haemoglobin are noted,\r the possibility of recurrent, unrecognised (especially nocturnal) episodes of\r hypoglycaemia must be considered. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Adherence of the patient to the dose and dietary regimen, correct\r insulin administration and awareness of hypoglycaemia symptoms are essential to\r reduce the risk of hypoglycaemia. Factors increasing the susceptibility to\r hypoglycaemia require particularly close monitoring and may necessitate dose\r adjustment. These include:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        change in the injection\r area,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        improved insulin\r sensitivity (e.g., by removal of stress factors),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        unaccustomed, increased\r or prolonged physical activity,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        intercurrent illness\r (e.g. vomiting, diarrhoea),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        inadequate food intake,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        missed meals,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        alcohol consumption,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        certain uncompensated\r endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or\r adrenocortical insufficiency),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        concomitant treatment\r with certain other medicinal products.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Injection\r technique<\/span><\/u><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients must be instructed to perform\r continuous rotation of the injection site to reduce the risk of developing\r lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed\r insulin absorption and worsened glycaemic control following insulin injections at\r sites with these reactions. A sudden change in the injection site to an\r unaffected area has been reported to result in hypoglycaemia. Blood glucose\r monitoring is recommended after the change in the injection site, and dose\r adjustment of antidiabetic medications may be considered.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Intercurrent illness<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Intercurrent illness requires intensified metabolic monitoring. In\r many cases urine tests for ketones are indicated, and often it is necessary to\r adjust the insulin dose. The insulin requirement is often increased. Patients\r with type 1 diabetes must continue to consume at least a small amount of\r carbohydrates on a regular basis, even if they are able to eat only little or\r no food, or are vomiting etc. and they must never omit insulin entirely. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Insulin antibodies<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin administration may cause insulin antibodies to form. In rare\r cases, the presence of such insulin antibodies may necessitate adjustment of\r the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see\r section 5.1).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Medication errors<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Medication\r errors have been reported in which other insulins, particularly short\u2011acting\r insulins, have been accidentally administered instead of insulin glargine.\r Insulin label must always be checked before each injection to avoid medication\r errors between ABASAGLAR pre-filled pen as well as other insulins.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Combination of ABASAGLAR with pioglitazone<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Cases of cardiac failure have been reported when pioglitazone was\r used in combination with insulin, especially in patients with risk factors for\r development of cardiac heart failure. This should be kept in mind if treatment\r with the combination of pioglitazone and ABASAGLAR is considered. If the\r combination is used, patients should be observed for signs and symptoms of\r heart failure, weight gain and oedema. Pioglitazone should be discontinued if\r any deterioration in cardiac symptoms occurs.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Tempo Pen<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The Tempo Pen\r contains a magnet (see section 6.5) that may interfere with the functions of an\r implantable electronic medical device, such as a pacemaker. T<\/span><span lang=\"EN-GB\">he magnetic field extends to approximately 1.5 cm<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Sodium\r content<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">This medicinal product contains less than 1 mmol sodium\r (23 mg) per dose, i.e., essentially \u201csodium\u2011free\u201d.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.5     Interaction with other medicinal products\r and other forms of interaction<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A number of substances affect glucose metabolism and may require\r dose adjustment of insulin glargine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Substances that may enhance the blood-glucose\u2011lowering effect\r and increase susceptibility to hypoglycaemia include oral antidiabetic\r medicinal products, angiotensin converting enzyme (ACE) inhibitors,\r disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,\r pentoxifylline, propoxyphene, salicylates, somatostatin anologues and\r sulphonamide antibiotics. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Substances that may reduce the blood-glucose-lowering effect include\r corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid,\r oestrogens, progestogens, phenothiazine derivatives, somatropin,\r sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,\r terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g.\r clozapine and olanzapine) and protease inhibitors. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Beta-blockers, clonidine, lithium salts or alcohol may either\r potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine\r may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In addition, under the influence of sympatholytic medicinal products\r such as beta-blockers, clonidine, guanethidine and reserpine, the signs of\r adrenergic counter-regulation may be reduced or absent.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.6     <\/span><\/b><b><span lang=\"EN-GB\">Fertility, p<\/span><\/b><b><span lang=\"EN-GB\">regnancy and lactation<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For insulin glargine no clinical data on exposed pregnancies from\r controlled clinical studies are available. A large amount of data on pregnant\r women (more than 1,000 pregnancy outcomes) indicate no specific adverse\r effects of insulin glargine on pregnancy and no specific malformative nor\r feto\/neonatal toxicity of insulin glargine. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Animal data do not indicate reproductive toxicity. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The use of ABASAGLAR may be considered during pregnancy, if clinically\r needed.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">It is essential for patients with pre-existing or gestational\r diabetes to maintain good metabolic control throughout pregnancy to prevent\r adverse outcomes associated with hyperglycaemia. Insulin requirements may\r decrease during the first trimester and generally increase during the second\r and third trimesters. Immediately after delivery, insulin requirements decline\r rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose\r control is essential. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">It is unknown whether insulin glargine is excreted in human milk. No\r metabolic effects of ingested insulin glargine on the breast\u2011fed\r newborn\/infant are anticipated since insulin glargine as a peptide is digested\r into amino acids in the human gastrointestinal tract. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Breast-feeding women may require adjustments in insulin dose and\r diet. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Animal studies do not indicate direct harmful effects with respect\r to fertility.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.7     Effects on ability to drive and use\r machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The patient's ability to concentrate and react may be impaired as a\r result of hypoglycaemia or hyperglycaemia or, for example, as a result of\r visual impairment. This may constitute a risk in situations where these\r abilities are of special importance (e.g. driving a car or using machines).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients should be advised to take precautions to avoid\r hypoglycaemia whilst driving. This is particularly important in those who have\r reduced or absent awareness of the warning symptoms of hypoglycaemia or have\r frequent episodes of hypoglycaemia. It should be considered whether it is\r advisable to drive or operate machines in these circumstances.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">4.8     Undesirable\r effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Summary of safety profile<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Hypoglycaemia (very common), in general the most frequent adverse reaction\r of insulin therapy, may occur if the insulin dose is too high in relation to\r the insulin requirement (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Tabulated list of adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">The following related adverse reactions from clinical\r trials are listed below as MedDRA preferred term by system organ class and in\r order of decreasing incidence (very common: \u22651\/10; common: \u22651\/100\r to &lt;1\/10; uncommon: \u22651\/1,000 to &lt;1\/100; rare: \u22651\/10,000 to\r &lt;1\/1,000; very rare: &lt;1\/10,000 <a name=\"_Hlk23422201\"><span style=\"color:black\">and not known (cannot be estimated from the available data<\/span><\/a>).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Within each frequency grouping, adverse reactions are presented in\r order of decreasing seriousness.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:12.5pt;border-collapse:collapse;border:none\" width=\"99%\"> <tr style=\"height:16.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">MedDRA system organ classes<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Very common<\/span><\/b><\/p> <\/td> <td style=\"width:12.28%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Common<\/span><\/b><\/p> <\/td> <td style=\"width:15.18%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Uncommon<\/span><\/b><\/p> <\/td> <td style=\"width:11.02%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Rare<\/span><\/b><\/p> <\/td> <td style=\"width:11.08%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Very rare<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Not known<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Immune system disorders <\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Allergic reactions<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.75pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Nervous system disorders<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:11.0pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Dysgeusia<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:11.0pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Eyes disorders<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Visual impairment <\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Retinopathy<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Lipohypertrophy<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Lipoatrophy<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Cutaneous amyloidosis<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Myalgia<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">General disorders and administration site conditions<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:22.1%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Injection site reactions<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td colspan=\"2\" style=\"width:12.42%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:22.1%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Oedema<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td colspan=\"2\" style=\"width:12.42%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"155\"><\/td> <td style=\"border:none\" width=\"1\"><\/td> <td style=\"border:none\" width=\"106\"><\/td> <td style=\"border:none\" width=\"1\"><\/td> <td style=\"border:none\" width=\"86\"><\/td> <td style=\"border:none\" width=\"106\"><\/td> <td style=\"border:none\" width=\"77\"><\/td> <td style=\"border:none\" width=\"78\"><\/td> <td style=\"border:none\" width=\"91\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Severe hypoglycaemic attacks, especially if recurrent, may lead to\r neurological damage. Prolonged or severe hypoglycaemic episodes may be\r life-threatening. In many patients, the signs and symptoms of neuroglycopenia\r are preceded by signs of adrenergic counter-regulation. Generally, the greater\r and more rapid the decline in blood glucose, the more marked is the phenomenon\r of counter-regulation and its symptoms.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Immune system disorders<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Immediate-type allergic reactions to insulin are rare. Such\r reactions to insulin (including insulin glargine) or the excipients may, for\r example, be associated with generalised skin reactions, angio-oedema,\r bronchospasm, hypotension and shock, and may be life-threatening.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Eyes disorders<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A marked change in glycaemic control may cause temporary visual\r impairment, due to temporary alteration in the turgidity and refractive index\r of the lens.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Long-term improved glycaemic control decreases the risk of progression\r of diabetic retinopathy. However, intensification of insulin therapy with\r abrupt improvement in glycaemic control may be associated with temporary\r worsening of diabetic retinopathy. In patients with proliferative retinopathy,\r particularly if not treated with photocoagulation, severe hypoglycaemic\r episodes may result in transient amaurosis.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Lipodystrophy and cutaneous amyloidosis may\r occur at the injection site and delay local insulin absorption. Continuous\r rotation of the injection site within the given injection area may help to\r reduce or prevent these reactions (<\/span><span lang=\"EN-GB\">see section 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><u><span lang=\"EN-GB\">General disorders and administration site\r conditions<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">Injection site reactions include redness, pain, itching,\r hives, swelling, or inflammation. Most minor reactions to insulins at the\r injection site usually resolve in a few days to a few weeks. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Rarely, insulin may cause sodium retention and oedema particularly\r if previously poor metabolic control is improved by intensified insulin therapy.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In general, the safety profile for children and adolescents\r (\u2264 18 years of age) is similar to the safety profile for\r adults. The adverse reaction reports received from post marketing surveillance\r included relatively more frequent injection site reactions (injection site\r pain, injection site reaction) and skin reactions (rash, urticaria) in children\r and adolescents (\u2264 18 years of age) than in adults. Clinical\r study safety data are not available for children under 2 years.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\r medicinal product is important. It allows continued monitoring of the\r benefit\/risk balance of the medicinal product. Healthcare professionals are\r asked to report any suspected adverse reactions via <span style=\"background:\r lightgrey\">the national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.9     Overdose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Symptoms<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin overdose may lead to severe and sometimes long-term and\r life-threatening hypoglycaemia. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Management<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Mild episodes of hypoglycaemia can usually be treated with oral\r carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or\r physical activity may be needed. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">More severe episodes with coma, seizure, or neurologic impairment\r may be treated with intramuscular\/subcutaneous glucagon or concentrated\r intravenous glucose. Sustained carbohydrate intake and observation may be\r necessary because hypoglycaemia may recur after apparent clinical recovery.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">5.1     Pharmacodynamic\r properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pharmacotherapeutic\r group: Drugs used in diabetes, insulins and analogues for injection,\r long-acting. ATC Code: A10AE04.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR is a\r biosimilar medicinal product. Detailed information is available on the website\r of the European Medicines Agency <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext\">http:\/\/www.ema.europa.eu<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Mechanism of\r action<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r is a human insulin analogue designed to have a low solubility at neutral pH. It\r is completely soluble at the acidic pH of the ABASAGLAR injection solution\r (pH 4). After injection into the subcutaneous tissue, the acidic solution\r is neutralised leading to formation of micro-precipitates from which small\r amounts of insulin glargine are continuously released, providing a smooth,\r peakless, predictable concentration\/time profile with a prolonged duration of\r action.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r is metabolised into 2 active metabolites M1 and M2 (see section 5.2).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Insulin\r receptor binding<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">In vitro<\/span><\/i><span lang=\"EN-GB\"> studies indicate that the affinity of insulin glargine and its\r metabolites M1 and M2 for the human insulin receptor is similar to the one of\r human insulin.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">IGF-1 receptor\r binding: The affinity of insulin glargine for the human IGF-1 receptor is\r approximately 5 to 8-fold greater than that of human insulin (but approximately\r 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1\r receptor with slightly lower affinity compared to human insulin.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The total therapeutic insulin concentration (insulin glargine and\r its metabolites) found in type 1 diabetic patients was markedly lower than\r what would be required for a half maximal occupation of the IGF-1 receptor and\r the subsequent activation of the mitogenic-proliferative pathway initiated by\r the IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may\r activate the mitogenic-proliferative pathway; however, the therapeutic\r concentrations found in insulin therapy, including in ABASAGLAR therapy, are\r considerably lower than the pharmacological concentrations required to activate\r the IGF-1 pathway. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Pharmacodynamic\r effects<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The primary\r activity of insulin, including insulin glargine, is regulation of glucose\r metabolism. Insulin and its analogues lower blood glucose levels by stimulating\r peripheral glucose uptake, especially by skeletal muscle and fat, and by\r inhibiting hepatic glucose production. Insulin inhibits lipolysis in the\r adipocyte, inhibits proteolysis and enhances protein synthesis.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In clinical\r pharmacology studies, intravenous insulin glargine and human insulin have been\r shown to be equipotent when given at the same doses. As with all insulins, the\r time course of action of insulin glargine may be affected by physical activity\r and other variables.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In euglycaemic\r clamp studies in healthy subjects or in patients with type 1 diabetes, the\r onset of action of subcutaneous insulin glargine was slower than with human NPH\r insulin, its effect profile was smooth and peakless, and the duration of its\r effect was prolonged.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The following\r graph shows the results from a study in patients:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Figure 1: <\/span><\/b><b>Activity profile in patients with type<\/b><b>1 diabetes<\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;line-height:normal;\r page-break-after:avoid\"><span style=\"position:absolute;z-index:251686912;\r left:0px;margin-left:-6px;margin-top:15px;width:652px;height:274px\"><img height=\"274\" src=\"data:image\/png;base64,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\" width=\"652\"\/><\/span><span style=\"position:absolute;z-index:251684864;left:0px;margin-left:161px;\r margin-top:233px;width:159px;height:39px\"><img alt=\"Time (h) after s.c injection\" height=\"39\" src=\"data:image\/png;base64,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\" width=\"159\"\/><\/span><span lang=\"EN-GB\"><img border=\"0\" height=\"286\" id=\"Picture 2\" src=\"data:image\/jpg;base64,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\" width=\"590\"\/><\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">* Determined as\r amount of glucose infused to maintain constant plasma glucose levels (hourly\r mean values)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The longer\r duration of action of subcutaneous insulin glargine is directly related to its\r slower rate of absorption and supports once daily administration. The time\r course of action of insulin and insulin analogues such as insulin glargine may\r vary considerably in different individuals or within the same individual<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a clinical\r study, symptoms of hypoglycaemia or counter-regulatory hormone responses were\r similar after intravenous insulin glargine and human insulin both in healthy\r volunteers and patients with type 1 diabetes.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Clinical safety and efficacy<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In clinical\r studies, antibodies that cross-react with human insulin and insulin glargine\r were observed with the same frequency in both NPH-insulin and insulin glargine\r treatment groups.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Effects of\r insulin glargine (once daily) on diabetic retinopathy were evaluated in an\r open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2\r diabetic patients in which progression of retinopathy by 3 or more steps on the\r Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by\r fundus photography. No significant difference was seen in the progression of\r diabetic retinopathy when insulin glargine was compared to NPH insulin.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The ORIGIN\r (Outcome Reduction with Initial Glargine INtervention) study was a multicenter,\r randomised, 2x2 factorial design study conducted in 12,537 participants at high\r cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired\r glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus\r treated with \u22641 antidiabetic oral agent (88% of participants).\r Participants were randomised (1:1) to receive insulin glargine (n=6,264),\r titrated to reach FPG \u226495 mg\/dL (5.3 mM), or standard care (n=6,273).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The first\r co-primary efficacy outcome was the time to the first occurrence of CV death,\r nonfatal myocardial infarction (MI), or nonfatal stroke, and the second\r co-primary efficacy outcome was the time to the first occurrence of any of the\r first co-primary events, or revascularisation procedure (coronary, carotid, or\r peripheral), or hospitalisation for heart failure.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Secondary\r endpoints included all-cause mortality and a composite microvascular outcome.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r did not alter the relative risk for CV disease and CV mortality when compared\r to standard of care. There were no differences between insulin glargine and\r standard care for the two co-primary outcomes; for any component endpoint\r comprising these outcomes; for all-cause mortality; or for the composite\r microvascular outcome.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Mean dose of\r insulin glargine by study end was 0.42 U\/kg. At baseline, participants had a\r median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9\r to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care\r group throughout the duration of follow-up. The rates of severe hypoglycaemia\r (affected participants per 100 participant years of exposure) were 1.05 for\r insulin glargine and 0.30 for standard care group and the rates of confirmed\r non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard\r care group. Over the course of this 6-year study, 42% of the insulin glargine\r group did not experience any hypoglycaemia. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At the last\r on-treatment visit, there was a mean increase in body weight from baseline of\r 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the\r standard care group.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a randomised,\r controlled clinical study, paediatric patients (age range 6 to 15 years)\r with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus\r insulin regimen where regular human insulin was used before each meal. Insulin\r glargine was administered once daily at bedtime and NPH human insulin was\r administered once or twice daily. Similar effects on glycohaemoglobin and the\r incidence of symptomatic hypoglycaemia were observed in both treatment groups,\r however fasting plasma glucose decreased more from baseline in the insulin\r glargine group than in the NPH group. There was less severe hypoglycaemia in\r the insulin glargine group as well. One hundred forty three of the patients\r treated with insulin glargine in this study continued treatment with insulin\r glargine in an uncontrolled extension study with mean duration of follow-up of\r 2 years. No new safety signals were seen during this extended treatment\r with insulin glargine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A crossover\r study comparing insulin glargine plus lispro insulin to NPH plus regular human\r insulin (each treatment administered for 16 weeks in random order) in 26\r adolescent type 1 diabetic patients aged 12 to 18 years was also\r performed. As in the paediatric study described above, fasting plasma glucose\r reduction from baseline was greater in the insulin glargine group than in the\r NPH group. HbA<sub>1c<\/sub> changes from baseline were similar between\r treatment groups; however blood glucose values recorded overnight were\r significantly higher in the insulin glargine\/ lispro group than the NPH\/regular\r group, with a mean nadir of 5.4 mM vs. 4.1 mM. Correspondingly, the\r incidences of nocturnal hypoglycaemia were 32 % in the insulin glargine \/\r lispro group vs. 52 % in the NPH \/ regular group.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A 24-week\r parallel group study was conducted in 125 children with type 1 diabetes\r mellitus aged 2 to 6 years, comparing insulin glargine given once daily in\r the morning to NPH insulin given once or twice daily as basal insulin. Both\r groups received bolus insulin before meals. The primary aim of demonstrating\r non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and\r there was a trend to an increase of hypoglycaemic events with insulin glargine\r [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)].\r Glycohaemoglobin and glucose variabilities were comparable in both treatment\r groups. No new safety signals were observed in this trial.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In healthy subjects and diabetic patients, insulin serum\r concentrations indicated a slower and much more prolonged absorption and showed\r a lack of a peak after subcutaneous injection of insulin glargine in comparison\r to human NPH insulin. Concentrations were thus consistent with the time profile\r of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the\r activity profiles over time of insulin glargine and NPH insulin. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin glargine injected once daily will reach steady state levels\r in 2-4 days after the first dose. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">After subcutaneous injection in diabetic patients, insulin glargine\r is rapidly metabolised at the carboxyl terminus of the Beta chain with\r formation of two active metabolites M1 (21A-Gly-insulin) and M2\r (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is\r the metabolite M1. The exposure to M1 increases with the administered dose of\r insulin glargine.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pharmacokinetic and pharmacodynamic findings indicate that the effect\r of the subcutaneous injection with insulin glargine is principally based on\r exposure to M1. Insulin glargine and the metabolite M2 were not detectable in\r the vast majority of subjects and, when they were detectable their\r concentration was independent of the administered dose of insulin glargine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">When given intravenously the elimination half-life of insulin\r glargine and human insulin were comparable. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"> <\/p> <p style=\"margin:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Special\r populations<\/span><\/u><\/p> <p style=\"margin:0in\"><\/p> <p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In clinical\r studies, subgroup analyses based on age and gender did not indicate any\r difference in safety and efficacy in insulin glargine-treated patients compared\r to the entire study population.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Pharmacokinetics in children aged 2 to less than 6 years with\r type 1 diabetes mellitus was assessed in one clinical study (see section\r 5.1). Plasma trough levels of insulin glargine and its main M1 and M2\r metabolites were measured in children treated with insulin glargine, revealing\r plasma concentration patterns similar to adults, and providing no evidence for\r accumulation of insulin glargine or its metabolites with chronic dosing.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.3     Preclinical safety data<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Non-clinical data reveal no special hazard for humans based on\r conventional studies of safety pharmacology, repeated dose toxicity,\r genotoxicity, carcinogenic potential, toxicity to reproduction.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Zinc oxide<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Metacresol<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Glycerol<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Hydrochloric acid (for pH adjustment)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Sodium hydroxide (for pH adjustment)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Water for injections<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">This medicinal product must not be mixed with other medicinal\r products. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">2 years.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Shelf life after first use <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The medicinal product may be stored for a maximum of 28 days up\r to 30\u00b0C and away from direct heat or direct light. Pens in use must not be\r stored in the refrigerator. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pen cap must be put back on the pen after each injection in\r order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Before use<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C - 8\u00b0C).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not store ABASAGLAR next to the freezer compartment or a freezer\r pack.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Keep the pre-filled pen in the outer carton in order to protect from\r light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">In use <\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For storage conditions after first opening of this medicinal\r product, see section 6.3.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><b><span lang=\"EN-GB\">6.5     Nature and contents of container<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><b><s><span lang=\"EN-GB\"><\/span><\/s><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">KwikPen<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">3 mL solution in a cartridge (type 1 colourless glass) with a\r plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and\r halobutyl rubber) with aluminium seal. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The cartridge is sealed in a disposable pen injector. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Packs of 5 pre-filled\r pens and multipacks containing 10 (2 packs of 5) pre-filled pens. <\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\">Tempo Pen<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">3 mL solution in a cartridge (type 1 colourless glass) with a\r plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and\r halobutyl rubber) with aluminium seal. The cartridge is sealed in a disposable\r pen injector. The Tempo Pen contains a magnet (see section 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Packs of 5 <a name=\"_Hlk44087754\">pre-filled pens<\/a> and\r multipacks containing 10 (2 packs of 5) pre-filled pens<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Needles are not\r included in the pack.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.6     Special precautions for disposal and other handling<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR must not be mixed with any other insulin or medicinal\r products or diluted. Mixing or diluting can change its time\/action profile and\r mixing can cause precipitation.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Inspect the cartridge before use. It must only be used if the\r solution is clear, colourless, with no solid particles visible, and if it is of\r water-like consistency. Since ABASAGLAR is a solution, it does not require\r re-suspension before use. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR must not be mixed with any other insulin or diluted.\r Mixing or diluting can change its time\/action profile and mixing can cause\r precipitation.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Empty pens must never be reused and must be properly discarded. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">To prevent the possible transmission of disease, each pen must be\r used by one patient only. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin label must always be checked before each injection to avoid\r medication errors between insulin glargine and other insulins (see section\r 4.4).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The patient should be advised to read the instructions for use\r included in the package leaflet carefully before using ABASAGLAR solution for\r injection in pre\u2011filled pen.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\"><a name=\"_Hlk20390276\"><u><span lang=\"EN-GB\">Tempo Pen<\/span><\/u><\/a><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"mdTblEntry\" style=\"line-height:normal\"><a name=\"_Hlk38978858\"><\/a><a name=\"_Hlk45820494\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The Tempo Pen is\r designed to work with the Tempo Smart Button. <\/span><\/a><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The Tempo Smart Button is an optional product that can\r be attached to the Tempo Pen dose knob and aids in transmitting Abasaglar dose\r information from the Tempo Pen to a compatible mobile application. The Tempo\r Pen injects insulin with or without the Tempo Smart Button attached. To\r transmit data to the mobile application, follow the instructions provided with\r the Tempo Smart Button and the instructions with the mobile application. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">7.       MARKETING\r AUTHORISATION HOLDER<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The\r Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">8.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/14\/944\/007<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ES-TRAD\">EU\/1\/14\/944\/008<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ES-TRAD\">EU\/1\/14\/944\/012<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ES-TRAD\">EU\/1\/14\/944\/013<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"ES-TRAD\" style=\"color:black\">EU\/1\/14\/944\/014<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"ES\" style=\"color:black\">EU\/1\/14\/944\/015<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Date of first authorisation: 9 September 2014<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Date of latest renewal: 25 July 2019<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Detailed information on this medicinal product is available on the\r website of the European Medicines Agency <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext\">http:\/\/www.ema.europa.eu<\/span><\/a><\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r line-height:normal;page-break-after:avoid;text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r line-height:normal;page-break-after:avoid;text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r line-height:normal;page-break-after:avoid;text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r line-height:normal;page-break-after:avoid;text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r line-height:normal;page-break-after:avoid;text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r line-height:normal;page-break-after:avoid;text-autospace:none\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;\r margin-bottom:0in;margin-left:6.35pt;margin-bottom:.0001pt;text-align:center;\r line-height:normal;page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">ANNEX II<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:14.0pt;margin-right:6.0pt;margin-bottom:\r 0in;margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:\r avoid;text-autospace:none\"><b><span lang=\"EN-GB\">A.    MANUFACTURER(S) OF THE\r BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH\r RELEASE <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:14.0pt;margin-right:6.0pt;margin-bottom:\r 11.0pt;margin-left:42.35pt;text-indent:-.5in;page-break-after:avoid;text-autospace:\r none\"><b><span lang=\"EN-GB\">B.    CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND\r USE<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:\r avoid;text-autospace:none\"><b><span lang=\"EN-GB\">C.    OTHER CONDITIONS AND\r REQUIREMENTS OF THE MARKETING AUTHORISATION<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:42.35pt;margin-bottom:.0001pt;text-indent:-.5in;page-break-after:\r avoid;text-autospace:none\"><b><span lang=\"EN-GB\">D.    CONDITIONS OR RESTRICTIONS\r WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;text-autospace:none\"><\/p> <p class=\"MsoNormal\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"TittleB\"><span lang=\"EN-GB\" style=\"color:windowtext\">A.    MANUFACTURER(S)\r OF THE BIOLOGICAL ACTIVE SUBSTANCE(S)    AND MANUFACTURER(S) RESPONSIBLE FOR\r BATCH RELEASE<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:7.1pt;margin-bottom:.0001pt;line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><u><span lang=\"EN-GB\">Name and address of the manufacturers of the biological\r active substance<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">Lilly del Caribe, Inc.<br\/>\r 12.3 km 65th Infantry Road<br\/>\r Carolina, PR 00985<br\/>\r Puerto Rico<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">Eli Lilly and Company<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">Indianapolis <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">Indiana 46285 <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">USA<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><u><span lang=\"EN-GB\">Name and address of the manufacturer responsible for\r batch release<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:7.1pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">ABASAGLAR<\/span><span lang=\"EN-GB\"> 100 units\/mL\r solution for injection in a cartridge and pre-filled pen<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">Lilly France S.A.S.<br\/>\r 2, rue du Colonel Lilly<br\/>\r F-67640 Fegersheim<br\/>\r France<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:7.1pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">ABASAGLAR<\/span><span lang=\"EN-GB\"> 100 units\/mL\r solution for injection in a cartridge<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:7.1pt\"><span lang=\"IT\">Eli Lilly Italia\r S.p.A., <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:7.1pt\"><span lang=\"IT\">Via Gramsci 731-733,\r <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:7.1pt\"><span lang=\"IT\">50019 Sesto\r Fiorentino, (FI) <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:7.1pt\"><span lang=\"IT\">Italy.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"TittleB\"><span lang=\"EN-GB\" style=\"color:windowtext\">B.    CONDITIONS OR\r RESTRICTIONS REGARDING SUPPLY AND USE<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">Medicinal product subject to medical prescription <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"TittleB\"><span lang=\"EN-GB\" style=\"color:windowtext\">C.    OTHER\r CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:23.4pt;text-indent:-.25in;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\">Periodic safety update reports (PSURs)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">The <\/span><span lang=\"EN-GB\" style='font-family:\"TimesNewRomanPSMT\",serif'>requirements\r for submission of<\/span><span lang=\"EN-GB\"> PSURs for this <\/span><span lang=\"EN-GB\" style='font-family:\"TimesNewRomanPSMT\",serif'>medicinal product are<\/span><span lang=\"EN-GB\"> set out in the list of Union reference dates (EURD list) provided\r for under Article 107c(7) of Directive 2001\/83\/EC and <\/span><span lang=\"EN-GB\" style='font-family:\"TimesNewRomanPSMT\",serif'>any subsequent updates<\/span><span lang=\"EN-GB\"> published on the European medicines web-portal.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"TittleB\"><span lang=\"EN-GB\" style=\"color:windowtext\">D.    CONDITIONS OR\r RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:23.4pt;text-indent:-.25in;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\">Risk management plan (RMP)<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">The marketing authorisation holder (MAH) shall perform\r the required pharmacovigilance activities and interventions detailed in the\r agreed RMP presented in Module 1.8.2 of the marketing authorisation and any\r agreed subsequent updates of the RMP.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:6.0pt;margin-bottom:0in;\r margin-left:6.35pt;margin-bottom:.0001pt;line-height:normal;text-autospace:\r none\"><span lang=\"EN-GB\">An updated RMP should be submitted:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:41.4pt;text-indent:-.25in;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><span lang=\"EN-GB\">At the request of the European Medicines Agency;<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:41.4pt;text-indent:-.25in;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><span lang=\"EN-GB\">Whenever the risk management system is modified,\r especially as the result of new information being received that may lead to a\r significant change to the benefit\/risk profile or as the result of an important\r (pharmacovigilance or risk minimisation) milestone being reached. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.95pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.95pt;line-height:normal;text-autospace:\r none\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ANNEX III<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET<\/span><\/b><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">A. LABELLING<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER CARTON \u2013 Cartridge. Pack of 5 and 10<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR 100 units\/mL\r solution for injection in a cartridge<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each mL contains\r 100 units insulin glargine (equivalent to 3.64 mg).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Excipients: zinc\r oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for\r injections. <\/span><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet\r for further information<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"background:\r lightgrey\">Solution for injection<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">5 cartridges of\r 3 mL.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">10 cartridges of 3 mL<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">These cartridges are\r for use with a Lilly 3 mL pen only.<\/span><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Subcutaneous use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the\r sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Discard 28 days\r after first use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL\r STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Before use:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in original package in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In use: <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store below <\/span><span lang=\"EN-GB\">30 \u00baC<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not refrigerate or freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"SV\">Eli Lilly Nederland B.V. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Papendorpseweg 83, 3528 BJ Utrecht <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR\">EU\/1\/14\/944\/003<\/span><span lang=\"FR\">          <span style=\"background:lightgrey\">5 cartridges<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR\" style=\"background:\r lightgrey\">EU\/1\/14\/944\/009          10 cartridges<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"FR\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"FR\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR\">ABASAGLAR<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"FR\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;border:\r none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE IDENTIFIER - HUMAN\r READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"X-NONE\">NN<\/span><\/p> <span lang=\"X-NONE\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">CARTRIDGE LABEL <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF\r ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR\r 100 units\/mL injection<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">SC use<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       METHOD OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Read the package leaflet before use<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><span lang=\"EN-GB\">3 mL<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER CARTON \u2013 KwikPen. Pack of 5<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR 100 units\/mL\r KwikPen solution for injection in a pre-filled pen<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each mL contains\r 100 units insulin glargine (equivalent to 3.64 mg).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Excipients: zinc\r oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for\r injections.<\/span><span lang=\"EN-GB\" style=\"background:lightgrey\"> See leaflet\r for further information<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"background:\r lightgrey\">Solution for injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">5 pens of\r 3 mL.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Subcutaneous use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the\r sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Discard pen 28 days\r after first use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL\r STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Before use:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in original package in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In use: <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store below <\/span><span lang=\"EN-GB\">30 \u00baC<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not refrigerate or freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Recap the pen after use to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"SV\">Eli Lilly Nederland B.V. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Papendorpseweg 83, 3528 BJ Utrecht <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\">EU\/1\/14\/944\/007<\/span><span lang=\"FR\">          <span style=\"background:lightgrey\">5 pens<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\" style=\"background:\r lightgrey\">EU\/1\/14\/944\/012<\/span><span lang=\"FR\" style=\"background:lightgrey\">          5\r pens<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"SV\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;border:\r none;padding:0in\"><b><span lang=\"FR\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"FR\">ABASAGLAR<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"FR\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:0in 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;border:\r none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE IDENTIFIER - HUMAN\r READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"X-NONE\">NN<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER CARTON for multipack (with blue box) \u2013 KwikPen<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR 100 units\/mL\r KwikPen solution for injection in a pre-filled pen<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each mL contains\r 100 units insulin glargine (equivalent to 3.64 mg).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Excipients: zinc\r oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for\r injections. <\/span><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet\r for further information<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"background:\r lightgrey\">Solution for injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Multipack: 10 (2\r packs of 5) pens of 3 mL. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Subcutaneous use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the\r sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Discard pen\r 28 days after first use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL\r STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Before use:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in original package in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In use: <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store below <\/span><span lang=\"EN-GB\">30 \u00baC<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not refrigerate or freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Recap the pen after use to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"SV\">Eli Lilly Nederland B.V. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Papendorpseweg 83, 3528 BJ Utrecht <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\">EU\/1\/14\/944\/008<\/span><span lang=\"FR\" style=\"background:lightgrey\">          10 (2 x 5) pens<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\" style=\"background:\r lightgrey\">EU\/1\/14\/944\/013<\/span><span lang=\"FR\" style=\"background:lightgrey\">          10\r (2 x 5) pens<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"SV\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"FR\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR\">ABASAGLAR<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"FR\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;border:\r none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE IDENTIFIER - HUMAN\r READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"X-NONE\">NN<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">INTERMEDIATE CARTON of a multipack (without blue box) - KwikPen<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR\r 100 units\/mL KwikPen solution for injection in a pre-filled pen<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each mL contains\r 100 units  insulin glargine (equivalent to 3.64 mg).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Excipients: zinc\r oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for\r injections. <\/span><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet\r for further information<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"background:\r lightgrey\">Solution for injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">5 pens of 3 mL.\r Component of a multipack, can\u2019t be sold separately.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Subcutaneous use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the\r sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Discard pen 28 days\r after first use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL\r STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Before use:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in original package in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In use: <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store below <\/span><a name=\"_Hlk47359922\"><span lang=\"EN-GB\">30 \u00baC<\/span><\/a><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not refrigerate or freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Recap the pen after use to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"SV\">Eli Lilly Nederland B.V. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Papendorpseweg 83, 3528 BJ Utrecht <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"SV\">EU\/1\/14\/944\/008          <\/span><span lang=\"FR\" style=\"background:lightgrey\">10 (2 x 5) <\/span><span lang=\"SV\" style=\"background:lightgrey\">pens<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR\" style=\"background:\r lightgrey\">EU\/1\/14\/944\/013          10 (2 x 5) pens<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"SV\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"FR\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"FR\">ABASAGLAR<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"FR\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">LABEL TEXT \u2013<\/span><\/b><b><span lang=\"EN-GB\">KwikPen<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF\r ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR\r 100 units\/mL <\/span><span lang=\"EN-GB\">KwikPen injection<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">SC use<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       METHOD OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Read the package leaflet before use<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><span lang=\"EN-GB\">3 mL<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER CARTON __ Tempo Pen. Pack of 5<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR\r 100 units\/mL Tempo Pen solution for injection in a pre-filled pen<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE\r SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each mL contains\r 100 units insulin glargine (equivalent to 3.64 mg).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Excipients: zinc\r oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for\r injections. <\/span><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet\r for further information<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"background:\r lightgrey\">Solution for injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">5 pens of\r 3 mL.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Subcutaneous use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the\r sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Discard pen\r 28 days after first use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL\r STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Before use:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">Store in a refrigerator.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in original package in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In use: <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store below <\/span><span lang=\"EN-GB\">30 \u00baC<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not refrigerate or freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Recap the pen after use to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"SV\">Eli Lilly Nederland B.V. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Papendorpseweg 83, 3528 BJ Utrecht <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/14\/944\/014<\/span>          <span style=\"background:lightgrey\">5 pens<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;border:\r none;padding:0in\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">ABASAGLAR<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;border:\r none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE IDENTIFIER - HUMAN\r READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"X-NONE\">NN<\/span><span lang=\"EN-GB\"><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">OUTER CARTON for multipack (with blue box) \u2013 Tempo Pen<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR\r 100 units\/mL Tempo Pen solution for injection in a pre-filled pen<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each mL contains\r 100 units insulin glargine (equivalent to 3.64 mg).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Excipients: zinc\r oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for\r injections. <\/span><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet\r for further information<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"background:\r lightgrey\">Solution for injection. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Multipack: 10 (2\r packs of 5) pens of 3 mL. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Subcutaneous use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the\r sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Discard pen\r 28 days after first use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL\r STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Before use:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in original package in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In use: <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store below <\/span><span lang=\"EN-GB\">30 \u00baC<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not refrigerate or freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Recap the pen after use to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"SV\">Eli Lilly Nederland B.V. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Papendorpseweg 83, 3528 BJ Utrecht <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/14\/944\/015<\/span><span lang=\"FR\" style=\"background:\r lightgrey\">10 (2 x 5)<\/span><span style=\"background:lightgrey\"> pens<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;border:\r none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE IDENTIFIER - HUMAN READABLE\r DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">PC<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">SN<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"X-NONE\">NN<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r color:black;background:#CCCCCC'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">INTERMEDIATE CARTON of a multipack (without blue box) \u2013 Tempo Pen<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE\r MEDICINAL PRODUCT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR\r 100 units\/mL Tempo Pen solution for injection in a pre-filled pen<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       STATEMENT OF\r ACTIVE SUBSTANCE(S)<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Each mL contains\r 100 units  insulin glargine (equivalent to 3.64 mg).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Excipients: zinc\r oxide, metacresol, glycerol, hydrochloric acid and sodium hydroxide, water for injections.\r <\/span><span lang=\"EN-GB\" style=\"background:lightgrey\">See leaflet for further\r information<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       PHARMACEUTICAL\r FORM AND CONTENTS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"background:\r lightgrey\">Solution for injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">5 pens of\r 3 mL. Component of a multipack, can\u2019t be sold separately.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       METHOD AND\r ROUTE(S) OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Read the package\r leaflet before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"text-align:justify;text-justify:inter-ideograph;\r line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Subcutaneous use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       SPECIAL WARNING\r THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF\r CHILDREN<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Keep out of the\r sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">7.       OTHER SPECIAL\r WARNING(S), IF NECESSARY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Discard pen\r 28 days after first use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;border:none;padding:0in\"><b><span lang=\"EN-GB\">9.       SPECIAL\r STORAGE CONDITIONS<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Before use:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in original package in order to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In use: <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store below <\/span><span lang=\"EN-GB\">30 \u00baC<\/span><span lang=\"EN-GB\">.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not refrigerate or freeze.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Recap the pen after use to protect from light.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"SV\">Eli Lilly Nederland B.V. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Papendorpseweg 83, 3528 BJ Utrecht <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The Netherlands<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S) <\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/14\/944\/015          <span style=\"background:lightgrey\">10 (2 x 5) pens<\/span><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Lot <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR SUPPLY<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:2.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">16.     INFORMATION IN BRAILLE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">17.       UNIQUE IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">18.       UNIQUE IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">LABEL TEXT \u2013<\/span><\/b><b><span lang=\"EN-GB\">Tempo Pen<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF\r ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR\r 100 units\/mL Tempo Pen injection<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">SC use<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">2.       METHOD OF ADMINISTRATION<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"background:lightgrey\">Read the package leaflet before use<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">3.       EXPIRY DATE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">5.       CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><span lang=\"EN-GB\">3 mL<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"MsoNormal\" style=\"line-height:normal;border:none;padding:0in\"><b><span lang=\"EN-GB\">6.       OTHER<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:5.65pt;line-height:normal\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"TitleA\"><\/p> <p class=\"TitleA\"><\/p> <p class=\"TitleA\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r background:white\"><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><b><span lang=\"EN-GB\">ABASAGLAR 100 units\/mL solution for injection<\/span><\/b><span lang=\"EN-GB\"> <b>in a cartridge<\/b><\/span><\/p> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">insulin glargine<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Read all of this leaflet carefully before you start using this medicine\r because it contains important information for you. The instructions for using\r the insulin pen are provided with your insulin pen. Refer to them before using\r your medicine.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it\r again. <\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-top:0in;margin-right:-.1pt;\r margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;\r line-height:normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor,\r pharmacist or nurse.<\/span><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-top:0in;margin-right:-.1pt;\r margin-bottom:0in;margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;\r line-height:normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">This medicine has been prescribed for you only.\r Do not pass it on to others. It may harm them, even if their signs of illness\r are the same as yours.<\/span><\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:28.35pt;text-indent:-28.35pt;\r line-height:normal\"><span lang=\"EN-GB\">-<\/span><span lang=\"EN-GB\">If you get any side effects, talk to your\r doctor, pharmacist or nurse.<\/span><span lang=\"EN-GB\"> This includes any possible\r side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">What is in this leaflet<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">1.       What ABASAGLAR is and what it is used for <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">2.       What you need to know before you use ABASAGLAR<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">3.       How to use ABASAGLAR<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">4.       Possible side effects <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">5.       How to store ABASAGLAR<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">1.       What ABASAGLAR is and what it is used for<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR contains insulin glargine. This is a modified insulin,\r very similar to human insulin.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is used to treat diabetes mellitus in adults, adolescents\r and children aged 2 years and above.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Diabetes mellitus is a disease where your body does not produce\r enough insulin to control the level of blood sugar. Insulin glargine has a long\r and steady blood-sugar-lowering action.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">2.       What you need to know before you use ABASAGLAR<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Do not use ABASAGLAR<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If you are allergic to insulin glargine or any of the other\r ingredients of this medicine (listed in section 6).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Warnings and\r precautions <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Talk to your doctor, pharmacist or nurse before using ABASAGLAR.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Follow closely the instructions for posology, monitoring (blood and\r urine tests), diet and physical activity (physical work and exercise) as\r discussed with your doctor.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If your blood sugar is too low (hypoglycaemia), follow the guidance\r for hypoglycaemia (see box at the end of this leaflet).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\"><i><span lang=\"EN-GB\">Skin changes at the injection site<\/span><\/i><u><span lang=\"EN-GB\">.<\/span><\/u><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">The injection site should be rotated to\r prevent skin changes such as lumps under the skin. The insulin may not work\r well if you inject into a lumpy area (See How to use Abasaglar). Contact your\r doctor if you are currently injecting into a lumpy area before you start\r injecting into a different area. Your doctor may tell you to check your blood\r sugar more closely, and to adjust your insulin or your other antidiabetic\r medications dose.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Travel<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Before travelling consult your doctor. You may need to talk about:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        the availability of your\r insulin in the country you are visiting,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        supplies of insulin etc.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        correct storage of your\r insulin while travelling,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        timing of meals and\r insulin administration while travelling,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        the possible effects of\r changing to different time zones,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        possible new health risks\r in the countries to be visited,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        what you should do in\r emergency situations when you feel unwell or become ill.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Illnesses and injuries<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In the following situations, the management of your diabetes may\r require a lot of care (for example, adjustment to insulin dose, blood and urine\r tests):<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        If you are ill or have a\r major injury then your blood sugar level may increase (hyperglycaemia).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        If you are not eating\r enough your blood sugar level may become too low (hypoglycaemia).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In most cases you will need a doctor. <b>Make sure that you contact\r a doctor early.<\/b><\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If you have type 1 diabetes (insulin dependent diabetes\r mellitus), do not stop your insulin and continue to get enough carbohydrates.\r Always tell people who are caring for you or treating you that you require\r insulin.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin treatment can cause the body to produce antibodies to\r insulin (substances that act against insulin). However, only very rarely, this\r will require a change to your insulin dose.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Some patients with long-standing type 2 diabetes mellitus and\r heart disease or previous stroke who were treated with pioglitazone and insulin\r experienced the development of heart failure. Inform your doctor as soon as\r possible if you experience signs of heart failure such as unusual shortness of\r breath or rapid increase in weight or localised swelling (oedema).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Insulin mix-ups<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">You must always check <\/span><span lang=\"EN-GB\">the pack and <\/span><span lang=\"EN-GB\">the insulin label before each injection to avoid mix-ups between\r ABASAGLAR and other insulins.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Children<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">There is no experience with the use of ABASAGLAR in children below\r the age of 2 years.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Other medicines and ABASAGLAR<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Some medicines cause changes in the blood sugar level (decrease,\r increase or both depending on the situation). In each case, it may be necessary\r to adjust your insulin dose to avoid blood sugar levels that are either too low\r or too high. Be careful when you start or stop taking another medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Tell your doctor or pharmacist if you are taking, have recently\r taken or might take any other medicines. Before taking a medicine ask your\r doctor if it can affect your blood sugar level and what action, if any, you\r need to take.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Medicines that may cause your blood sugar level to fall\r (hypoglycaemia) include:<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        all other medicines to\r treat diabetes,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        angiotensin converting\r enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood\r pressure),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        disopyramide (used to\r treat certain heart conditions),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        fluoxetine (used to treat\r depression),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        fibrates (used to lower\r high levels of blood lipids),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        monoamine oxidase (MAO)\r inhibitors (used to treat depression),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        pentoxifylline,\r propoxyphene, salicylates (such as aspirin, used to relieve pain and lower\r fever), <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        somatostatin analogues\r (such as octreotide, used to treat an uncommon condition in which you make too\r much growth hormone),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\"> -        sulphonamide\r antibiotics.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><span lang=\"EN-GB\">Medicines that may cause your blood sugar level to\r rise (hyperglycaemia) include:<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">-        corticosteroids\r (such as \"cortisone\" used to treat inflammation),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;text-autospace:none\"><span lang=\"EN-GB\">-        danazol\r (medicine acting on ovulation),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        diazoxide (used to treat\r high blood pressure),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        diuretics (used to treat\r high blood pressure or excessive fluid retention),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        glucagon (pancreas\r hormone used to treat severe hypoglycaemia),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        isoniazid (used to treat\r tuberculosis),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        oestrogens and\r progestogens (such as in the contraceptive pill used for birth control), <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        phenothiazine derivatives\r (used to treat psychiatric disorders),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        somatropin (growth\r hormone),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        sympathomimetic medicines\r (such as epinephrine [adrenaline], salbutamol, terbutaline used to treat\r asthma),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        thyroid hormones (used to\r treat thyroid gland disorders),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        atypical antipsychotic\r medicines (such as clozapine, olanzapine),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        protease inhibitors (used\r to treat HIV).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Your blood sugar level may either rise or fall if you take:<\/span><\/i><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        beta-blockers (used to\r treat high blood pressure),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        clonidine (used to treat\r high blood pressure),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        lithium salts (used to\r treat psychiatric disorders).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Pentamidine (used to treat some infections caused by parasites) may\r cause hypoglycaemia which may sometimes be followed by hyperglycaemia.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Beta-blockers like other sympatholytic medicines (such as clonidine,\r guanethidine, and reserpine) may weaken or suppress entirely the first warning\r symptoms which help you to recognise a hypoglycaemia. <\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">If you are not sure whether you are taking one of those medicines\r ask your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">ABASAGLAR with alcohol<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Your blood sugar levels may either rise or fall if you drink\r alcohol.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Pregnancy and breast-feeding<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Ask your doctor or pharmacist for advice before taking any medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Inform your doctor if you are planning to become pregnant, or if you\r are already pregnant. Your insulin dose may need to be changed during pregnancy\r and after giving birth. Particularly careful control of your diabetes, and\r prevention of hypoglycaemia, is important for the health of your baby.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If you are breast-feeding consult your doctor as you may require\r adjustments in your insulin doses and your diet.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Driving and using machines<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Your ability to concentrate or react may be reduced if:<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        you have hypoglycaemia\r (low blood sugar levels),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        you have hyperglycaemia\r (high blood sugar levels),<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        you have problems with\r your sight.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Keep this possible problem in mind in all situations where you might\r put yourself and others at risk (such as driving a car or using machines). You\r should contact your doctor for advice on driving if:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">-        you have frequent episodes of hypoglycaemia,<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">-        the first warning symptoms which help you to recognise\r hypoglycaemia are reduced or absent.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><b><span lang=\"EN-GB\">ABASAGLAR contains sodium<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">This medicine contains less than 1 mmol (23 mg)\r sodium per dose, which means it is essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">3.       How to use ABASAGLAR<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Always use this medicine exactly as your doctor has told you. Check\r with your doctor or pharmacist if you are not sure.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Although ABASAGLAR contains the same active substance as Toujeo\r (insulin glargine 300 units\/mL), these medicines are not interchangeable.\r The switch from one insulin therapy to another requires medical prescription,\r medical supervision and blood glucose monitoring. Please consult your doctor\r for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Dose<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Based on your life-style and the results of your blood sugar\r (glucose) tests and your previous insulin usage, your doctor will:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        determine how much ABASAGLAR\r per day you will need and at what time,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        tell you when to check\r your blood sugar level, and whether you need to carry out urine tests,<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        tell you when you may\r need to inject a higher or lower dose of ABASAGLAR.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is a long-acting insulin. Your doctor may tell you to use\r it in combination with a short-acting insulin or with tablets used to treat\r high blood sugar levels.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Many factors may influence your blood sugar level. You should know\r these factors so that you are able to react correctly to changes in your blood\r sugar level and to prevent it from becoming too high or too low. See the box at\r the end of this leaflet for further information.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Use in children and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR can be used in adolescents and children aged 2 years\r and above. Use this medicine exactly as your doctor has told you.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Frequency of administration<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">You need one injection of ABASAGLAR every day, at the same time of\r the day.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Method of administration<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is injected under the skin. Do NOT inject ABASAGLAR in a\r vein, since this will change its action and may cause hypoglycaemia.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Your doctor will show you in which area of the skin you should\r inject ABASAGLAR. With each injection, change the puncture site within the\r particular area of skin that you are using.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">How to handle the cartridges<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The ABASAGLAR cartridges are to be used only in Lilly insulin pens\r to ensure you get the correct dose. Not all of these pens may be marketed in\r your country.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pen should be used as recommended in the information provided.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The instructions for using the pen must be followed carefully for\r loading the cartridge, attaching the needle, and administering the insulin\r injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">To prevent the possible transmission of disease, each pen must be\r used by one patient only.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Look at the cartridge before you use it. Only use it if the solution\r is clear, colourless and water-like, and has no visible particles in it. Do not\r shake or mix it before use.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Always use a new cartridge if you notice that your blood sugar\r control is unexpectedly getting worse. This is because the insulin may have\r lost some of its effectiveness. If you think you may have a problem with ABASAGLAR,\r have it checked by your doctor or pharmacist.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Special care before injection<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Before injection remove any air bubbles (see instructions for using\r the pen).<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Make sure that neither alcohol nor other disinfectants or other\r substances contaminate the insulin.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not re-fill and re-use empty cartridges. Do not add any other\r insulin to the cartridge. Do not mix ABASAGLAR with any other insulins or\r medicines. Do not dilute it. Mixing or diluting may change the action of ABASAGLAR.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Problems with the insulin pen?<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Refer to the instructions for using the pen.<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><u><span lang=\"EN-GB\">If the insulin pen is damaged or not working properly (due to\r mechanical defects) it has to be discarded, and a new insulin pen has to be used.<\/span><\/u><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">If you use more ABASAGLAR than you should<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        If you <b>have injected\r too much ABASAGLAR<\/b><\/span><span lang=\"EN-GB\"> or are unsure how much you have\r injected<\/span><span lang=\"EN-GB\">, your blood sugar level may become too low\r (hypoglycaemia). Check your blood sugar frequently. In general, to prevent\r hypoglycaemia you must eat more food and monitor your blood sugar. For\r information on the treatment of hypoglycaemia, see box at the end of this\r leaflet.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">If you forget to use ABASAGLAR<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        If you have missed a dose\r of ABASAGLAR or if you have not injected enough insulin <\/span><span lang=\"EN-GB\">or are unsure how much you have injected<\/span><span lang=\"EN-GB\">,\r your blood sugar level may become too high (hyperglycaemia). Check your blood\r sugar frequently. For information on the treatment of hyperglycaemia, see box\r at the end of this leaflet.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">-        Do not take a double dose to make up for a forgotten dose.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:.55pt;line-height:normal;page-break-after:\r avoid\"><b><span lang=\"EN-GB\">After injecting<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If you are unsure how much you have injected then check your blood\r sugar levels before deciding if you need another injection.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">If you stop using ABASAGLAR<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">This could lead to severe hyperglycaemia (very high blood sugar) and\r ketoacidosis (build-up of acid in the blood because the body is breaking down\r fat instead of sugar). Do not stop ABASAGLAR without speaking to a doctor, who\r will tell you what needs to be done.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If you have any further questions on the use of this medicine, ask\r your doctor, pharmacist or nurse.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">Like all medicines, this medicine can cause side effects, although\r not everybody gets them.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><b><span lang=\"EN-GB\">If you notice signs of your blood sugar being too low\r (hypoglycaemia), <\/span><\/b><span lang=\"EN-GB\">taketheaction to\r increase your blood sugar levels <b>immediately<\/b><\/span><span lang=\"EN-GB\">. Hypoglycaemia\r (low blood sugar) can be very serious and is very common with insulin treatment\r (may affect more than 1 in 10 people). Low blood sugar means that there is not\r enough sugar in your blood. If your blood sugar level falls too low, you may\r pass out (become unconscious). Serious hypoglycaemia may cause brain damage and\r may be life-threatening. For more information, see the box at the end of this\r leaflet.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><b><span lang=\"EN-GB\">Severe allergic reactions <\/span><\/b><span lang=\"EN-GB\">(rare, may\r affect up to 1 in 1,000 people) \u2013 the signs <\/span><span lang=\"EN-GB\">may include\r large-scale skin reactions (rash and itching all over the body), severe\r swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall\r in blood pressure with rapid heartbeat and sweating. Severe allergic reactions\r to insulins may become life-threatening. Tell a doctor straight away if you\r notice signs of severe allergic reaction.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-top:0in;margin-right:0in;\r margin-bottom:10.0pt;margin-left:0in;line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Skin changes at the injection site<\/span><\/b><\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-top:0in;margin-right:0in;\r margin-bottom:10.0pt;margin-left:0in;line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If you inject insulin too often at the same place, the fatty tissue may\r shrink (lipoatrophy, may affect up to 1 in 100 people) or thicken (lipohypertrophy,\r may affect up to 1 in 10 people). Lumps under the skin may also be caused by build-up\r of a protein called amyloid (cutaneous amyloidosis, how often they occur is not\r known). The insulin may not work very well if you inject into a lumpy area. Change\r the injection site with each injection to help prevent these skin changes.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Common side effects <\/span><\/b><span lang=\"EN-GB\">(may affect up to 1\r in 10 people)<\/span><\/p> <p class=\"MsoListParagraphCxSpFirst\" style=\"margin-top:0in;margin-right:0in;\r margin-bottom:10.0pt;margin-left:0in;line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-top:0in;margin-right:0in;\r margin-bottom:10.0pt;margin-left:28.35pt;text-indent:-28.35pt;line-height:normal;\r text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\">Skin and allergic reactions at the injection\r site<\/span><\/b><\/p> <p class=\"MsoListParagraphCxSpMiddle\" style=\"margin-top:0in;margin-right:0in;\r margin-bottom:10.0pt;margin-left:28.35pt;line-height:normal;text-autospace:\r none\"><\/p> <p class=\"MsoListParagraphCxSpLast\" style=\"margin-left:0in;line-height:normal;\r text-autospace:none\"><span lang=\"EN-GB\">The signs may include reddening,\r unusually intense pain when injecting, itching, hives, swelling or\r inflammation. They can spread around the injection site. Most minor reactions\r to insulins usually disappear in a few days to a few weeks.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Rare side effects <\/span><\/b><span lang=\"EN-GB\">(may affect up to 1 in\r 1,000 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\">Eye reactions<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A marked change (improvement or worsening) in your blood sugar\r control can disturb your vision temporarily. If you have proliferative\r retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks\r may cause temporary loss of vision.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><span lang=\"EN-GB\" style=\"font-family:Symbol\">\u00b7<\/span><b><span lang=\"EN-GB\">General disorders<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In rare cases, insulin treatment may also cause temporary build-up\r of water in the body, with swelling in the calves and ankles.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Very rare side-effects <\/span><\/b><span lang=\"EN-GB\">(may affect up\r to1 in 10,000 people)<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In very rare cases, dysgeusia (taste disorders) and myalgia\r (muscular pain) can occur.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">Use in children and adolescents<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><span lang=\"EN-GB\">In general, the side effects in children and adolescents of 18 years\r of age or less are similar to those seen in adults.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-1.45pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Complaints of injection site reactions (injection site pain,\r injection site reaction) and skin reactions (rash, urticaria) are reported\r relatively more frequently in children and adolescents of 18 years of age or\r less than in adults.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">Reporting of\r side effects<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. You can also\r report side effects directly via <span style=\"background:lightgrey\">the\r national reporting system listed in<\/span> <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">. By reporting side effects you can help provide more information on\r the safety of this medicine.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-top:0in;margin-right:-.1pt;margin-bottom:0in;\r margin-left:28.35pt;margin-bottom:.0001pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.       How to store ABASAGLAR<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Keep this medicine out of the sight and reach of children.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Do not use this medicine after the expiry date which is stated on\r the carton and on the label of the cartridge after \u201cEXP\u201d. The expiry date\r refers to the last day of that month.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Unopened cartridges<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C - 8\u00b0C). Do not freeze. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not put ABASAGLAR next to the freezer compartment or a freezer\r pack. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Keep the cartridge in the outer carton in order to protect from\r light.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">In-use cartridges<\/span><\/u><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Cartridges in use (in the insulin pen) or carried as a spare may be\r stored for a maximum of 28 days up to 30\u00b0C and away from direct heat or\r direct light. The cartridge in use must not be stored in a refrigerator. Do not\r use it after this time period.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not use ABASAGLAR if you notice particles in it. Only use ABASAGLAR\r if the solution is clear, colourless and water like.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not throw away any medicines via wastewater or household waste.\r Ask your pharmacist how to throw away medicines you no longer use. These\r measures will help protect the environment.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">What ABASAGLAR contains<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        The active substance is\r insulin glargine. Each millilitre of the solution contains 100 units of\r the active substance insulin glargine (equivalent to 3.64 mg).<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        The other ingredients\r are: zinc oxide, metacresol, glycerol, sodium hydroxide (see section 2 \u201cABASAGLAR\r contains sodium\u201d), hydrochloric acid and water for injections.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal;page-break-after:\r avoid\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">What ABASAGLAR looks like and contents of the pack<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR 100 units\/mL solution for injection in a cartridge is\r a clear and colourless solution.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR comes in a special cartridge to be used only in a Lilly\r insulin pen. Each cartridge contains 3 mL of solution for injection\r (equivalent to 300 units) and they are available in packs of 5 and 10\r cartridges.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Marketing Authorisation Holder <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The\r Netherlands.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Manufacturer<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim,\r France.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\" style=\"background:lightgrey\">Eli Lilly Italia\r S.p.A., Via Gramsci 731-733, 50019 Sesto Fiorentino, (FI) Italy.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">For any information about this medicine, please contact the local\r representative of the Marketing Authorisation Holder:<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\"> <tr> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"FR\">Belgi\u00eb\/Belgique\/Belgien<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"FR\">Eli Lilly Benelux S.A.\/N.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:1.7pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"NL\">T\u00e9l\/Tel: + 32-(0)2 548 84 84<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><b><span lang=\"SV\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-22.45pt;line-height:normal;\r   page-break-after:avoid\"><span lang=\"SV\">Eli Lilly <\/span><span lang=\"BG\" style=\"color:black\">Lietuva<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"LT\">Tel. +370 (5) 2649600<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"margin-right:1.7pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"page-break-after:avoid;text-autospace:none\"><span lang=\"BG\">\u0422\u041f \"\u0415\u043b\u0438\r   \u041b\u0438\u043b\u0438\r   \u041d\u0435\u0434\u0435\u0440\u043b\u0430\u043d\u0434\"\r   \u0411.\u0412. - \u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"BG\">\u0442\u0435\u043b. +359 2 491 41 40<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Luxembourg\/Luxemburg<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Eli Lilly Benelux S.A.\/N.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"NL\">T\u00e9l\/Tel: + 32-(0)2 548 84 84<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"SV\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"CS\">ELI LILLY \u010cR, s.r.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"NL\">Tel: + 420 234 664 111<\/span><\/p> <p class=\"MsoNormal\" style=\"margin-right:1.7pt;line-height:normal;page-break-after:\r   avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"EN-GB\">Lilly Hung\u00e1ria Kft.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Tel: + 36 1 328 5100<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Danmark<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Eli Lilly Danmark A\/S <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Tlf: +45 45 26 60 00<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"FR\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"ES\">Charles de Giorgio Ltd.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"NL\">Tel: + 356 25600 500<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Deutschland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"DE\">Lilly Deutschland GmbH<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"DE\">Tel. + 49-(0) 6172 273 2222<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"DA\">Nederland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"DA\">Eli Lilly Nederland B.V. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"NL\">Tel: + 31-(0) 30 60 25 800<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"SV\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\">Eli Lilly Nederland B.V.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"ET\">Tel<\/span><span lang=\"ET\">: <\/span><span lang=\"EN-GB\">+372 6 817 280<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"DA\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"NO-NYN\">Eli Lilly Norge A.S. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"NO-NYN\">Tlf: + 47 22 88 18 00<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EL\" style=\"layout-grid-mode:line\">\u03a6\u0391\u03a1\u039c\u0391\u03a3\u0395\u03a1\u0392-\u039b\u0399\u039b\u039b\u03a5\r   \u0391.\u0395.\u0392.\u0395. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EL\" style=\"layout-grid-mode:line\">\u03a4\u03b7\u03bb: +30 210 629 4600<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"SV\">\u00d6sterreich<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"ET\">Eli Lilly Ges.m.b.H. <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"ET\">Tel: + 43-(0) 1 711 780<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"ES-TRAD\">Espa\u00f1a<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"ES\">Lilly S.A.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"ES\">Tel: + 34-91 663 50 00<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"DA\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\">Eli Lilly Polska Sp. z o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"PL\">Tel: <\/span><span lang=\"EN-GB\">+48 22 440 33 00<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">France<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"FR\">Lilly France SAS<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"FR\">T\u00e9l: +33-(0) 1 55 49 34 34<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"FR\">Portugal<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"PT\">Lilly Portugal Produtos Farmac\u00eauticos, Lda<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"NL\">Tel: + 351-21-4126600<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"><span lang=\"DA\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"DA\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"DA\">Eli Lilly Hrvatska d.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Tel: +385 1 2350 999<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"RO\">Eli Lilly Rom\u00e2nia S.R.L.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"RO\">Tel: + 40 21 4023000<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Ireland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Eli Lilly and Company (Ireland) Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Tel: + 353-(0) 1 661 4377<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"RO\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"RO\">Eli Lilly farmacevtska dru\u017eba, d.o.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"RO\">Tel: +386 (0)1 580 00 10<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"DA\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;\r   text-autospace:none\"><span lang=\"DA\">Icepharma hf.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"DA\">S\u00edmi + 354 540 8000<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"DA\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SK\">Eli Lilly Slovakia s.r.o.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SK\">Tel: <\/span><span lang=\"SK\">+ 421 220 663 111<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"ES-TRAD\">Italia<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"FI\">Eli Lilly Italia S.p.A.<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Tel: + 39- 055 42571<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"DA\">Suomi\/Finland<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"SV\">Oy Eli Lilly Finland Ab <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Puh\/Tel: + 358-(0) 9 85 45 250<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Phadisco Ltd <\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EL\">\u03a4\u03b7\u03bb<\/span><span lang=\"EN-GB\">: +357 22 715000<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"DA\">Sverige<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"DE\">Eli Lilly Sweden AB<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"DE\">Tel: + 46-(0) 8 7378800<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"SV\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"LV\" style=\"color:black\">Eli Lilly (Suisse) S.A\r   P\u0101rst\u0101vniec\u012bba Latvij\u0101<\/span><span lang=\"LV\">Tel: <\/span><b><span lang=\"NL\">+<\/span><\/b><span lang=\"NL\">371 67364000<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">United Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Eli Lilly and Company Limited<\/span><\/p> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Tel: + 44-(0) 1256 315000<\/span><\/p> <p class=\"PIbodytext\" style=\"page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"2\"><\/td> <td style=\"border:none\" width=\"310\"><\/td> <td style=\"border:none\" width=\"312\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">This leaflet was last <\/span><span lang=\"EN-GB\">revised in <\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><b><span lang=\"EN-GB\">Other sources of information<\/span><\/b><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p> <p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><span lang=\"EN-GB\">Detailed information on this medicine is available on the European\r Medicines Agency web site: <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext\">http:\/\/www.ema.europa.eu<\/span><\/a><\/span><span lang=\"EN-GB\">. <\/span><\/p> <\/div>","ID":"c3fea244-c576-484b-8378-4d1a65545a06","Styles":"None","Classes":"['WordSection1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ","ParentId":"4b88c602-7d35-4023-b69a-a14a2a9fabd1"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"27b00bab-377b-4af4-afdd-cfb8fe0c1f33","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"a18c1653-c76b-4817-9d0e-5ec305ac8a40","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"58668269-9081-4b4a-a575-29530b3a81de","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"0352194b-a175-4cc1-9413-8a7fbcf0b5c6","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"846e7c50-fed9-4dd0-a0f9-b2e1dee93a40","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"b472f497-1ec7-4d01-91d6-5a5e6f7ffc1c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"106d6ae1-9e4e-4d29-a2c3-44bcccde9798","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"7c66c710-d6e2-47ae-a520-bdc5e029631e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"4f8e0744-544d-43f5-8fb4-5b0109ff5fa0","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"087d4143-ff95-49c2-988a-ec1e29cdc1b6","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"4d0cf818-da2f-458a-a9d7-6d5c5f96ec62","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"bb302856-7119-4c37-a48e-88281b1f0e2a","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"37fa76b6-44c3-48c9-b9b9-784e20dc310c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"0de77e8e-7675-45a2-9867-e47229eb62a1","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"cb4a808b-3bad-497c-837c-96d78dcb2d11","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"a385ed5e-3d69-4e58-8753-90a2bf1b54be","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"6e81fcf2-9e3f-480f-a24f-54b5d9583c90","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"dd5f19b2-cf5b-4f5d-88c0-9f09a59750fe","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"5971bbad-cc7a-4b3d-a119-9239a9019909","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"5caaa55c-e18e-4e6c-b2fe-8f2e181588d7","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"01bba073-b0c0-440e-af7c-fe8cd53afa4d","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"5e60aa24-3e84-43b6-a27c-4787ce4256a4","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"52eea4d1-c069-4023-9b3d-56c21237ff74","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p align=\"center\" class=\"MsoNormal\" style=\"text-align:center\"><b><span lang=\"EN-GB\">ANNEX\r I<\/span><\/b><\/p>","ID":"0d20b3ea-9f01-4400-964e-f1572f570878","Styles":"text-align:center","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ANNEX\r I","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"TitleA\"><\/p>","ID":"5bdc438d-9f1e-434d-b4cb-5389a9d5b31a","Styles":"None","Classes":"['TitleA']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"TitleA\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/p>","ID":"5e029ce5-806f-4f23-b3a6-daeacca079d4","Styles":"None","Classes":"['TitleA']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"SUMMARY OF PRODUCT CHARACTERISTICS","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"3403b310-2fc6-43b8-ac8d-71ce860fdc06","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":" ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"23541ef5-7235-4ca3-9020-6d3d5f6cca20","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"3403b310-2fc6-43b8-ac8d-71ce860fdc06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">1.       NAME OF <\/span><\/b><b><span lang=\"EN-GB\">THE\r MEDICINAL PRODUCT<\/span><\/b><\/p>","ID":"7a7679a6-06b3-4713-bbe7-d43a318b23ae","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"1.       NAME OF THE\r MEDICINAL PRODUCT","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"5a2dbc83-47c2-46ec-86c0-351cff68e9f2","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR<\/span><span lang=\"EN-GB\"> 100 units\/mL solution for\r injection in a cartridge<\/span><\/p>","ID":"b828c754-ea37-4159-8a95-6248a0934921","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR 100 units\/mL solution for\r injection in a cartridge","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"0fe4ff18-0331-4a69-a835-220b686557f4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"d261b628-b5d0-4dfd-a20a-ed81e978d906","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION<\/span><\/b><\/p>","ID":"198a078a-94ac-4b3b-b21b-6b4a48785807","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"2.       QUALITATIVE AND QUANTITATIVE COMPOSITION","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"8d97e1d5-2e64-441d-9c17-5641919a6f2b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each mL\r contains 100 units insulin glargine* (equivalent to 3.64 mg). <\/span><\/p>","ID":"9f8f7a90-6679-4417-9d74-db07363a64e2","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Each mL\r contains 100 units insulin glargine* (equivalent to 3.64 mg). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><\/p>","ID":"6f7f5983-e737-411f-8732-218641da243e","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Each cartridge contains 3 mL of solution for injection,\r equivalent to 300 units. <\/span><\/p>","ID":"12b920ad-a4f6-4f37-a576-fc42aabff323","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Each cartridge contains 3 mL of solution for injection,\r equivalent to 300 units. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><\/p>","ID":"e20cc4e3-ceff-4428-86a9-3bd7a6a22a42","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">*produced by recombinant DNA technology in <i>Escherichia coli<\/i>. <\/span><\/p>","ID":"0090b1ca-2c02-428f-982b-5dd84ee3445b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"*produced by recombinant DNA technology in Escherichia coli. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b6706885-a208-4c0b-81c8-81dc84a9d405","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For the full list of excipients, see section 6.1.<\/span><\/p>","ID":"243c27c7-b66c-47ce-acf0-1470b86ba92d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For the full list of excipients, see section 6.1.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"4423c11c-3205-48e3-81f9-6d4fcdefc916","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"ffe9bca8-3e60-40e2-8a33-d88f722d8877","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/b><\/p>","ID":"4684d071-f259-4fed-bbeb-d27df18b7bf7","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"3.       PHARMACEUTICAL FORM","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"d57fe2ba-76da-4c38-8a8e-dc0d862ca44a","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Solution for\r injection (injection).<\/span><\/p>","ID":"bfd3c111-d8f8-4b28-b057-033c8287d2c1","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Solution for\r injection (injection).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"1c5dc7aa-ba80-41ed-8570-ef81a57fe0e1","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Clear,\r colourless solution.<\/span><\/p>","ID":"e1623036-fe6e-4e8f-9695-7f18f42f5e27","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Clear,\r colourless solution.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"638a4684-f572-4da2-9b67-c592f1f88e11","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"ed2f37ae-24d0-4d32-b743-b7039b620d68","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><\/b><b><span lang=\"EN-GB\">CLINICAL PARTICULARS<\/span><\/b><\/p>","ID":"488c247d-e04d-4530-8717-2c20705d69f1","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.       CLINICAL PARTICULARS","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"c3bcd759-c5a9-4adc-886b-5af43ccf16dc","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/b><\/p>","ID":"0436938b-d0a1-4ef2-b022-4e069b5bdfaa","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.1     Therapeutic indications","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"5ef666e8-1a5f-4ee9-96e5-cd7689a2d0d6","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Treatment of diabetes mellitus in adults, adolescents and children\r aged 2 years and above.<\/span><\/p>","ID":"b60c4c2d-4f01-4582-8467-abd519504dad","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Treatment of diabetes mellitus in adults, adolescents and children\r aged 2 years and above.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"6441cb8b-73e3-4785-8740-7d8055250f48","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">4.2     Posology\r and method of administration<\/span><\/b><\/p>","ID":"a5f9bb26-19ff-4c69-9051-991ededa6675","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.2     Posology\r and method of administration","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b1588015-04a3-4824-a0a4-5f54253ddfa9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p>","ID":"4480b6f0-9d57-42bc-852b-5e348c9afb7e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Posology","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"bed72de8-91b2-40d2-8503-e6b819423566","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR contains insulin glargine, an insulin analogue and has a\r prolonged duration of action. <\/span><\/p>","ID":"b3ecfc11-db9f-4649-847a-4773a14d2a8d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR contains insulin glargine, an insulin analogue and has a\r prolonged duration of action. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"df10b920-e6d5-4ff2-b0b7-6e550091388f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR should be administered once daily at any time but at the\r same time each day. <\/span><\/p>","ID":"9ff4b36a-1374-4723-9f4b-2bbd6f4894ee","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR should be administered once daily at any time but at the\r same time each day. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"90249d1e-9ff8-4165-aea0-99d51510ce67","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The dose regimen (dose and timing) should be individually adjusted.\r In patients with type 2 diabetes mellitus, ABASAGLAR can also be given\r together with orally active antidiabetic medicinal products. <\/span><\/p>","ID":"3d385f9a-d492-4de6-8936-9060efdfddf7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The dose regimen (dose and timing) should be individually adjusted.\r In patients with type 2 diabetes mellitus, ABASAGLAR can also be given\r together with orally active antidiabetic medicinal products. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"3473acbf-c7de-4f5c-8c6a-a97243afd322","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The potency of this medicinal product is stated in units. These\r units are exclusive to insulin glargine and are not the same as IU or the units\r used to express the potency of other insulin analogues (see section 5.1). <\/span><\/p>","ID":"c0382d71-b961-4b9c-9e91-acefb54a311d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The potency of this medicinal product is stated in units. These\r units are exclusive to insulin glargine and are not the same as IU or the units\r used to express the potency of other insulin analogues (see section 5.1). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"078dc6aa-2a14-49de-adb4-82eb836f64f5","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/i><\/p>","ID":"f749447f-5197-4e7d-b68b-050d0c07de51","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Special populations","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"8b33cb7f-0294-4b14-8cad-06ae15c717ed","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Elderly population (\u226565 years old)<\/span><\/i><\/p>","ID":"fbeea783-9b44-4145-ae04-ef7c079b8a6a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Elderly population (\u226565 years old)","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In the elderly, progressive deterioration of renal function may lead\r to a steady decrease in insulin requirements.<\/span><\/p>","ID":"b7a99acc-f32d-4a72-8764-a249360e0ba6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In the elderly, progressive deterioration of renal function may lead\r to a steady decrease in insulin requirements.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b76a7420-7aec-41c1-828d-9699666e15fc","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"8dca5a90-337b-4d71-832a-42d51ab004fd","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Renal impairment","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">In patients with renal impairment, insulin requirements\r may be diminished due to reduced insulin metabolism.<\/span><\/p>","ID":"563226b4-3ee0-49b1-ba8e-30117dd3624a","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In patients with renal impairment, insulin requirements\r may be diminished due to reduced insulin metabolism.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"ee99e08f-89e0-47bd-bfd4-51c5e9a4f15e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p>","ID":"02546f87-2d75-4c8b-b39e-39ed617e7636","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hepatic impairment","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In patients with hepatic impairment, insulin requirements may be\r diminished due to reduced capacity for gluconeogenesis and reduced insulin\r metabolism.<\/span><\/p>","ID":"b264d02e-4a81-4c10-9f2c-97fa01937aac","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In patients with hepatic impairment, insulin requirements may be\r diminished due to reduced capacity for gluconeogenesis and reduced insulin\r metabolism.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"732cfebe-158e-4912-85dc-7fcd22438f1f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p>","ID":"2022d66e-74e4-44c2-bd98-89a5a9b5a663","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Paediatric population","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"77d717a8-b77f-4734-8d0f-8cbf186b1437","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Adolescents and children aged 2 years and older<\/span><\/i><\/p>","ID":"99ca9ed1-12f5-4f9c-ac65-412022733dab","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Adolescents and children aged 2 years and older","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The safety and efficacy of insulin glargine have been established in\r adolescents and children aged 2 years and older (see section 5.1). The\r dose regimen (dose and timing) should be individually adjusted. <\/span><\/p>","ID":"e06f6aa9-3530-4fef-a42c-e4fb58b8e22e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The safety and efficacy of insulin glargine have been established in\r adolescents and children aged 2 years and older (see section 5.1). The\r dose regimen (dose and timing) should be individually adjusted. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"d7a97479-cdac-4d5d-bdcf-d6440febce90","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Children below 2 years of age<\/span><\/i><\/p>","ID":"b3cbf5da-f3a9-4815-a65d-05c53165a60e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Children below 2 years of age","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The safety and efficacy of insulin glargine have not been\r established No data are available. <\/span><\/p>","ID":"3c92ed9c-5832-41a7-b91f-06bbe5db25e9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The safety and efficacy of insulin glargine have not been\r established No data are available. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"7a7aad1e-4c18-4e4c-8c77-4d150a41d64b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Switch from other insulins to ABASAGLAR<\/span><\/u><\/i><\/p>","ID":"a335e174-ca53-4337-ab37-55b2364fffa6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Switch from other insulins to ABASAGLAR","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"f149a2f0-ac4e-46a1-8f12-0deb1d87523e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">When switching from\r a treatment regimen with an intermediate or long-acting insulin to a regimen\r with ABASAGLAR, a change of the dose of the basal insulin may be required and\r the concomitant antidiabetic treatment may need to be adjusted (dose and timing\r of additional regular insulins or fast-acting insulin analogues or the dose of\r oral antidiabetic medicinal products). <\/span><\/p>","ID":"cd12191a-b4a7-4a02-a8ed-5caffc6169ef","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"When switching from\r a treatment regimen with an intermediate or long-acting insulin to a regimen\r with ABASAGLAR, a change of the dose of the basal insulin may be required and\r the concomitant antidiabetic treatment may need to be adjusted (dose and timing\r of additional regular insulins or fast-acting insulin analogues or the dose of\r oral antidiabetic medicinal products). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"11dd805c-4115-437d-be67-1db9fbb48f6c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Switch from twice daily NPH insulin to ABASAGLAR<\/span><\/u><\/i><\/p>","ID":"d1629101-dc94-44bc-b82f-8021a284a8fb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Switch from twice daily NPH insulin to ABASAGLAR","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"528fef78-c10f-4bf3-b203-7c6d4c4fd9b0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">To reduce the risk of nocturnal and early morning hypoglycaemia,\r patients who are changing their basal insulin regimen from a twice daily NPH\r insulin to a once daily regimen with ABASAGLAR should reduce their daily dose\r of basal insulin by 20-30 % during the first weeks of treatment. <\/span><\/p>","ID":"89654901-3433-4039-a26c-926dc550bf68","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"To reduce the risk of nocturnal and early morning hypoglycaemia,\r patients who are changing their basal insulin regimen from a twice daily NPH\r insulin to a once daily regimen with ABASAGLAR should reduce their daily dose\r of basal insulin by 20-30 % during the first weeks of treatment. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"4fae6824-f869-4717-8cf6-0514092692b6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Switch\r from insulin glargine 300 units\/ml to ABASAGLAR<\/span><\/u><\/i><\/p>","ID":"21bf62b0-eae4-4d53-9376-8318f96fbda4","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Switch\r from insulin glargine 300 units\/ml to ABASAGLAR","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"68fa8caa-1532-4f1b-824f-aefbe881b480","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR and\r Toujeo (insulin glargine 300 units\/ml) are not bioequivalent and are not directly\r interchangeable. To reduce the risk of hypoglycemia, patients who are changing\r their basal insulin regimen from an insulin regimen with once daily insulin\r glargine 300 units\/ml to a once daily regimen with ABASAGLAR should reduce\r their dose by approximately 20%.<\/span><\/p>","ID":"b8341411-2619-4c59-9ad1-09a56826d19a","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR and\r Toujeo (insulin glargine 300 units\/ml) are not bioequivalent and are not directly\r interchangeable. To reduce the risk of hypoglycemia, patients who are changing\r their basal insulin regimen from an insulin regimen with once daily insulin\r glargine 300 units\/ml to a once daily regimen with ABASAGLAR should reduce\r their dose by approximately 20%.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"92f2ade4-1bae-40be-b4ac-8961f108c87a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">During the first weeks the reduction should, at least partially, be\r compensated by an increase in mealtime insulin, after this period the regimen\r should be adjusted individually. <\/span><\/p>","ID":"f8344257-3593-4834-8aae-0fc562231ceb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"During the first weeks the reduction should, at least partially, be\r compensated by an increase in mealtime insulin, after this period the regimen\r should be adjusted individually. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"3668170c-2153-47f2-b8db-999e0338c56f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Close metabolic monitoring is recommended during the switch and in\r the initial weeks thereafter. <\/span><\/p>","ID":"9e770358-e625-4c34-8dac-b6d7d6ae096f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Close metabolic monitoring is recommended during the switch and in\r the initial weeks thereafter. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">With improved metabolic control and resulting increase in insulin\r sensitivity a further adjustment in dose regimen may become necessary. Dose\r adjustment may also be required, for example, if the patient's weight or\r life-style changes, change of timing of insulin dose or other circumstances\r arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see\r section 4.4). <\/span><\/p>","ID":"07dcc49f-6cf2-4f9e-a289-bed7b5929207","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"With improved metabolic control and resulting increase in insulin\r sensitivity a further adjustment in dose regimen may become necessary. Dose\r adjustment may also be required, for example, if the patient's weight or\r life-style changes, change of timing of insulin dose or other circumstances\r arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see\r section 4.4). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"c293fe49-322d-4882-81ba-5a3f794bf266","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients with high insulin doses because of antibodies to human\r insulin may experience an improved insulin response with ABASAGLAR.<\/span><\/p>","ID":"4d1187da-0e21-4a70-822b-ca8fcf9bd2aa","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Patients with high insulin doses because of antibodies to human\r insulin may experience an improved insulin response with ABASAGLAR.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"97e3ccc7-4a23-4fd5-93a1-745856602ec8","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Method of administration<\/span><\/u><\/p>","ID":"02dd1a52-ef0f-497a-adec-c9b778762c12","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Method of administration","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"caa57104-be0b-43c2-a4f9-5238df9ceb16","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is administered subcutaneously.<\/span><\/p>","ID":"7ca3834d-658e-46ea-8bd9-67a11cde1d8a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR is administered subcutaneously.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"ba455cc0-ca16-4fff-b2bb-5317f042cac2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR should not be administered intravenously. The prolonged\r duration of action of insulin glargine is dependent on its injection into\r subcutaneous tissue. Intravenous administration of the usual subcutaneous dose\r could result in severe hypoglycaemia.<\/span><\/p>","ID":"0a84d113-c0f8-40f0-95ca-a18284d7251c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR should not be administered intravenously. The prolonged\r duration of action of insulin glargine is dependent on its injection into\r subcutaneous tissue. Intravenous administration of the usual subcutaneous dose\r could result in severe hypoglycaemia.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"ed2c1469-6310-47bc-9c08-575ab521f985","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">There are no clinically relevant differences in serum insulin or\r glucose levels after abdominal, deltoid or thigh administration of insulin\r glargine. <\/span><\/p>","ID":"8e2c9e06-de59-498e-85fb-61d6b81325c9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"There are no clinically relevant differences in serum insulin or\r glucose levels after abdominal, deltoid or thigh administration of insulin\r glargine. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"a1279c51-0462-4607-888f-e04f522480d6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Injection sites should always be rotated within the same region in\r order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see\r section 4.4 and 4.8).<\/span><\/p>","ID":"5a08606a-607b-47be-a1f0-4da6ab538bdd","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Injection sites should always be rotated within the same region in\r order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see\r section 4.4 and 4.8).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"3cd82dbe-26e9-4138-96a0-f3f2149debd3","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR must not be mixed with any other insulin or diluted.\r Mixing or diluting can change its time\/action profile and mixing can cause\r precipitation. <\/span><\/p>","ID":"d4be86d8-cd3c-41c0-8308-c1f9993f46b2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR must not be mixed with any other insulin or diluted.\r Mixing or diluting can change its time\/action profile and mixing can cause\r precipitation. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"d6c5d297-0192-411e-9b40-a485eeb83ac5","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For further details on handling, see section 6.6.<\/span><\/p>","ID":"a8b09031-199d-4b77-8e68-b01c8e7c3b72","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For further details on handling, see section 6.6.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"6e401d9c-51d9-4c9c-be7a-793a2266e34d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/b><\/p>","ID":"9a6a0d28-9309-46d1-ad22-0ac46f0b6d03","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.3     Contraindications","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"696825de-c556-47b3-bdd1-9ead7d41e73e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Hypersensitivity to the active substance or to any of the excipients\r listed in section 6.1.<\/span><\/p>","ID":"7b88c8f8-9cd5-44b7-8858-175f140ed4b7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hypersensitivity to the active substance or to any of the excipients\r listed in section 6.1.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"d9e31e14-653f-40f1-974f-9cc1eadb176b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.4     Special warnings and precautions for use<\/span><\/b><\/p>","ID":"6f1f74ab-34f3-4886-b591-c3cc99fab183","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.4     Special warnings and precautions for use","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p>","ID":"6aa9cd5d-ba38-43b8-ab19-6997e98cf3b7","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Traceability<\/span><\/u><\/p>","ID":"ef0d0048-7f5c-4001-91af-abdc732cd797","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Traceability","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e06c41f4-4bad-498b-aad0-1cbb4dbffdf1","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered product should be clearly recorded.<\/span><\/p>","ID":"ed0fcea6-6d51-471f-bae9-3199249c7ad2","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered product should be clearly recorded.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p>","ID":"8646f1b1-e213-45e1-8ee0-e46369f07dfe","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Diabetic ketoacidosis<\/span><\/u><\/p>","ID":"dc252319-76a7-4dcc-8b1d-a7761ab3545c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Diabetic ketoacidosis","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"7e6cd2d2-ae91-452f-8db4-7b75582acf46","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is not the insulin of choice for the treatment of diabetic\r ketoacidosis. Instead, regular insulin administered intravenously is\r recommended in such cases. <\/span><\/p>","ID":"9cea18d4-5806-46e4-bbed-3dbf0821bd43","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR is not the insulin of choice for the treatment of diabetic\r ketoacidosis. Instead, regular insulin administered intravenously is\r recommended in such cases. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"8b512e67-a7af-43ef-96ea-a8ec3b5744ec","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><a name=\"_Hlk38983853\"><u><span lang=\"EN-GB\">Insulin requirements and dose\r adjustments<\/span><\/u><\/a><\/p>","ID":"61422bf4-c9d8-4e10-8d4e-46b90663553c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin requirements and dose\r adjustments","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"fc7b9040-d8f4-437d-9bf9-371607a56e69","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In case of insufficient glucose control or a tendency to hyperglycaemic\r or hypoglycaemic episodes, the patient's adherence to the prescribed treatment\r regimen, injection sites and proper injection technique and all other relevant\r factors must be reviewed before dose adjustment is considered.<\/span><\/p>","ID":"997752a3-9e35-44e1-a119-42d964f86ffa","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In case of insufficient glucose control or a tendency to hyperglycaemic\r or hypoglycaemic episodes, the patient's adherence to the prescribed treatment\r regimen, injection sites and proper injection technique and all other relevant\r factors must be reviewed before dose adjustment is considered.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"63564754-4c32-4f41-9fe8-b2451492b70a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Transferring a patient to another type or brand of insulin should be\r done under strict medical supervision. Changes in strength, brand\r (manufacturer), type (regular, NPH, lente, long\u2011acting, etc.), origin\r (animal, human, human insulin analogue) and\/or method of manufacture may result\r in the need for a change in dose.<\/span><\/p>","ID":"d5dde78a-84b3-4c86-928a-032842d56c5d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Transferring a patient to another type or brand of insulin should be\r done under strict medical supervision. Changes in strength, brand\r (manufacturer), type (regular, NPH, lente, long\u2011acting, etc.), origin\r (animal, human, human insulin analogue) and\/or method of manufacture may result\r in the need for a change in dose.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"6306bda0-d2b9-4a1c-bf25-8dbb81637580","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/u><\/p>","ID":"b2ec2112-0493-4cab-8a7b-58abbc0a0f93","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hypoglycaemia","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"020dd5bf-b832-4bb8-a153-41001bcf2040","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The time of occurrence of hypoglycaemia depends on the action\r profile of the insulins used and may, therefore, change when the treatment\r regimen is changed. Due to more sustained basal insulin supply with insulin\r glargine, less nocturnal but more early morning hypoglycaemia can be expected.<\/span><\/p>","ID":"33074938-66c2-4657-8e88-4f649a446d03","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The time of occurrence of hypoglycaemia depends on the action\r profile of the insulins used and may, therefore, change when the treatment\r regimen is changed. Due to more sustained basal insulin supply with insulin\r glargine, less nocturnal but more early morning hypoglycaemia can be expected.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"935c491b-09cc-453b-831c-bf3a825b01c9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Particular caution should be exercised, and intensified blood\r glucose monitoring is advisable in patients in whom hypoglycaemic episodes\r might be of particular clinical relevance, such as in patients with significant\r stenoses of the coronary arteries or of the blood vessels supplying the brain\r (risk of cardiac or cerebral complications of hypoglycaemia) as well as in\r patients with proliferative retinopathy, particularly if not treated with\r photocoagulation (risk of transient amaurosis following hypoglycaemia). <\/span><\/p>","ID":"36f133d7-42cc-4b5d-9f18-822589670cb3","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Particular caution should be exercised, and intensified blood\r glucose monitoring is advisable in patients in whom hypoglycaemic episodes\r might be of particular clinical relevance, such as in patients with significant\r stenoses of the coronary arteries or of the blood vessels supplying the brain\r (risk of cardiac or cerebral complications of hypoglycaemia) as well as in\r patients with proliferative retinopathy, particularly if not treated with\r photocoagulation (risk of transient amaurosis following hypoglycaemia). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1dcef088-12e5-4aee-8c30-4e9565146651","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients should be aware of circumstances where warning symptoms of\r hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be\r changed, be less pronounced or be absent in certain risk groups. These include\r patients:<\/span><\/p>","ID":"8ed658f3-2f55-4937-b76b-d5f7738c0f8b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Patients should be aware of circumstances where warning symptoms of\r hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be\r changed, be less pronounced or be absent in certain risk groups. These include\r patients:","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom glycaemic control\r is markedly improved,<\/span><\/p>","ID":"e0683bfd-dea6-4e89-824d-046cb6781f4d","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        in whom glycaemic control\r is markedly improved,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom hypoglycaemia\r develops gradually,<\/span><\/p>","ID":"18af5886-e411-46be-bcb2-f188e8df8347","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        in whom hypoglycaemia\r develops gradually,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        who are elderly,<\/span><\/p>","ID":"d89da858-c48a-4aed-97de-05902daf8a69","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        who are elderly,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        after transfer from\r animal insulin to human insulin,<\/span><\/p>","ID":"5bb7e593-cb53-4566-8a6b-ca823e8c94d5","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        after transfer from\r animal insulin to human insulin,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom an autonomic\r neuropathy is present,<\/span><\/p>","ID":"2ee13e10-88a0-4a51-a1d5-774ab2d15fd4","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        in whom an autonomic\r neuropathy is present,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        with a long history of\r diabetes,<\/span><\/p>","ID":"df721a50-3e55-4fb3-9d2e-89672ced9dca","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        with a long history of\r diabetes,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        suffering from a\r psychiatric illness,<\/span><\/p>","ID":"e763c102-06b5-44d1-9553-9ec59626023c","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        suffering from a\r psychiatric illness,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        receiving concurrent\r treatment with certain other medicinal products (see section 4.5).<\/span><\/p>","ID":"2ffdc0ea-e9ca-4f67-8f18-ac967edd975f","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        receiving concurrent\r treatment with certain other medicinal products (see section 4.5).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"7ed1b0c0-be6a-4f8a-807a-850e40b22465","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Such situations may result in severe hypoglycaemia (and possibly\r loss of consciousness) prior to the patient's awareness of hypoglycaemia.<\/span><\/p>","ID":"e6024651-872c-4535-9b57-24611a92e425","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Such situations may result in severe hypoglycaemia (and possibly\r loss of consciousness) prior to the patient's awareness of hypoglycaemia.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"ce92b029-2398-4372-9556-6d2467e8cc11","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The prolonged effect of subcutaneous insulin glargine may delay\r recovery from hypoglycaemia.<\/span><\/p>","ID":"7fef32bb-5f96-4fac-9495-e41b68e17647","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The prolonged effect of subcutaneous insulin glargine may delay\r recovery from hypoglycaemia.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"d8d4b70a-e145-4f19-aace-d131863d00bb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If normal or decreased values for glycated haemoglobin are noted,\r the possibility of recurrent, unrecognised (especially nocturnal) episodes of\r hypoglycaemia must be considered. <\/span><\/p>","ID":"d33b7f83-61d8-458b-8fa0-9ef2190370ae","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"If normal or decreased values for glycated haemoglobin are noted,\r the possibility of recurrent, unrecognised (especially nocturnal) episodes of\r hypoglycaemia must be considered. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"054f0f12-7603-4237-8946-5825a7726eac","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Adherence of the patient to the dose and dietary regimen, correct\r insulin administration and awareness of hypoglycaemia symptoms are essential to\r reduce the risk of hypoglycaemia. Factors increasing the susceptibility to\r hypoglycaemia require particularly close monitoring and may necessitate dose\r adjustment. These include:<\/span><\/p>","ID":"08a5a31b-2d2e-4717-97c4-8091aa28818a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Adherence of the patient to the dose and dietary regimen, correct\r insulin administration and awareness of hypoglycaemia symptoms are essential to\r reduce the risk of hypoglycaemia. Factors increasing the susceptibility to\r hypoglycaemia require particularly close monitoring and may necessitate dose\r adjustment. These include:","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        change in the injection\r area,<\/span><\/p>","ID":"d75ac333-5a8c-4be3-9803-6b864f25355b","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        change in the injection\r area,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        improved insulin\r sensitivity (e.g., by removal of stress factors),<\/span><\/p>","ID":"63d848b9-4365-441f-9f58-5bc0c6f97dd1","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        improved insulin\r sensitivity (e.g., by removal of stress factors),","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        unaccustomed, increased\r or prolonged physical activity,<\/span><\/p>","ID":"76c80b53-596a-496a-ba51-4f9a54f6aca3","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        unaccustomed, increased\r or prolonged physical activity,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        intercurrent illness\r (e.g. vomiting, diarrhoea),<\/span><\/p>","ID":"158ade2a-b47c-4d14-9559-5369cb825cd8","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        intercurrent illness\r (e.g. vomiting, diarrhoea),","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        inadequate food intake,<\/span><\/p>","ID":"f237d458-c631-4440-8c4c-a33704e056b1","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        inadequate food intake,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        missed meals,<\/span><\/p>","ID":"6c4248bb-4e9a-4782-bbda-5293e1c97289","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        missed meals,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        alcohol consumption,<\/span><\/p>","ID":"9c2418f1-cd03-4036-8e32-919abc7aba4d","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        alcohol consumption,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        certain uncompensated\r endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or\r adrenocortical insufficiency),<\/span><\/p>","ID":"6a2eca1a-faa8-4608-9bae-5bfce9119fd5","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        certain uncompensated\r endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or\r adrenocortical insufficiency),","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        concomitant treatment\r with certain other medicinal products.<\/span><\/p>","ID":"896d119b-bb9e-4220-a610-2bd932f6d89a","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        concomitant treatment\r with certain other medicinal products.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"24cd416c-5fea-4e4d-81bb-b552ad14a34f","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Injection\r technique<\/span><\/u><\/p>","ID":"3fddb1c8-4f7f-4340-9f2c-1e672fcd302f","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Injection\r technique","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"9d8970d7-7cb3-4928-87cc-5b4f9c87e3fa","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients must be instructed to perform\r continuous rotation of the injection site to reduce the risk of developing\r lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed\r insulin absorption and worsened glycaemic control following insulin injections\r at sites with these reactions. A sudden change in the injection site to an\r unaffected area has been reported to result in hypoglycaemia. Blood glucose\r monitoring is recommended after the change in the injection site, and dose\r adjustment of antidiabetic medications may be considered.<\/span><\/p>","ID":"6d3b60d6-1a67-4bc5-9b34-90f6700409d5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Patients must be instructed to perform\r continuous rotation of the injection site to reduce the risk of developing\r lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed\r insulin absorption and worsened glycaemic control following insulin injections\r at sites with these reactions. A sudden change in the injection site to an\r unaffected area has been reported to result in hypoglycaemia. Blood glucose\r monitoring is recommended after the change in the injection site, and dose\r adjustment of antidiabetic medications may be considered.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"bd4bcc23-d875-48d9-ab48-786bf16be5f5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Intercurrent illness<\/span><\/u><\/p>","ID":"07776e46-73f8-4fc4-9fa8-c1ab07885f06","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Intercurrent illness","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"4101f055-03a3-4d37-a55b-80e0a418e0e1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Intercurrent illness requires intensified metabolic monitoring. In\r many cases urine tests for ketones are indicated, and often it is necessary to\r adjust the insulin dose. The insulin requirement is often increased. Patients\r with type 1 diabetes must continue to consume at least a small amount of\r carbohydrates on a regular basis, even if they are able to eat only little or\r no food, or are vomiting etc. and they must never omit insulin entirely. <\/span><\/p>","ID":"b8d447ee-ddde-4c8d-8956-353e96a87a73","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Intercurrent illness requires intensified metabolic monitoring. In\r many cases urine tests for ketones are indicated, and often it is necessary to\r adjust the insulin dose. The insulin requirement is often increased. Patients\r with type 1 diabetes must continue to consume at least a small amount of\r carbohydrates on a regular basis, even if they are able to eat only little or\r no food, or are vomiting etc. and they must never omit insulin entirely. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"caa2b486-1cca-4bb6-8612-fefd5f84351c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Insulin antibodies<\/span><\/u><\/p>","ID":"e4c9734a-2028-4093-8d68-793f08a0d336","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin antibodies","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1f385f39-d2f0-47bc-8bbd-c71893a3e867","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin administration may cause insulin antibodies to form. In rare\r cases, the presence of such insulin antibodies may necessitate adjustment of\r the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see\r section 5.1).<\/span><\/p>","ID":"6ee87bcb-02e7-4ee1-867f-b72cfcdc5e3a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin administration may cause insulin antibodies to form. In rare\r cases, the presence of such insulin antibodies may necessitate adjustment of\r the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see\r section 5.1).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"1e9bba79-b8b7-4890-aaf6-1aba06c3555b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Pens to be used with ABASAGLAR cartridges <\/span><\/u><\/p>","ID":"b3c65425-7730-434d-916b-552999c07843","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Pens to be used with ABASAGLAR cartridges ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"a22a00ca-3d93-4618-ba14-6ce478c7255c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The cartridges should only be used in conjunction with a Lilly reusable\r insulin pen and should not be used with any other reusable pen as the dosing\r accuracy has not been established with other pens. <\/span><\/p>","ID":"f5e4ee8e-c235-4e84-b5ec-dc504d82420e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The cartridges should only be used in conjunction with a Lilly reusable\r insulin pen and should not be used with any other reusable pen as the dosing\r accuracy has not been established with other pens. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"69b7152c-3bea-4a02-8704-25c3d3cb94cd","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Medication errors<\/span><\/u><\/p>","ID":"c67f99e6-4e67-4893-8d3b-b9bb580f2640","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Medication errors","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"d4da567b-889d-4fae-b46a-854193e61292","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Medication\r errors have been reported in which other insulins, particularly short\u2011acting\r insulins, have been accidentally administered instead of insulin glargine.\r Insulin label must always be checked before each injection to avoid medication\r errors between ABASAGLAR and other insulins.<\/span><\/p>","ID":"36fb5dfd-a183-48b8-a8e3-898181eeb190","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Medication\r errors have been reported in which other insulins, particularly short\u2011acting\r insulins, have been accidentally administered instead of insulin glargine.\r Insulin label must always be checked before each injection to avoid medication\r errors between ABASAGLAR and other insulins.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"a6478dd3-621d-481d-a65f-6123c78e284e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Combination of ABASAGLAR with pioglitazone<\/span><\/u><\/p>","ID":"412d1378-9923-4b4d-a8b8-49b5c450567c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Combination of ABASAGLAR with pioglitazone","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"1d275801-9fe9-4993-9db9-de578746a874","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Cases of cardiac\r failure have been reported when pioglitazone was used in combination with\r insulin, especially in patients with risk factors for development of cardiac\r heart failure. This should be kept in mind if treatment with the combination of\r pioglitazone and ABASAGLAR is considered. If the combination is used, patients\r should be observed for signs and symptoms of heart failure, weight gain and\r oedema. Pioglitazone should be discontinued if any deterioration in cardiac\r symptoms occurs.<\/span><\/p>","ID":"ae299c3a-f2b7-4510-be19-c8ebcbbfe13e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Cases of cardiac\r failure have been reported when pioglitazone was used in combination with\r insulin, especially in patients with risk factors for development of cardiac\r heart failure. This should be kept in mind if treatment with the combination of\r pioglitazone and ABASAGLAR is considered. If the combination is used, patients\r should be observed for signs and symptoms of heart failure, weight gain and\r oedema. Pioglitazone should be discontinued if any deterioration in cardiac\r symptoms occurs.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"0b6a01b1-3a10-4c29-a818-52f39d9da636","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Sodium\r content<\/span><\/u><\/p>","ID":"4b7695a1-6468-4362-87ae-1858ceb4d96c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Sodium\r content","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"cef25a9b-ed53-4d6a-845a-fd3d7f3b9a6f","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">This medicinal product contains less than 1 mmol sodium\r (23 mg) per dose, i.e., essentially \u201csodium\u2011free\u201d.<\/span><\/p>","ID":"57930b6d-04ce-42ab-849b-aaca90356418","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"This medicinal product contains less than 1 mmol sodium\r (23 mg) per dose, i.e., essentially \u201csodium\u2011free\u201d.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"b82b8c25-68a6-4cb5-8a7d-7a9f33442d93","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.5     Interaction with other medicinal products\r and other forms of interaction<\/span><\/b><\/p>","ID":"3f09f2b8-e2fe-4491-b396-2adb7d1876de","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.5     Interaction with other medicinal products\r and other forms of interaction","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"3f82cd65-fc0f-4e85-87a8-e88c7bdc4da1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A number of substances affect glucose metabolism and may require\r dose adjustment of insulin glargine.<\/span><\/p>","ID":"9e2cf326-2e2d-4dfd-b43a-7cf0be453b6b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"A number of substances affect glucose metabolism and may require\r dose adjustment of insulin glargine.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"135571c2-1cab-409d-b30b-5ea1655ff10d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Substances that may enhance the blood-glucose\u2011lowering effect\r and increase susceptibility to hypoglycaemia include oral antidiabetic\r medicinal products, angiotensin converting enzyme (ACE) inhibitors,\r disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,\r pentoxifylline, propoxyphene, salicylates, somatostatin anologues and sulphonamide\r antibiotics. <\/span><\/p>","ID":"bb146ceb-04c2-430e-b008-c36c5b4dbc78","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Substances that may enhance the blood-glucose\u2011lowering effect\r and increase susceptibility to hypoglycaemia include oral antidiabetic\r medicinal products, angiotensin converting enzyme (ACE) inhibitors,\r disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,\r pentoxifylline, propoxyphene, salicylates, somatostatin anologues and sulphonamide\r antibiotics. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"f2ebbb5b-d72a-4b51-8a2a-cae3385d39d1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Substances that may reduce the blood-glucose-lowering effect include\r corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid,\r oestrogens, progestogens, phenothiazine derivatives, somatropin,\r sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,\r terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g.\r clozapine and olanzapine) and protease inhibitors. <\/span><\/p>","ID":"0bf6f484-6a04-4ce7-a0bd-829702b90e69","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Substances that may reduce the blood-glucose-lowering effect include\r corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid,\r oestrogens, progestogens, phenothiazine derivatives, somatropin,\r sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,\r terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g.\r clozapine and olanzapine) and protease inhibitors. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"49ab59ab-07e0-43f6-b273-b2126b670686","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Beta-blockers, clonidine, lithium salts or alcohol may either\r potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine\r may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. <\/span><\/p>","ID":"7fcd86fd-3451-4b93-8b48-31d7ef52ace6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Beta-blockers, clonidine, lithium salts or alcohol may either\r potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine\r may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"9654fa59-6aea-440d-a30f-d71142358e08","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In addition, under the influence of sympatholytic medicinal products\r such as beta-blockers, clonidine, guanethidine and reserpine, the signs of\r adrenergic counter-regulation may be reduced or absent.<\/span><\/p>","ID":"6941078b-f434-4f9e-951c-235ff528e6f0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In addition, under the influence of sympatholytic medicinal products\r such as beta-blockers, clonidine, guanethidine and reserpine, the signs of\r adrenergic counter-regulation may be reduced or absent.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"007c8fd3-5fb0-4b01-b595-398920e81b9b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.6     <\/span><\/b><b><span lang=\"EN-GB\">Fertility, p<\/span><\/b><b><span lang=\"EN-GB\">regnancy and lactation<\/span><\/b><\/p>","ID":"c7766d52-d1fb-4273-8c0f-6482d784b652","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.6     Fertility, pregnancy and lactation","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"04bc37f9-b112-4ca0-9ba8-d5edb3b40c24","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p>","ID":"87f3acbb-241c-47c6-b4da-606a55f634c7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Pregnancy","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"e6c6a943-d6ec-4d1f-9c6c-a42d650f57c4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For insulin glargine no clinical data on exposed pregnancies from\r controlled clinical studies are available. A large amount of data on pregnant\r women (more than 1,000 pregnancy outcomes) indicate no specific adverse\r effects of insulin glargine on pregnancy and no specific malformative nor\r feto\/neonatal toxicity of insulin glargine. <\/span><\/p>","ID":"9b208e5f-e4f5-42f3-b82b-db01ba016f62","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For insulin glargine no clinical data on exposed pregnancies from\r controlled clinical studies are available. A large amount of data on pregnant\r women (more than 1,000 pregnancy outcomes) indicate no specific adverse\r effects of insulin glargine on pregnancy and no specific malformative nor\r feto\/neonatal toxicity of insulin glargine. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"e2bf63cb-0f1c-49d9-a128-f8bbca08ed6b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Animal data do not indicate reproductive toxicity. <\/span><\/p>","ID":"01650d0a-335b-4166-a49f-f856f0195984","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Animal data do not indicate reproductive toxicity. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"28196222-fb7a-4f09-9797-820b06b96438","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The use of ABASAGLAR may be considered during pregnancy, if clinically\r needed. <\/span><\/p>","ID":"ca91671a-3b74-47ba-ac7a-bc3b9b000b6f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The use of ABASAGLAR may be considered during pregnancy, if clinically\r needed. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"209d5b95-0298-4293-9843-46ec931d7d55","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">It is essential for patients with pre-existing or gestational\r diabetes to maintain good metabolic control throughout pregnancy to prevent\r adverse outcomes associated with hyperglycaemia. Insulin requirements may\r decrease during the first trimester and generally increase during the second\r and third trimesters. Immediately after delivery, insulin requirements decline\r rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose\r control is essential. <\/span><\/p>","ID":"0cf75751-9a85-432d-b79d-503f0e777841","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"It is essential for patients with pre-existing or gestational\r diabetes to maintain good metabolic control throughout pregnancy to prevent\r adverse outcomes associated with hyperglycaemia. Insulin requirements may\r decrease during the first trimester and generally increase during the second\r and third trimesters. Immediately after delivery, insulin requirements decline\r rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose\r control is essential. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"4da71263-12d7-487b-b05e-47caad7e427b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p>","ID":"3c9bd87e-c8a5-4410-8a4d-746cced226c5","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Breast-feeding","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"243e2e82-e313-4e8d-a746-be5f9ad9a913","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">It is unknown whether insulin glargine is excreted in human milk. No\r metabolic effects of ingested insulin glargine on the breast\u2011fed\r newborn\/infant are anticipated since insulin glargine as a peptide is digested\r into amino acids in the human gastrointestinal tract. <\/span><\/p>","ID":"ab055938-e0bf-4493-9e83-8a63fe76b678","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"It is unknown whether insulin glargine is excreted in human milk. No\r metabolic effects of ingested insulin glargine on the breast\u2011fed\r newborn\/infant are anticipated since insulin glargine as a peptide is digested\r into amino acids in the human gastrointestinal tract. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"483c43e2-5eb6-4008-8191-4af409c6fe80","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Breast-feeding women may require adjustments in insulin dose and\r diet. <\/span><\/p>","ID":"1b35199a-c878-44de-8665-f7ffd02b82bb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Breast-feeding women may require adjustments in insulin dose and\r diet. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"4bcfdc27-aa67-4f27-9f1e-a960ae6fe460","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","ID":"1d9db74c-c915-4136-8fac-50dc125d2893","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Fertility","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"cbce157b-c9c3-41ff-bbc3-d4babf2e3e19","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Animal studies do not indicate direct harmful effects with respect\r to fertility.<\/span><\/p>","ID":"10511084-b74a-4c72-bdf7-bdc275c06153","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Animal studies do not indicate direct harmful effects with respect\r to fertility.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"84e036c2-1f76-4d73-a50b-0864233adf31","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.7     Effects on ability\r to drive and use machines<\/span><\/b><\/p>","ID":"9df5d0b7-e5dc-490f-b2b5-83a1823cc5c6","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.7     Effects on ability\r to drive and use machines","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","ID":"d45aa44a-4c1c-4b9c-9099-033da8905a88","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">The patient's ability to concentrate and react may be\r impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a\r result of visual impairment. This may constitute a risk in situations where\r these abilities are of special importance (e.g. driving a car or using machines).<\/span><\/p>","ID":"d6cb784f-1f28-4427-8c36-5c8bd9969392","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The patient's ability to concentrate and react may be\r impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a\r result of visual impairment. This may constitute a risk in situations where\r these abilities are of special importance (e.g. driving a car or using machines).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"c7ea163a-4044-49e7-a5dc-91adf458a537","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients should be advised to take precautions to avoid\r hypoglycaemia whilst driving. This is particularly important in those who have\r reduced or absent awareness of the warning symptoms of hypoglycaemia or have\r frequent episodes of hypoglycaemia. It should be considered whether it is\r advisable to drive or operate machines in these circumstances.<\/span><\/p>","ID":"492d8cc9-a17b-4c2d-8fbf-2aa4c47b3323","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Patients should be advised to take precautions to avoid\r hypoglycaemia whilst driving. This is particularly important in those who have\r reduced or absent awareness of the warning symptoms of hypoglycaemia or have\r frequent episodes of hypoglycaemia. It should be considered whether it is\r advisable to drive or operate machines in these circumstances.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"64b7b65a-d78e-4e64-b4a3-9f0f6102a2d9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">4.8     Undesirable\r effects<\/span><\/b><\/p>","ID":"64554027-0d39-4575-aa3e-ee0266909a87","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.8     Undesirable\r effects","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"62b484cc-3697-4827-8b71-103db8c84614","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Summary of safety profile<\/span><\/u><\/p>","ID":"776133f1-1899-4b8d-bd2f-c7bd72483080","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Summary of safety profile","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"92758cea-5607-482c-9056-147dd5492c6b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Hypoglycaemia (very common), in general the most frequent adverse\r reaction of insulin therapy, may occur if the insulin dose is too high in\r relation to the insulin requirement (see section 4.4).<\/span><\/p>","ID":"42c18915-c2a7-4847-bf52-529011ec8ce0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hypoglycaemia (very common), in general the most frequent adverse\r reaction of insulin therapy, may occur if the insulin dose is too high in\r relation to the insulin requirement (see section 4.4).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"7d1742e8-26ee-4dab-a9af-fa18771be251","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Tabulated list of adverse reactions<\/span><\/u><\/p>","ID":"d5f596b5-6e90-4142-a092-1cfd17270af6","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Tabulated list of adverse reactions","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","ID":"6a434048-eb85-4ca7-b209-1b574c3be928","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">The following related adverse reactions from clinical trials\r are listed below as MedDRA preferred term by system organ class and in order of\r decreasing incidence (very common: \u22651\/10; common: \u22651\/100 to\r &lt;1\/10; uncommon: \u22651\/1,000 to &lt;1\/100; rare: \u22651\/10,000 to\r &lt;1\/1,000; very rare: &lt;1\/10,000<span style=\"color:black\"> and not known\r (cannot be estimated from the available data<\/span>).<\/span><\/p>","ID":"1c30603c-1b75-4d21-95b9-1c73d07f132b","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The following related adverse reactions from clinical trials\r are listed below as MedDRA preferred term by system organ class and in order of\r decreasing incidence (very common: \u22651\/10; common: \u22651\/100 to\r <1\/10; uncommon: \u22651\/1,000 to <1\/100; rare: \u22651\/10,000 to\r <1\/1,000; very rare: <1\/10,000 and not known\r (cannot be estimated from the available data).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"8db08c87-44a0-4a0e-9947-4b33d02a5dfb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Within each frequency grouping, adverse reactions are presented in\r order of decreasing seriousness.<\/span><\/p>","ID":"0e69ac68-cbae-4f35-b9bb-77bcc7ac9be9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Within each frequency grouping, adverse reactions are presented in\r order of decreasing seriousness.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"a519dfca-161a-4a40-b78d-826bebc79867","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:12.5pt;border-collapse:collapse;border:none\" width=\"99%\"> <tr style=\"height:16.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">MedDRA system organ classes<\/span><\/b><\/p> <\/td> <td style=\"width:15.4%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Very common<\/span><\/b><\/p> <\/td> <td style=\"width:12.32%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Common<\/span><\/b><\/p> <\/td> <td style=\"width:13.84%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Uncommon<\/span><\/b><\/p> <\/td> <td style=\"width:10.76%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Rare<\/span><\/b><\/p> <\/td> <td style=\"width:11.66%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Very rare<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal\"><b><span lang=\"EN-GB\">Not known<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Immune system disorders <\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Allergic reactions<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:16.75pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Nervous system disorders<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:11.0pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Dysgeusia<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:11.0pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Eyes disorders<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Visual impairment <\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Retinopathy<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Lipohypertrophy<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Lipoatrophy<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Cutaneous amyloidosis<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"6\" style=\"width:87.04%;border-top:none;\r   border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;\r   border-right:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Myalgia<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"6\" style=\"width:87.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">General disorders and administration site conditions<\/span><\/b><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Injection site reactions<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:23.04%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"23%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Oedema<\/span><\/p> <\/td> <td style=\"width:15.4%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.32%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:13.84%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:10.76%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"10%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.66%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <td style=\"width:12.96%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal\"><\/p> <\/td> <\/tr> <\/table>","ID":"1d303cd8-dafd-43f2-ae7f-9ddb3cd9a41c","Styles":"margin-left:12.5pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"   MedDRA system organ classes   Very common   Common   Uncommon   Rare   Very rare   Not known     Immune system disorders         Allergic reactions            X           Metabolism and nutrition disorders        Hypoglycaemia   X                    Nervous system disorders        Dysgeusia               X        Eyes disorders        Visual impairment             X           Retinopathy            X           Skin and subcutaneous tissue disorders        Lipohypertrophy      X                 Lipoatrophy         X              Cutaneous amyloidosis                  X     Musculoskeletal and connective tissue disorders        Myalgia               X        General disorders and administration site conditions        Injection site reactions      X                 Oedema            X         ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b38d8aa7-43b0-4dca-a148-6370f4ec01e3","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/u><\/p>","ID":"4fab6363-e422-4d05-a1bb-76e8546def9e","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Description of selected adverse reactions","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","ID":"a5fea2f9-b2b4-458d-b74a-d1baebc464f3","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><u><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/u><\/i><\/p>","ID":"b8d7106c-196e-484f-81bc-76b29eef3be3","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Metabolism and nutrition disorders","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"7bf02fe6-ad55-4995-9ab2-c285b40f851a","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">Severe hypoglycaemic attacks, especially if recurrent,\r may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may\r be life-threatening. In many patients, the signs and symptoms of\r neuroglycopenia are preceded by signs of adrenergic counter-regulation.\r Generally, the greater and more rapid the decline in blood glucose, the more\r marked is the phenomenon of counter-regulation and its symptoms.<\/span><\/p>","ID":"e98b7e17-1383-419c-bceb-90c44d2ffbda","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Severe hypoglycaemic attacks, especially if recurrent,\r may lead to neurological damage. Prolonged or severe hypoglycaemic episodes may\r be life-threatening. In many patients, the signs and symptoms of\r neuroglycopenia are preceded by signs of adrenergic counter-regulation.\r Generally, the greater and more rapid the decline in blood glucose, the more\r marked is the phenomenon of counter-regulation and its symptoms.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"e50bf4ed-1767-4597-a8cd-20051c7227a1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Immune system disorders<\/span><\/u><\/i><\/p>","ID":"8928a893-bd7a-49c6-a29a-cd15193f4047","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Immune system disorders","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"f45c6434-9fb3-4e4f-810b-2fdcd48833b6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Immediate-type allergic reactions to insulin are rare. Such\r reactions to insulin (including insulin glargine) or the excipients may, for\r example, be associated with generalised skin reactions, angio-oedema,\r bronchospasm, hypotension and shock, and may be life-threatening.<\/span><\/p>","ID":"8f6dde9c-1d9c-4692-b04f-e6f507cd6c1e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Immediate-type allergic reactions to insulin are rare. Such\r reactions to insulin (including insulin glargine) or the excipients may, for\r example, be associated with generalised skin reactions, angio-oedema,\r bronchospasm, hypotension and shock, and may be life-threatening.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"91c17b30-ab79-464d-ac59-8784d2953788","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Eyes disorders<\/span><\/u><\/i><\/p>","ID":"b71777b5-dfc2-4ca2-a4fc-ba3240fb38c6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Eyes disorders","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"fb2fd833-771d-4279-8801-f80f22db60d7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A marked change in glycaemic control may cause temporary visual\r impairment, due to temporary alteration in the turgidity and refractive index\r of the lens.<\/span><\/p>","ID":"44c8abbc-a791-4609-9060-4e76a90463b4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"A marked change in glycaemic control may cause temporary visual\r impairment, due to temporary alteration in the turgidity and refractive index\r of the lens.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"73011d05-74ed-43ef-89c5-957e8404fa42","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Long-term improved glycaemic control decreases the risk of\r progression of diabetic retinopathy. However, intensification of insulin\r therapy with abrupt improvement in glycaemic control may be associated with\r temporary worsening of diabetic retinopathy. In patients with proliferative\r retinopathy, particularly if not treated with photocoagulation, severe\r hypoglycaemic episodes may result in transient amaurosis.<\/span><\/p>","ID":"6e0fa1b7-36f3-4a07-af53-bfee28d05a4b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Long-term improved glycaemic control decreases the risk of\r progression of diabetic retinopathy. However, intensification of insulin\r therapy with abrupt improvement in glycaemic control may be associated with\r temporary worsening of diabetic retinopathy. In patients with proliferative\r retinopathy, particularly if not treated with photocoagulation, severe\r hypoglycaemic episodes may result in transient amaurosis.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"c2ec314e-9124-4ec5-9258-ee2cc674b3a6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/u><\/i><\/p>","ID":"577a8822-57ab-4748-ba3e-93dde7de8c51","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Skin and subcutaneous tissue disorders","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"475ed938-0f22-4242-bb55-b9dba0b48779","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Lipodystrophy and cutaneous amyloidosis may occur at the injection\r site and delay local insulin absorption. Continuous rotation of the injection\r site within the given injection area may help to reduce or prevent these reactions\r (see section 4.4).<\/span><\/p>","ID":"86815e9c-5242-429d-b619-35a0335dc8a4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Lipodystrophy and cutaneous amyloidosis may occur at the injection\r site and delay local insulin absorption. Continuous rotation of the injection\r site within the given injection area may help to reduce or prevent these reactions\r (see section 4.4).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"35264407-afca-40cb-9139-87e5e984c0df","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">General disorders and administration site conditions<\/span><\/u><\/i><\/p>","ID":"d13e097d-aeeb-428e-8264-1911e5fd712a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"General disorders and administration site conditions","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"eeff1a6a-8197-4f8a-aeb9-f780d60366d7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Injection site reactions include redness, pain, itching, hives,\r swelling, or inflammation. Most minor reactions to insulins at the injection\r site usually resolve in a few days to a few weeks. <\/span><\/p>","ID":"2bec2c98-ea06-4891-b48e-20897df94d2f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Injection site reactions include redness, pain, itching, hives,\r swelling, or inflammation. Most minor reactions to insulins at the injection\r site usually resolve in a few days to a few weeks. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"05724d43-1da3-4f5b-a665-983f7d9d147a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Rarely, insulin may cause sodium retention and oedema particularly\r if previously poor metabolic control is improved by intensified insulin\r therapy.<\/span><\/p>","ID":"aad6a462-dd8e-4c8c-b2ef-fcba7bedd313","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Rarely, insulin may cause sodium retention and oedema particularly\r if previously poor metabolic control is improved by intensified insulin\r therapy.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><\/b><\/p>","ID":"0ef79f0f-b988-47e2-9890-2761cbcfda81","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p>","ID":"99313860-8c13-493a-9275-ef5794cf8a90","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Paediatric population","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"16485340-c421-41f7-b1c6-1b4d30929dbb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In general, the safety profile for children and adolescents (\u2264 18 years\r of age) is similar to the safety profile for adults. The adverse reaction\r reports received from post marketing surveillance included relatively more\r frequent injection site reactions (injection site pain, injection site\r reaction) and skin reactions (rash, urticaria) in children and adolescents\r (\u2264 18 years of age) than in adults. Clinical study safety data\r are not available for children under 2 years.<\/span><\/p>","ID":"f332ea9e-e245-4fb0-bab5-fdc7ca2ce20e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In general, the safety profile for children and adolescents (\u2264 18 years\r of age) is similar to the safety profile for adults. The adverse reaction\r reports received from post marketing surveillance included relatively more\r frequent injection site reactions (injection site pain, injection site\r reaction) and skin reactions (rash, urticaria) in children and adolescents\r (\u2264 18 years of age) than in adults. Clinical study safety data\r are not available for children under 2 years.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><\/b><\/p>","ID":"af7bd6f2-6cd4-4fbf-8992-b5831a3205c6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p>","ID":"bcda2969-c162-4bba-9138-5d9b941e630f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Reporting of suspected adverse reactions","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"31117374-f1f1-4b3d-8246-a3cf44ca2548","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\r medicinal product is important. It allows continued monitoring of the\r benefit\/risk balance of the medicinal product. Healthcare professionals are\r asked to report any suspected adverse reactions via <span style=\"background:\r lightgrey\">the national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p>","ID":"d9656c6d-c19d-47ba-96a5-92dba5a80579","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Reporting suspected adverse reactions after authorisation of the\r medicinal product is important. It allows continued monitoring of the\r benefit\/risk balance of the medicinal product. Healthcare professionals are\r asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"98aa0aa9-ac48-4e4f-bcd7-102a08d52687","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.9     Overdose<\/span><\/b><\/p>","ID":"a996dabe-ad36-42e6-9fb5-ffe9eb37b20c","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.9     Overdose","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"01e0c5ce-ef83-4ba0-a60c-a11e98b6340e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Symptoms<\/span><\/u><\/p>","ID":"85ca596a-b09c-4409-817d-fc7f83607ac0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Symptoms","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1db8f4bf-7a34-414a-8ec8-2050281db0bb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin overdose may lead to severe and sometimes long-term and\r life-threatening hypoglycaemia. <\/span><\/p>","ID":"bd6db9d6-5c60-487c-9f12-f688ad21416d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin overdose may lead to severe and sometimes long-term and\r life-threatening hypoglycaemia. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"0716569f-ff7e-4c23-9721-34dcb46a8eb0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Management<\/span><\/u><\/p>","ID":"79f1264b-6b45-4c91-aeb9-e332b9d57d44","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Management","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","ID":"532f46d5-e776-4e81-83b5-deadd0271062","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">Mild episodes of hypoglycaemia can usually be treated\r with oral carbohydrates. Adjustments in dose of the medicinal product, meal\r patterns, or physical activity may be needed. <\/span><\/p>","ID":"880debd9-54a8-4a59-b98f-659f86224268","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Mild episodes of hypoglycaemia can usually be treated\r with oral carbohydrates. Adjustments in dose of the medicinal product, meal\r patterns, or physical activity may be needed. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"79280b9e-7e1e-49c1-97c1-8e625a7e33d8","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">More severe episodes with coma, seizure, or neurologic impairment\r may be treated with intramuscular\/subcutaneous glucagon or concentrated\r intravenous glucose. Sustained carbohydrate intake and observation may be\r necessary because hypoglycaemia may recur after apparent clinical recovery.<\/span><\/p>","ID":"9319fbd7-4c7f-4a1c-90db-1da314601bf4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"More severe episodes with coma, seizure, or neurologic impairment\r may be treated with intramuscular\/subcutaneous glucagon or concentrated\r intravenous glucose. Sustained carbohydrate intake and observation may be\r necessary because hypoglycaemia may recur after apparent clinical recovery.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"2acf340f-3d73-41b2-b431-9ae0621f8173","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"24da690f-b8f1-4fa0-979b-c96c7a524f57","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/b><\/p>","ID":"73bbfded-7516-489e-9afb-b2315ccc99b5","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"1a1d831b-559f-4539-a114-98047226cc86","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">5.1     Pharmacodynamic\r properties<\/span><\/b><\/p>","ID":"46730eea-e0d2-42d0-90a2-3054bc1125ae","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"5.1     Pharmacodynamic\r properties","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"7474e694-2940-4970-bf26-f3a19f410dd9","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pharmacotherapeutic\r group: Drugs used in diabetes, insulins and analogues for injection,\r long-acting. ATC Code: A10AE04.<\/span><\/p>","ID":"fe136de4-29f3-497f-ae55-b4d19b23d61a","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Pharmacotherapeutic\r group: Drugs used in diabetes, insulins and analogues for injection,\r long-acting. ATC Code: A10AE04.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"af9d17ed-5052-4250-a736-137149e108a1","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR is a\r biosimilar medicinal product. Detailed information is available on the website\r of the European Medicines Agency <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext\">http:\/\/www.ema.europa.eu<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p>","ID":"abfa414d-ec02-4552-87a6-79d01a0e3bad","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR is a\r biosimilar medicinal product. Detailed information is available on the website\r of the European Medicines Agency http:\/\/www.ema.europa.eu.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"b0e21d81-3e72-4a87-a902-4e4de4f7c781","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Mechanism of\r action<\/span><\/u><\/p>","ID":"94319f70-957d-4099-85b6-7097a3f8dfa8","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Mechanism of\r action","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"349cb757-3b04-48ab-ac1a-391e2b1a9936","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r is a human insulin analogue designed to have a low solubility at neutral pH. It\r is completely soluble at the acidic pH of the ABASAGLAR injection solution (pH 4).\r After injection into the subcutaneous tissue, the acidic solution is\r neutralised leading to formation of micro-precipitates from which small amounts\r of insulin glargine are continuously released, providing a smooth, peakless,\r predictable concentration\/time profile with a prolonged duration of action.<\/span><\/p>","ID":"7d22fee2-de19-4e2e-a1cb-377ae8db7ea1","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin glargine\r is a human insulin analogue designed to have a low solubility at neutral pH. It\r is completely soluble at the acidic pH of the ABASAGLAR injection solution (pH 4).\r After injection into the subcutaneous tissue, the acidic solution is\r neutralised leading to formation of micro-precipitates from which small amounts\r of insulin glargine are continuously released, providing a smooth, peakless,\r predictable concentration\/time profile with a prolonged duration of action.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"dfe91d6c-3f81-4a33-a24c-12468102cba4","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r is metabolised into 2 active metabolites M1 and M2 (see section 5.2).<\/span><\/p>","ID":"66c13222-e45e-4903-bd2a-5a67dffccee3","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin glargine\r is metabolised into 2 active metabolites M1 and M2 (see section 5.2).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","ID":"a1f68490-ea84-467c-856f-b1739524bf83","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":" ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Insulin\r receptor binding<\/span><\/u><\/i><\/p>","ID":"82d16bea-d30b-4b90-8649-9950236111b0","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin\r receptor binding","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"b468dae1-cae9-4b50-97a8-9a5972fde4d6","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">In vitro<\/span><\/i><span lang=\"EN-GB\"> studies indicate that the affinity of insulin glargine and its\r metabolites M1 and M2 for the human insulin receptor is similar to the one of\r human insulin.<\/span><\/p>","ID":"87426b30-ef99-4c20-a56c-4eafe82b017f","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In vitro studies indicate that the affinity of insulin glargine and its\r metabolites M1 and M2 for the human insulin receptor is similar to the one of\r human insulin.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"14518462-a920-4947-94df-be3f03005f46","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">IGF-1 receptor\r binding: The affinity of insulin glargine for the human IGF-1 receptor is\r approximately 5 to 8-fold greater than that of human insulin (but approximately\r 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1\r receptor with slightly lower affinity compared to human insulin.<\/span><\/p>","ID":"7e9fb7a2-52e8-4021-9068-c06fa4a520ae","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"IGF-1 receptor\r binding: The affinity of insulin glargine for the human IGF-1 receptor is\r approximately 5 to 8-fold greater than that of human insulin (but approximately\r 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1\r receptor with slightly lower affinity compared to human insulin.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"0ae3ceac-f508-4163-a04e-fd702c461e73","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The total therapeutic insulin concentration (insulin glargine and\r its metabolites) found in type 1 diabetic patients was markedly lower than\r what would be required for a half maximal occupation of the IGF-1 receptor and\r the subsequent activation of the mitogenic-proliferative pathway initiated by the\r IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may activate\r the mitogenic-proliferative pathway; however, the therapeutic concentrations\r found in insulin therapy, including in ABASAGLAR therapy, are considerably\r lower than the pharmacological concentrations required to activate the IGF-1\r pathway. <\/span><\/p>","ID":"4ebc9670-7a8f-48b8-9101-01810846c8b1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The total therapeutic insulin concentration (insulin glargine and\r its metabolites) found in type 1 diabetic patients was markedly lower than\r what would be required for a half maximal occupation of the IGF-1 receptor and\r the subsequent activation of the mitogenic-proliferative pathway initiated by the\r IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may activate\r the mitogenic-proliferative pathway; however, the therapeutic concentrations\r found in insulin therapy, including in ABASAGLAR therapy, are considerably\r lower than the pharmacological concentrations required to activate the IGF-1\r pathway. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"67b1bc86-1693-4f01-9285-29840ae2a965","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Pharmacodynamic\r effects<\/span><\/u><\/p>","ID":"2d45c2a2-1324-4c00-9ae1-5d804809572b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Pharmacodynamic\r effects","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"852d5e15-b9ca-444f-94a7-9272aa6a570d","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The primary\r activity of insulin, including insulin glargine, is regulation of glucose\r metabolism. Insulin and its analogues lower blood glucose levels by stimulating\r peripheral glucose uptake, especially by skeletal muscle and fat, and by\r inhibiting hepatic glucose production. Insulin inhibits lipolysis in the\r adipocyte, inhibits proteolysis and enhances protein synthesis.<\/span><\/p>","ID":"22a6dc26-5de0-4687-9d0d-33ca18364853","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The primary\r activity of insulin, including insulin glargine, is regulation of glucose\r metabolism. Insulin and its analogues lower blood glucose levels by stimulating\r peripheral glucose uptake, especially by skeletal muscle and fat, and by\r inhibiting hepatic glucose production. Insulin inhibits lipolysis in the\r adipocyte, inhibits proteolysis and enhances protein synthesis.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"3bae02f1-35e1-4700-a4e0-5dda2be54b13","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In clinical\r pharmacology studies, intravenous insulin glargine and human insulin have been\r shown to be equipotent when given at the same doses. As with all insulins, the\r time course of action of insulin glargine may be affected by physical activity\r and other variables.<\/span><\/p>","ID":"792289c3-1990-420a-b86e-a98a8d362834","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In clinical\r pharmacology studies, intravenous insulin glargine and human insulin have been\r shown to be equipotent when given at the same doses. As with all insulins, the\r time course of action of insulin glargine may be affected by physical activity\r and other variables.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"87017c76-01c9-47ff-9e30-e40e96205cc6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In euglycaemic\r clamp studies in healthy subjects or in patients with type 1 diabetes, the\r onset of action of subcutaneous insulin glargine was slower than with human NPH\r insulin, its effect profile was smooth and peakless, and the duration of its\r effect was prolonged.<\/span><\/p>","ID":"ce4da446-5f6c-47c5-ab0e-f3dfb4c5f241","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In euglycaemic\r clamp studies in healthy subjects or in patients with type 1 diabetes, the\r onset of action of subcutaneous insulin glargine was slower than with human NPH\r insulin, its effect profile was smooth and peakless, and the duration of its\r effect was prolonged.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"84309149-0e9a-4a4a-884b-1f1cc5ebddcf","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The following\r graph shows the results from a study in patients:<\/span><\/p>","ID":"e5d56e9c-3a72-4e31-9882-e8c6c8030540","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The following\r graph shows the results from a study in patients:","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"b741546e-5814-4d20-81af-c6edd5e83c93","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Figure 1: <\/span><\/b><b>Activity profile in patients with type<\/b><b>1 diabetes<\/b><\/p>","ID":"ac032011-c432-4348-989a-90f7cdc18823","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Figure 1: Activity profile in patients with type1 diabetes","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","ID":"ac74c434-3812-41d4-9db7-a7957a6fde6a","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;line-height:normal;\r page-break-after:avoid\"><span style=\"position:absolute;z-index:251682816;\r left:0px;margin-left:-6px;margin-top:15px;width:652px;height:274px\"><img height=\"274\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAowAAAESCAYAAAB3t4R4AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAACz\/SURBVHja7d0JlM31\/8fxyE5CkiSJIjFRKpUte1KWLK1CJNGCVlL8RIpkX5It+xZCyjqy75FJWYsie9axe\/+93uf\/vWdMjLHVzPR8n\/M47tx7v99779SYl\/dn+V71v\/\/97yoAwOXxww8\/9DezU0ZRcbS+\/vrrF07\/kYifV1wIvgkAQGCkCIwAgREACIwURWAEgREACIwURWAEgREACIwURWAEgREACIwURWAEgREACIwURWAEgREACIwURWAEgREAQGCkCIwgMAIACIwUgREgMAIAgZEiMAIERgAgMFIUgREERgAgMFIUgREERgAgMFIUgREERgAgMFIUgREERgAgMFIUgREERgAgMBIYKQIjCIwAAAIjRWDEfykw9ujRo8DAgQNL\/Jd9\/PHHKfifAQCBkSIwAucIjL\/++mv4f\/2H59NPP83O\/wwACIwUgREgMBIYARAYKQIjgREERgIjAAIjRREYQWAkMAIgMFIUgREERgIjAAIjRREYQWAkMAIgMCaQOnXq1BU95+U6\/8mTJ6\/4eyUwgsBIYAQAAmO06tGjhxUoUMD27t17Wc53\/Phx++yzz+zRRx+1BQsW+H0PPvigffDBB5cczObNm2cVKlSwNm3aXLaQt2TJEsubN6\/\/SWAEgZHACAAExrPU6NGjrXLlynbgwIHLds5+\/fpZokSJbOTIkR7snnrqKevevfslh7ydO3da4sSJrVSpUt5tvBy1Zs0ae+yxxywiIoLACAIjgREACIzR69ChQ7Z69WrbsGGDB7C1a9fa8uXL7c8\/\/7TvvvvOwsPDQyFvz549NmnSJJs\/f77t27fPn3P6e2WbNm2yHTt2+HHr1q3z5w4dOtQD47hx4+z333+39evXe9g7cuSILV261MOZjvvqq69s69atZ31vOueYMWNsypQptmzZMj9O70GBsWLFiv6+ZOXKlf68X375xY\/Ta+j5ej+HDx+2qVOn2s8\/\/+zPXbFihY0dO9bmzJljCxcutNO\/P\/2z630fPXrUtm3b5sfpPavj+M0333jHNCg9ruN1DIERBEYCIwAC438iMCpQaYhX4U6BTmFItxXIateu7bcVuBQmCxUq5Ldfe+01Gz9+vIcnhbdKlSp5uLv66qutaNGi\/twgME6ePNk2b97sz1MXU6Hs4YcftiRJkljLli0te\/bslitXLg95UUshMFOmTNa7d29r3ry5JUuWzLuW+\/fvD51LAVB\/6jzqXiZPntwWLVrkr1GzZk1\/\/bffftvSpEnjf\/bv39+uvfZaD8Eagr7zzjtt8eLF1qVLF39u8JmSJk1qt912m7Vo0cLvf++99\/y1dO5ixYrZjBkz\/HENj\/9bcx8JjCAwEhgBEBj\/0WrUqFEoMKoDp0CmOYhBIOzQoYOHMN1WuFT37o8\/\/vDOm0Ki5ioqOKVKlcqKFClyRmCcMGGCP6ZjNewbDE\/rMR0fvLbOF7VeffVVv19BUqFOx6sLeOzYMb\/9xBNP+Lk091JzMKdPn+73d+3a1e9v1aqVHz9w4EDbsmWLz89Mnz69B0W9v+eff94yZszot9UF1bHqdupYfaYSJUr4YylTpvSQqNtlypSx\/Pnze7dSn1Wh+nINixMYQWAkMAIgMMbpatCgQSgwahhWt9XN07CrgtSHH37oQapz587+tYLXTz\/95CFSncLHH3\/cH1cnLwhXQWCcOHFiKDAGw8jVq1f3x\/S8evXq+W0NT0ctDYcrlCkIKrwq3On9aZ6lzhW85q5du\/T3v7377rt+nm7duvn96grqa3Uqg2rYsKFdf\/319ttvv9k999xjVapU8fegeZZ6rrqrQWAMHtN7CMKjuqEKqOqyaqhaQ9f\/VhEYQWAkMAIgMP6jFXT5NC8x6DBq+DYYSlYgU4dOw86av6hh3fr164eCYBCuNCRcvHjxM0LYt99+G3peMIz85JNPhgKjzqPbmg8Zvdq1a2c9e\/a04cOHh1Zw60+dS6FTHUoNZ+t5mkup+zWErdfQMLXOG3UhizqmjRs3thEjRvhczGA4WZ1FHRs13Oq96v2lSJEiFBj12dKmTetBWaXvD4ERBEYCIwAC40WXFpNovt2VoC7b5Zo7FxkZ6UPFCldaVKIumwKT5u8p7Ol2kyZNfNFKyZIlvWOnwKcQp\/dQuHBhy5YtmwfE1KlTW1hYmIe6jz76yI9Vx0\/H6rbmQG7fvt3nMOr1Vq1a5Z1C3dYClKilRSzq6A0YMMAGDx7s70XD0Xp9nUvn0MIU3VbXT0PQuq15lwqStWrVCs1LDL5XNWrU8CF1hWGFRm35o8cUOHVsp06dPASqw6jPpUU0uq3PpO\/77NmzveN48803W506dXxOI4ERBEYCIwAC40WVQoiCiebLXQkKMwowl6MUbDW0qs7ixo0bPdzptjpzmqun2z\/++KN3H\/WnhooV9IJSOFRnTsPXwQpr3afjdazOofPqdrD6WrdF29koAOp29CFp3ZcuXToPfXLVVVf53EcFuuBcBw8e9D+1CEVzHfWnVnwrMKrjGLxGlN8THgyjnnPIkCH+efRcHasQGrw\/fR79qXMFWw7ps4waNepf34KHwAgCI4ERQALoMCp4aMuWK0Hh6t9abPFPVfv27UMBUQti1EEM5kBebIjX4pw+ffr4IhgtoCldurR\/Hd+u8kJgBIGRwAgggQRG6tJKncmOHTv64hl19DRErT0YL6W0UEVD5BpO1zm1oCa+Bm8CIwiMBEYABEbqClZ87CgSGEFgJDACIDBSFIERBEYCIwACI0URGEFgJDACIDBSFIERBEYCIwACI0URGEFgJDACAIGRIjCCwEhgBAACI0VgBIGRwAgABEaKwAgQGAmMAAiMFIGRn1cQGAmMAAiMFEVgBIGRwAiAwEhRBEYQGAmMAAiMFEVgBIGRwAiAwEhRBEYQGAmMAAiMFEVgBIGRwAgABEaKwAgCI4ERAAiMFIERBEYCIwAQGCkCI0BgJDACIDBSBEYCIwiMBEYABEaKIjCCwEhgBEBgpCgCIwiMBEYABEaKIjCCwEhgBEBgpCgCIxJOYDx16pTt27fP9u7dG3Ly5EkCIwAQGCkCIwiMZuvWrbOCBQtaokSJ7KqrrnJJkiSxjRs3EhgBgMBIERhBYDR7+eWXLVWqVPb+++9b27ZtXbt27eyvv\/4iMAIAgZEiMILAaNa6dWurU6dOgv3hITACIDBSBEbgEgPjggUL7NZbb7VmzZpZ165dXffu3X1OI4ERAAiMFIERBEbr1auXpUyZ0ucwRrVhw4ZY\/c+pBTN\/\/PGHzZ8\/38Pnli1b\/D4CIwACI0URGJFAAmNkZKQdPnzYDh48aLt377Zjx455d\/HEiRMxHqfn9ezZ0+68805fKBM1bN5xxx3WsWNHPyeBEQCBkaIIjIjngVH1\/fff28MPP2y333671a1b97wLXtRBfOaZZyxHjhz26quv2ogRI2zOnDk2d+5cGz16tL311lt21113WdmyZe348eMERgAERipW9U+MUMWlUTACI+JNYFy2bJl3CMPCwuyxxx6zNGnSWP78+e3o0aMx\/rCtWrXqvP\/j\/vTTT96JJDACIDDGr9qxY4fvmFGvXj2f1x6ErOnTp9vrr79us2fP9m3ZWrVqZS+++KJ169bN2rRp49OcNHK1c+dO++KLL\/yxN954w05\/7\/z5p7+Pfl\/79u3t9O+oM15z06ZNVq5cOW9AXK7SdKn69evb559\/7p9B8\/SfeOKJGH\/HERhBYDxLvfDCC1aiRInQ1+ouak7jzJkzY\/U\/5\/79+\/0HsUWLFiH6CyOuFIERAIHxwkvhasKECZY4cWJvKgwdOtTv09\/5CpEKhfpaW7NpKlJ4eLj9+OOP\/vyiRYv6tKapU6f6Yw899JCPNkV9vsJo9AtEKECqeTFlypTL1gX8\/fff\/T2VKVPGX087gzz44IM+FYvACFxAYNS\/vDQcrR9OUWDUvoz612Ns6sknnwxt9p0sWTKnvxwIjAAIjPG7li9fbi+99JIlTZrUkidP7l3C\/\/97NRToWrZs6QFw4cKFft8999zjX+uKYTpeYa1y5cqh56sjqcd79+79t1CoBZRbt271sKm59L\/99pv\/TlLoW7JkyRnP19caIdPce3ULdbEJLbrU3Hkt2ty8ebMHRHU69R6qVavmIVevoft0LnU0RccsXrzYO6AERhAYz1EaWr766qstb9689uijj1rq1Kn9yi+xnXuYOXNm69y5s\/\/ABv7tYWgCI4C4GhgVTjRMOm\/ePA8oCjfB19u2bfPgpdtr16710BM89ueff9rSpUv9dkRExBmPKQBdidLws+amDxw40ENezpw5bfv27T5EHXQHddEHPabnBR3GoJun96bH1JTQ7xq9bwVQ3aeRqOiBUSFSv4P69evnnylLliw+t17bvun31JtvvunHKHQ2btzYBg0a5B1LdQtLlizpU6p27dplFStW9JEyDaurI6r3pObGgQMHvPuZNm1a\/z2lYfQUKVJYrVq1rHz58v7aK1euJDCCwBjTvyKrVKli999\/v7322mv+Axbb0g+u\/sIIhhsCBEYABMa\/l7p0CjAKTTVr1gwFKOnRo4eHFt1+9tlnQ9076dKli2XNmtVvly5d2qf\/BI8NGTLkivy9q8A4btw4P7cu8KDX0hSmTz75JPR6QWDU7wLNS1TYC+YHai6iHtO8eIVBTV9SY+JcgVELMPW90WfVY9dff70vrlT4vPnmmy137tx++7777vP7Fy1a5J1GVfXq1f28erxBgwZ+W+E2CIyat6jHKlWqFHret99+648pEK9YscJva95lfF4UQ2DEZQ+M+lfunj177MiRI96m17+2Dh06FBoKON+2OkE9\/\/zzPiSt4YprrrnGFS9enMAIgMB4lgqGT0UdMHXSgq\/1d6\/m8QWP6e\/oqI9p+FS31W2M+pg6Z1eiFBi184UClH5HPPDAA\/73vbpx0QOj9uGNXkFgVFgLnq85hOcKjDNmzPDHgkU2mTJl8tdUuMuWLZvlyZPHbytYquOo9zJ8+HB\/btWqVf1YNS801Sp6YNTj0QPjxIkT\/bHJkyd7+NTtYHEMgREExv+vJk2a2L333mv9+\/f3H7roYrtxt\/5l1rx5c18F17RpU9epUycCIwACYzwvDTNPmjQpFKA0l1DDuZqnHj0Aag5g9FII02Nnm8PYt2\/fc3YYg\/mNCowa+VK4u+WWW3zqlG5rnqN+R+l3mN6P7qtRo0YoCGoVtm5reFoNEZ1THUg9pvcSPE9BMQiMmg+p2\/qdSGAEgTHav\/xGjhzp\/5odMGCAz0MUDQVoXoi6jTGVftiCH6qoQ9EMSQMgMMb\/0rxArWRWcyHqpWLHjx9vpUqV8r\/n1eXU3EAFsD59+pzxe0NBTaFQIaxAgQI+P1MLWJ566il\/vpoLWhgTtfS7SM\/XnEWFPS2mzJ49u3dWNVSvAKmOoaZQKVzqNTVfUe\/lo48+8mO1L3CxYsX8NVavXm3r16\/3+xVy1c1VANVjWvyi4Wc9pm6nfh\/qtqYBRF+9TWDEfzowRg2OasEHpR+8tm3b+oTrmKpQoUL28ccf+35c6dKlO4MmHxMYARAY428pJGpIWvP8NAQetdasWRNaZaytc2TWrFlnXPRBtxXq9Ji2ydECHy3U0Tl1n4afo59XXUo9psU8eu60adP8+drTN3gdhT51AzW3cuzYsaGQqiHzwYMH+\/vV4ho9Vw0RdSKD19Oqa\/2pr\/V+NH9ft\/W6mgsZvDaBEQTGKKUfVM0\/1Ao0\/StO\/+oTbT2gIWn9gMdUGlbQUIUmWzdq1Miv+BLo0KEDgREAgZGiCIyI74FRE4O1Qk\/7JiogagWaqP2v+y\/kOtAMSQMgMFIUgREJMDAGpSGDYcOGXcr\/nB4yg0272bgbAIGRogiMSGCBUaXLP33wwQe+PYJWPGv\/L23VEJvSyjVdZknHBXr27ElgBEBgpKh\/uCZOnFiHwIgrEhi1IlpD0lo1Fvypq7dEX712rtIGstpaJy4ORxMYAVxOI0aMqBQeHt7ytFZAXNSjR4+7+VnFFQmM2ptKe1aNGTPGtyfQyjjtoq\/9tmJTWpGmTbsLFy7sq6NFl2oiMAIAACSQwKjrcera0domQZda0pYDmoeojUxjU5qvqI6kzqGLzstzzz1HYAQAAEgogXHLli129913+wXXFfQ0JB0WFnbGfloxlTqLo0aNirPzOQiMAAAAlxgYtb1OMF9Rt4ONUnU7NnX6hTxgapf9jh07uqFDhxIYAQAAEkpg1FVebrrpJp+LqNKu+RkyZLCff\/45VoFMm31rDqM6kwENSxMYAQAAEkhg7Natm6+OFl3HU53F9OnTxxgYtRJ61apVtnv37tCqaB2na3zqvtiusCYwAgAAxIPAqIvL60Ltun60QmODBg2846hFMDHV448\/btdff70f+9577\/liGa2wZlsdAACABBYYFfby5cvnt3v16hXaj3H9+vUxHhcZGWkLFy60jz\/+2MqXL+8beGfKlMkX0LRu3ZrACAAAkFACozqDmscY1OzZs31vxm3btl1wONu8ebN9+eWX1r59ewIjAABAfA+MERERHg537txp4eHhNm7cOKcV0gqR6iDGprQqulatWvb0009bnTp1rGnTpr5xd8uWLW3Hjh0ERgAAgPgaGBs2bOhD0X369DljhXPgfEPSQdWrV8+HsLNkyWI33HCD386VK5dv\/v3www8TGAEAAOJrYNRK5mA189atW\/\/mxIkTsQpkCp6tWrUKff3WW28ppPk5UqVKdVFD2wRGAACAOBAYf\/nlF79Cy7Bhw\/w60lGNHTvWDh48GKtApj0bu3fv7qujRRt433HHHTZz5kzfn5HACAAAEE8DY4sWLc46FH2hQ9LqKGoYukCBAnbXXXf5ba2czps3r+XJk+df32aHwAgAAHCRgVEbbet60X\/++ad3E6O7kKDXs2dPK1eunD3yyCM2ePBgv09dx3Xr1jGHEQAAIL4GxgULFtjEiRPt9HN84UtUffv29au2nK8UKleuXPm3+7S1TlwpAiMAAMBFBsbGjRvbfffdZ4MGDbLEiROfMRytuYcKkrGpBx54wN544w3vWPbv399Sp05tYWFhBEYAAID4HhgPHTpkhw8f9n0YV6xY4R1F0eX9Fi9e7I\/HpmbNmmUpUqSw3Llze1h88803\/RwERgAAgHgeGI8ePWqbNm2y5s2bW5EiRWz79u3u999\/98v8aQPvmEpzH3\/77TcPnAMHDvTFLlWqVPF5kbt37yYwAgAAxPfAuGvXLg+GCnrRaVh61apVMQaxQoUKnTGMHfV4rZAmMAIAAMTzwKhavny5PfXUUx7wtFBFnUL9qSHp89XUqVPt66+\/tgkTJtjo0aNt+PDhNmTIED+HFtMQGAEAAOJ5YAw22j5y5Ihvrh18HZvtdPSc+vXr2\/PPP29Dhw71oe3YHktgBAAAiCeBsUOHDn6VlkyZMtmNN97ot3U96JIlS\/qWO+eradOmWaNGjaxgwYJ+jmzZsvk+jNq0W51LAiMAAEA8D4y6BGCNGjXOULVqVcuYMaO7kJXO2lJn\/vz51qZNGytTpoxVr16dwAgAABDfA+O5SpcE1MKV8PDYHapuoq4bPXfuXJ\/7qD\/Hjx9\/3kUzBEYAAIB4Ghj37NnjgXHKlCmxen6lSpVCK6ujr5bW9aoJjAAAAPE0MOqSfloRHVW\/fv2sVKlSfuUX7bMYm\/rwww+tbNmytnDhQu8ulihRwrp06eKrpVOlSvWvb+JNYAQAALjIwPjOO++csY9iQFdrUXCMbWXPnv2MbXQGDx5sRYsW9Q2806RJY5s3byYwAgAAxMfAqK10dEnAqNauXXvBHcHixYvbTTfd5F3FTp06+YppLXrRVV9SpkzpV5QhMAIAAMTDwHi5SpcHVEcx6FBqeFphVCuu+\/fvzxxGAACA\/3pgVGnD7sjISBfXNu8mMAIAAPzLgVFD2ZUrV7b777\/f3X333fbMM88QGAEAABJSYFy0aJFf5q9ly5Y2efLkC9pDsUCBAnbdddf5ht0BXQGGwAgAAJBAAuPSpUstSZIkfnnAcuXK2csvv+yXCdy\/f3+sAlm+fPlsxIgRcWoYmsAIAABwGQOjOotaoLJr1y4PjKr06dN7pzE2pS11br31VmvatKk1b97c9ezZk8AIAACQUAJj48aNrWDBgjZ79mwPjBqe1sbdusxfbOrJJ5\/0q7okT548pHDhwgRGAACAhBIYt27dajly5Ahdzk9b4zz99NOxXu2cO3fuC9rom8AIAAAQzwJjUEOGDLEvvvjCFixYcEGBrG3btr5J94wZM2zOnDlOK6cJjAAAAAkoMCrkqcLDw61+\/fo2b968WAeySpUq\/e3yguo6EhgBAAASSGD89ttvfSh62rRpPv9QC150eb+dO3fGKpCtW7fOFi5c6J3JQEREBIERAAAgoQTGZ5991l5\/\/XUbPXq0B0cFRW2+\/fXXX5\/zmJMnT\/rw9fLly88611H3KUj26tWLa0kDAADE98BYu3Zta9CggVWrVs23x9m3b593GDU8HVO9\/\/77ljZtWrvtttt8pfRbb71lb7\/9tgfQvHnzeqfypZde+tcvFUhgBAAAuMTAqPmKwdzDkSNHWsOGDS179uyx6gyqi6igGBYW5uHxmmuu8Y28mzRpckFXiyEwAgAAxOHAqFq7dq3PYVQ3UEFv9+7dFxzMjh8\/7uJaERgBAAAuQ2D85ptv7L777vMOobbI2bJlS5wLfgRGAACAfykwzp071xe7lCxZ0urWrWtZs2a1nDlzWmRkJIERAACAwGhWs2ZNK1++fOjrEydOWJo0aWzq1KnnDWPbt28nMAIAACT0wPjKK69YoUKFfP6ibNq0yfdjnD9\/\/nnDmFZXt27d2r766isCIwAAQEINjOvXr7fUqVNb5syZrWDBgj48XaJECd9r8VylYNmsWTOf96hu5LJlywiMAAAACTUwqk4\/zy8JWLp0aevQoYMdOXLkvMds3rzZKlSo4HswDhs2jMAIAACQkAPjnj177NixY377p59+8nmMsSldEjDoOP7xxx+2Y8cOAiMAAEBCC4xr1qzxYeUBAwb411myZLGHHnoo1nsq6lKCDz\/8sA9lt2zZ0mrUqGEzZ84kMAIAACSUwKiFK5q7uHfvXv86IiLCkiZNarNnz45VIKtYsaLdf\/\/99txzz1mLFi3sxRdf9EsMxrZLSWAEAACI44FR15LW3MVglfRff\/1lKVOmtOnTp8cqkGXIkMGWLl1qEyZMsLZt2\/rwdooUKezAgQMERgAAgIQQGH\/44QdLkiSJ3XTTTX4d6MSJE9u9994bq4UvqmrVqlmePHmscuXKVrZsWStcuHBomx4CIwAAQAIIjCptrdO0aVN75plnrGPHjhcU9vRchcZkyZL5ULYCo7qMzGEEAABIIIFx69atPqSsuYurVq2y1atX++rnw4cPxyqQjRs3ztatWxcKj1ptrQU0Me3jSGAEAACIR4Hxs88+s0SJEoVotbNs2LAhxuMWL15s7dq1s3Tp0lmRIkWsc+fO1qVLF6tTp44ff+jQIQIjAABAQgiM6jDOmTMnRCFQcxEjIyNjPO6XX36x9OnTeziMGji14EUrr5nDCAAAkEACYzCUHFWOHDlidS1phco33niDa0kDAAAk5MA4efJke\/zxx0O0Qlpdwwu5PrQ6k2PHjrUxY8bYqFGjfGiafRgBAAASSGDUdaBz584dosDYtWvXWAcydRiDeY+Bxx57jA4jAABAQgiM0Yeio4ptaf\/GPn36WNWqVX0BTY8ePaxWrVoERgAAgPgeGAcOHGjFihVzxYsXP0OJEiV8MUxsKlu2bH6u3r17++UBFyxYYMmTJ2eVNAAAQHwPjH379vVrQAceeOABe\/DBB91DDz1kW7ZsiVUg03Y62bNnt7Vr1\/oKaQ1JB5caJDACAADE48AY0\/D0hdbu3bv9zyVLltjw4cNtx44dbNwNAACQEAKjtsNp3769h7uSJUv6djq5cuWK9TY5CoctWrSwlStXhkKnjtWiF1ZJAwAAxPPAqMsBavhYcxh1OT9dC7pgwYK+iEXzEnVfTKWtc6Ju2q25i1r4ovuqVKnCohcAAID4HhhffPFFu\/HGG23v3r128OBBD3rh4eF+BRfdXr58eYxBTOGyQoUKtn37dt+KR4Hz6quvtl69esWZ+YsERgAAgEsIjFqYEnQCjxw5Yt27d7eNGzfa8ePHPTBqQ++YSns2vvvuu367evXqdu211\/rCl7hWBEYAAICLDIyvvfaaZc6c+W+LU0aPHu2Bcf369TEGsTx58vg5jh496vMfdZUYdRb19fmGswmMAAAA8SAwKhBqv8T8+fN7d3HQoEHWpEkTD4s1atQ4bxDLly+fPzd16tShK7zotmheJIERAAAgngdG1bx58ywsLCy0cCVx4sRWv359H6I+X3Xs2NHq1q1rNWvWtHr16jndlpYtWxIYAQAAEkJgDEpzFyMiIuyvv\/6Kc3MQCYwAAABxIDAm5CIwAgAAEBgJjAAAAARGAiMAAACBkcAIAABAYCQwAgAAEBgJjAAAAARGAiMAAACBkcAIAABAYCQwAgAA4KqxY8fWDg8Pb\/VfdrrS8T8DAADAOQIj3wQAAAAQGAEAAEBgBAAAAIERAAAABEYAAAAQGAEAAEBgBAAAAIERAAAABEYAAACAwAgAAAACIwAAAAiMAAAAIDACAACAwAgAAAACIwAAAAiMAAAAIDACAACAwAgAAAAQGAEAAEBgBAAAAIERAAAABEYAAAAQGAEAAEBgBAAAAIERAAAABEYAAAAQGAEAAAACIwAAAAiMAAAAIDACAACAwAgAAAACIwAAAAiMAAAAIDACAACAwAgAAAACIwAAAEBgBAAAAIERAAAABEYAAAAQGAEAAEBgBAAAAIERAAAABEYAAAAQGAEAAEBgBAAAAAiMAAAAIDACAACAwAgAAAACIwAAAAiMAAAAIDACAACAwAgAAAACIwAAAAiMAAAAAIERAAAABEYAAAAQGAEAAEBgBAAAAIERAAAABEYAAAAQGAEAAEBgBAAAAIERAAAAIDACAACAwAgAQFwwYsSISuHh4a2A+M7MEvNDDQDAFfDDDz\/0P\/2L9pRRVPyvpPxQAwBAYKQoAiMAAARGiiIwAgBAYKQoAiMAAARGiiIwAgBAYKQoAiMAAARGiiIwAgBAYPyXA+OpU6fs2LFjl3SOP\/74w06ePPmPv+4\/VSdOnCAKEhgBAIj7gVHh6vvvv7e2bdvahx9+aJ988knIu+++a+Hh4R7CLiQEjR071goVKuTnvZBjg9q\/f7\/169fPPv30U8udO7eNGjUqVueZO3eulShRwo+9mNf9J0vf18yZM9vGjRuJgwRGAADidmBUsDp48KDddtttlitXLlu2bJmdPtaWL19uH330kb399tsXFL7UEVyxYoUlTpzYvvvuu4sKbo0aNfIAq2PbtGljrVq1itV5tmzZYtdcc421b98+TgbGqOHwt99+88\/4119\/EQcJjAAAxO3AGFSZMmWsVKlSfxsCXrJkyUWFr2uvvdYmT558Ucdmz57dRo4ceVHH3nHHHR4YL3Qo+0rX1KlTrUWLFnHufREYAQAgMMY6cZUsWdJKly59RqDZtGmT\/3n06FFbuHCh9e\/f33bu3Omdsffee8\/27dt3xjlGjx5tXbt29edlyJAhxg7juHHjrFu3bj70rXOqdu\/ebQMGDPAu4YsvvmhffvmlHThw4G\/HRkZG2uDBg61Lly7Wq1cvO378eOgxDWHrvF9\/\/bV3KhXUgveg9\/v555\/7Md27d7c\/\/\/zT79fj33zzjZ9P71\/n01D9\/Pnz\/XV+\/PFHa968uZ+rd+\/e\/vk2bNjgx+ocep+rVq3y88ybN8\/P3bp1a+\/S6r7Zs2dbpkyZrEiRIqHPpOf36NHjjA7jTz\/95O+vXbt2Nn36dD9W\/z1Wrlzpr7tt2zY\/5s0337StW7cSGAEAwD8bGB955BG76667PDipM\/jZZ5+FhoV37dpltWvXtiRJkngYUrC66aab\/L4gYDZp0sQDmoJUx44dfUh65syZZw2MDRo08HNriFbB8+abb\/YApCCojuZ1111npz+DLV261MNq9LBYsWJF70Dq+EqVKlmxYsVCC10KFChg5cqV8\/PqsUSJEoXmQNatW9c\/n4aDK1SoEJqfqYCm2wqumgOp78WePXvsueees+TJk\/uweFhYmL\/mCy+84J9Nw\/gqBb46derYjh07bMKECf59WbNmjQe7tGnT+vdO3xPN6dT71ufTMZofqvMEwU+vr9dVaFywYIFlzJjRz3HkyBHvTOq5ep\/6\/t97771WvHjx\/9KiGQIjAABxITA++uijPpz7xRdfWN++fa1x48YeuoLAp46dhpkPHTrkX3fq1MmHjhUYFezUUVSYUynkpE6d+qwdRnXbFIaidjKzZMniQSy478Ybb7Thw4efNWwqjN5zzz2h56prePXVV3vXT8\/XPEx1A4PHn376aZ+fqXB1++23h4arddzvv\/\/uAU1BediwYTZkyBBr2LChhzM9rnCpzxGEQ5VWbuv15syZ4683Y8YMGzNmjN\/WOTTnU+fXPNCkSZNaRESEP6bvb\/369UPvS91HnVtdQ5Xeg8Jg8LjCot6HupEKoAqua9euDXVD1YUN\/lsQGAEAwD8SGDUkrXmMUYOcFq8EpQCnYdWgq6Wh2xw5cvjzP\/jgA++sBccq5Chcfvvtt38Lfc2aNfPVwVFfp1atWnbrrbeG7tPjGro9W2BUB1DhK+rxCrpPPvmk36fAqO5ocGwQ+tSBnDRpkqVLl87y5MljEydO9OcoIN99993+WRXifv75Z188o2HpQYMG+eeK3slTd7Js2bJ+vwLo9u3bQ4\/pWH1v1CHV6waBUV3PqKFYw91p0qTxbuPevXu9e6tQHrxvBVkF08WLF9svv\/zi5wqG0PWZ9DmiTwkgMAIAgCsaGLXgRWEs+qIMddcUTNRFu\/7660NDv507d7acOXP68zW8qvATBCt1vhQYz9Zh1NY96papCxmUOm8FCxb0c+n5N9xwwzkDY\/ny5S1\/\/vxnvE9151555ZVQYOzQoUPoWAXDbNmyhd63wp2Gz9W90xCywpc6ntFDoZ6v+YvqdkZ\/TGFP3UMFvKhb+EybNs1Dt0Ki5mNGDYwKmBoSjx4YNfStgK3AqPmLwbnUTVRgXL9+vYdHnUvdzeAzKTCebX4ngREAAFyxwKgFL+oyRg+Mmr+nUKNwFXUoWUOmQYdx1qxZHsCC8KRQplCoYBP9fOrgKQh99dVXoXBUtGhRX6gSfK1gquHdswVGzUfUa\/3666+hx\/U+FMD0tbqT6jAGr\/vyyy\/70Lq+HjhwYOh+zaOsWrWq7\/mosPbss8\/6PERRGNbwukJy1K5q1NKcRH0\/NKwdlBa1qNOp52tPyGTJknnY09f63mquo24rLKubmTJlytCiFz2uTmfwWtrLUsFYX2uBTIoUKfy9qaZMmeLzI+PLBuUERgAA4nlgDAKJVhdnzZrVw5YWtWiOYvXq1a1mzZq+8EShK1WqVL5iVyFLC1zSp0\/vAVClOY8KcgphGqJWB0xdP4XN6KVApk6gVkprSLhp06ahIKXFHwpHOr8Wp5ytXnrpJStcuLB3B9Wx1LzGIDwqID700EN+bnUp1f3U+9fjCmDa01FD5VqwE6xE1tCzQqxeV8PbWu2tLqmO1X16XvRwpm6ghpmjBmJ9Lp1HQ+waltaxComHDx\/2oWvN89QcRy2u0edWoNQCI312Bc+8efPaO++84\/epG6nhaL13rZBWR1MdW3UVtbJc51YojesblBMYAQBIAIFRc\/VWr17tW8eIFqUE1LVTQFGQU6hUt0wrfhUY9VwNt0bdjFoBZ\/z48T4cq+fHtChDCzn0XG3XE4QevY4Cqd6P5hSqi3iuWrRokQ8J6z1FL70vPab3E5xboWzdunW+SEXd0qidQZW2EFIA1RCwSkPx+ow6v95T9MCozxZ0\/KKWvm\/quOp1tSI6OJ++VvDU90+3dW59Tgm6inoNdWUVGIPOowKjvpd6nuYy6n1F\/ZrACAAArnhgpCgCIwAABEaKIjACAAACI0VgBAAABEaKwAgAAAiMFEVgBADgPxEY\/yMrdykCIwAABMaLKW1IrQ2sN2\/efEHHaUsd7X+oaz9v3bqViEQRGAEASKiBUfsWVqtWLXTd49iWNrfWZtfa\/Du4BB5FERgBAEiAgfFSSptc63J50TfVpgiM\/FADAPAvBkbNN9QVS3SFEl1VRNdqHj58+N+un6yrvugSenPmzPFjdEk8XYlFV1PR8LOO0dVPdClAXU1l3759oWP37t3r10bWtZx1ZZjocxynTZtmQ4cOtcGDB\/slBQmMFIERAIA4FBgV8Bo0aGBp0qTxa0CXL1\/er4dctmzZ0OXwunfv7tdf1qXudA1oXctY8wxLly5tt9xyizVr1syP17WOW7dubYkSJQrNYVy7dq1VqVLFpk6d6nMUs2TJ4td5DkLja6+95tdsVmDVtauTJ0\/OHEaKwAgAQFwKjCp1BJMlS+bXZ1aQW7Zsmc8lnDJlis9JLFq0qIWHh9v333\/v4U+BUB3Gjh072rXXXuvdRF37WAFTxyr0bdmyxc9dpkwZa9myZSggnn5vPuwcXDc5Z86cfi7VggULLGnSpMxhpAiMAADEtcCozqCGgrVSOai8efN6t7BPnz5WvHhxD3ei4WMFR4W8Nm3aWFhYWCjwqZYuXWqpUqXyYe7IyEhLkiSJjRkzJhQYIyIiPIyuWrXKnn32We9oBseffs+WOnVqhqQpAiMAAHE1MO7fvz90n0Jihw4dfOXyPffcc0YoVCkAfvjhh3bnnXeeNTDu3LnTDhw44MPb\/fr1CwVGzWFUYFTn8pFHHrFixYqFjld3UscSGCkCIwAAcSwwauhZcxCjdxi1p+LKlSs94KnTqGAnX375pf\/Zvn17y5cv3xmBUc8PAqOqQIECPtcxeI4WzWTNmtUX1bRo0cKHtzV8rUCpBTQpUqSw7du3E5EoAiMAAHEpMM6cOdPnMHbp0sV+\/PFH7xw2bdo01BXUohiFxty5c9t9990XWhH9wgsv+HzFNWvW+PMUAocMGeLP1ZxHhcQVK1ZYhgwZ\/Nwacq5du7avxNa5FSrz5MljmTNn9vD46quv+rF6rvZlpCgCIwAAcajDmDFjRhs\/frwPH0+YMOFvW99MmjTJ2rZta7NmzQqFvcmTJ\/t2OdpyR\/epQ6kFNDqPOonHjx\/3Y7ViWkPb2lZHQ9FRS1vudO7c2bp162arV6\/2Y7XohcsLUgRGAADiUGCcPn26r3aOPk+RogiMAAAQGL0r+Pnnn4cWohAaKQIjAAAExjNK13zWtje9evXyoWnmDlIERgAACIwURWAEAAAERorACAAACIwUgREAAFyKFStW9DvF3jQUgREAAJzLkCFDKoWHh7c8rRUQn50OjIn5oQYAAECM\/g8VAylve5I6GAAAAABJRU5ErkJggg==\" width=\"652\"\/><\/span><span style=\"position:absolute;z-index:251680768;left:0px;margin-left:161px;\r margin-top:233px;width:159px;height:39px\"><img alt=\"Time (h) after s.c injection\" height=\"39\" src=\"data:image\/png;base64,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\" width=\"159\"\/><\/span><span lang=\"EN-GB\"><img border=\"0\" height=\"286\" src=\"data:image\/jpg;base64,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\" width=\"590\"\/><\/span><\/p>","ID":"cde495ec-b9e9-45c4-8487-2266a58788e4","Styles":"text-align:right;line-height:normal;\r\npage-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"ed4c1620-cf5a-43e5-ac8e-3dd1a919ef9b","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">* Determined as\r amount of glucose infused to maintain constant plasma glucose levels (hourly\r mean values)<\/span><\/p>","ID":"ca22bdf5-ec15-4e6b-a2ad-4a57b03c3367","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"* Determined as\r amount of glucose infused to maintain constant plasma glucose levels (hourly\r mean values)","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"cde6774a-48c9-4842-b0f3-971430113357","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The longer\r duration of action of subcutaneous insulin glargine is directly related to its\r slower rate of absorption and supports once daily administration. The time\r course of action of insulin and insulin analogues such as insulin glargine may\r vary considerably in different individuals or within the same individual<\/span><\/p>","ID":"73c316c9-21e8-4abe-b2d6-c41f05baab3b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The longer\r duration of action of subcutaneous insulin glargine is directly related to its\r slower rate of absorption and supports once daily administration. The time\r course of action of insulin and insulin analogues such as insulin glargine may\r vary considerably in different individuals or within the same individual","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"2e9d4820-f5ee-49f5-bee9-817e796573bf","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a clinical\r study, symptoms of hypoglycaemia or counter-regulatory hormone responses were\r similar after intravenous insulin glargine and human insulin both in healthy\r volunteers and patients with type 1 diabetes.<\/span><\/p>","ID":"f99b6737-da89-4240-8d47-01f551b6bf10","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In a clinical\r study, symptoms of hypoglycaemia or counter-regulatory hormone responses were\r similar after intravenous insulin glargine and human insulin both in healthy\r volunteers and patients with type 1 diabetes.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","ID":"02347a19-eebd-4494-a588-5d24e2b13d34","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Clinical safety and efficacy<\/span><\/u><\/p>","ID":"3645bdcc-a063-474f-9f72-ac72dfe5fd5f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Clinical safety and efficacy","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"f98919f7-e6d9-40e4-bc8c-7cca3f8508cd","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In clinical\r studies, antibodies that cross-react with human insulin and insulin glargine\r were observed with the same frequency in both NPH-insulin and insulin glargine\r treatment groups.<\/span><\/p>","ID":"542b6a2b-a87c-4944-af01-f6f8034d2a8c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In clinical\r studies, antibodies that cross-react with human insulin and insulin glargine\r were observed with the same frequency in both NPH-insulin and insulin glargine\r treatment groups.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"c4645dfc-ec89-4a84-9fb5-22c71932671c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Effects of\r insulin glargine (once daily) on diabetic retinopathy were evaluated in an\r open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2\r diabetic patients in which progression of retinopathy by 3 or more steps on the\r Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by\r fundus photography. No significant difference was seen in the progression of\r diabetic retinopathy when insulin glargine was compared to NPH insulin.<\/span><\/p>","ID":"ab333d2d-59fc-4ad3-93c7-efd82a2d2453","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Effects of\r insulin glargine (once daily) on diabetic retinopathy were evaluated in an\r open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2\r diabetic patients in which progression of retinopathy by 3 or more steps on the\r Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by\r fundus photography. No significant difference was seen in the progression of\r diabetic retinopathy when insulin glargine was compared to NPH insulin.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"1009bfe0-6373-4483-a00f-351033477886","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The ORIGIN\r (Outcome Reduction with Initial Glargine INtervention) study was a multicenter,\r randomised, 2x2 factorial design study conducted in 12,537 participants at high\r cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired\r glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus\r treated with \u22641 antidiabetic oral agent (88% of participants).\r Participants were randomised (1:1) to receive insulin glargine (n=6,264),\r titrated to reach FPG \u226495 mg\/dL (5.3 mM), or standard care (n=6,273).<\/span><\/p>","ID":"4f014c78-4889-4402-8fb5-aa51c89e6336","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The ORIGIN\r (Outcome Reduction with Initial Glargine INtervention) study was a multicenter,\r randomised, 2x2 factorial design study conducted in 12,537 participants at high\r cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired\r glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus\r treated with \u22641 antidiabetic oral agent (88% of participants).\r Participants were randomised (1:1) to receive insulin glargine (n=6,264),\r titrated to reach FPG \u226495 mg\/dL (5.3 mM), or standard care (n=6,273).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"e5dc96a3-1331-45ca-8659-4f0826befc14","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The first\r co-primary efficacy outcome was the time to the first occurrence of CV death,\r nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary\r efficacy outcome was the time to the first occurrence of any of the first\r co-primary events, or revascularisation procedure (coronary, carotid, or\r peripheral), or hospitalisation for heart failure.<\/span><\/p>","ID":"00f1e957-ad43-44a4-8098-ba886b943dd7","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The first\r co-primary efficacy outcome was the time to the first occurrence of CV death,\r nonfatal myocardial infarction (MI), or nonfatal stroke, and the second co-primary\r efficacy outcome was the time to the first occurrence of any of the first\r co-primary events, or revascularisation procedure (coronary, carotid, or\r peripheral), or hospitalisation for heart failure.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"460181b6-e77a-4d95-bdcd-33270ee17e0c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Secondary\r endpoints included all-cause mortality and a composite microvascular outcome.<\/span><\/p>","ID":"43bde18e-50ab-40de-9ec7-c055b47a7bbe","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Secondary\r endpoints included all-cause mortality and a composite microvascular outcome.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"0b9970c0-f6e2-4c15-ac46-7a40e815ee22","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r did not alter the relative risk for CV disease and CV mortality when compared\r to standard of care. There were no differences between insulin glargine and\r standard care for the two co-primary outcomes; for any component endpoint\r comprising these outcomes; for all-cause mortality; or for the composite\r microvascular outcome.<\/span><\/p>","ID":"40e0cf9b-8d44-4c09-b981-74144513dee6","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin glargine\r did not alter the relative risk for CV disease and CV mortality when compared\r to standard of care. There were no differences between insulin glargine and\r standard care for the two co-primary outcomes; for any component endpoint\r comprising these outcomes; for all-cause mortality; or for the composite\r microvascular outcome.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"2412fb1b-6366-4970-8e46-62ede7eaeaeb","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Mean dose of\r insulin glargine by study end was 0.42 U\/kg. At baseline, participants had a\r median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9\r to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care\r group throughout the duration of follow-up. The rates of severe hypoglycaemia\r (affected participants per 100 participant years of exposure) were 1.05 for\r insulin glargine and 0.30 for standard care group and the rates of confirmed\r non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard\r care group. Over the course of this 6-year study, 42% of the insulin glargine\r group did not experience any hypoglycaemia. <\/span><\/p>","ID":"4854ed33-d3ec-4fc1-a38b-ab260227d62e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Mean dose of\r insulin glargine by study end was 0.42 U\/kg. At baseline, participants had a\r median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9\r to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care\r group throughout the duration of follow-up. The rates of severe hypoglycaemia\r (affected participants per 100 participant years of exposure) were 1.05 for\r insulin glargine and 0.30 for standard care group and the rates of confirmed\r non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard\r care group. Over the course of this 6-year study, 42% of the insulin glargine\r group did not experience any hypoglycaemia. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"630baccc-8f0c-4657-84a1-172499d76931","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At the last\r on-treatment visit, there was a mean increase in body weight from baseline of\r 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the\r standard care group.<\/span><\/p>","ID":"60a7fd8a-94fb-4f2c-ad04-1d05e180f920","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"At the last\r on-treatment visit, there was a mean increase in body weight from baseline of\r 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the\r standard care group.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","ID":"fe085426-cace-4205-a3d0-f0ea2522b666","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"ac64eb23-81de-472c-ad87-866e523ca706","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Paediatric\r population","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"b14ad34c-bc7d-4721-bbdb-17292212ced8","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a randomised,\r controlled clinical study, paediatric patients (age range 6 to 15 years)\r with type 1 diabetes (n=349) were treated for 28 weeks with a\r basal-bolus insulin regimen where regular human insulin was used before each\r meal. Insulin glargine was administered once daily at bedtime and NPH human\r insulin was administered once or twice daily. Similar effects on\r glycohaemoglobin and the incidence of symptomatic hypoglycaemia were observed\r in both treatment groups, however fasting plasma glucose decreased more from\r baseline in the insulin glargine group than in the NPH group. There was less\r severe hypoglycaemia in the insulin glargine group as well. One hundred forty\r three of the patients treated with insulin glargine in this study continued\r treatment with insulin glargine in an uncontrolled extension study with mean\r duration of follow-up of 2 years. No new safety signals were seen during\r this extended treatment with insulin glargine.<\/span><\/p>","ID":"832ca8c1-3778-4a81-8bcb-c88427dad050","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In a randomised,\r controlled clinical study, paediatric patients (age range 6 to 15 years)\r with type 1 diabetes (n=349) were treated for 28 weeks with a\r basal-bolus insulin regimen where regular human insulin was used before each\r meal. Insulin glargine was administered once daily at bedtime and NPH human\r insulin was administered once or twice daily. Similar effects on\r glycohaemoglobin and the incidence of symptomatic hypoglycaemia were observed\r in both treatment groups, however fasting plasma glucose decreased more from\r baseline in the insulin glargine group than in the NPH group. There was less\r severe hypoglycaemia in the insulin glargine group as well. One hundred forty\r three of the patients treated with insulin glargine in this study continued\r treatment with insulin glargine in an uncontrolled extension study with mean\r duration of follow-up of 2 years. No new safety signals were seen during\r this extended treatment with insulin glargine.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"5b57967a-c12c-4852-b12e-87840a013aee","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A crossover\r study comparing insulin glargine plus lispro insulin to NPH plus regular human\r insulin (each treatment administered for 16 weeks in random order) in 26\r adolescent type 1 diabetic patients aged 12 to 18 years was also\r performed. As in the paediatric study described above, fasting plasma glucose\r reduction from baseline was greater in the insulin glargine group than in the\r NPH group. HbA<sub>1c<\/sub> changes from baseline were similar between treatment\r groups; however blood glucose values recorded overnight were significantly\r higher in the insulin glargine\/ lispro group than the NPH\/regular group, with a\r mean nadir of 5.4 mM vs. 4.1 mM. Correspondingly, the incidences of\r nocturnal hypoglycaemia were 32 % in the insulin glargine \/ lispro group\r vs. 52 % in the NPH \/ regular group.<\/span><\/p>","ID":"01f82983-6163-4ca3-85b2-8e5bc3ef5dcc","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"A crossover\r study comparing insulin glargine plus lispro insulin to NPH plus regular human\r insulin (each treatment administered for 16 weeks in random order) in 26\r adolescent type 1 diabetic patients aged 12 to 18 years was also\r performed. As in the paediatric study described above, fasting plasma glucose\r reduction from baseline was greater in the insulin glargine group than in the\r NPH group. HbA1c changes from baseline were similar between treatment\r groups; however blood glucose values recorded overnight were significantly\r higher in the insulin glargine\/ lispro group than the NPH\/regular group, with a\r mean nadir of 5.4 mM vs. 4.1 mM. Correspondingly, the incidences of\r nocturnal hypoglycaemia were 32 % in the insulin glargine \/ lispro group\r vs. 52 % in the NPH \/ regular group.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"4ccabd85-88c2-4161-a67d-a450c6f356a8","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A 24-week\r parallel group study was conducted in 125 children with type 1 diabetes\r mellitus aged 2 to 6 years, comparing insulin glargine given once daily in\r the morning to NPH insulin given once or twice daily as basal insulin. Both\r groups received bolus insulin before meals. The primary aim of demonstrating\r non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and\r there was a trend to an increase of hypoglycaemic events with insulin glargine\r [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. Glycohaemoglobin\r and glucose variabilities were comparable in both treatment groups. No new\r safety signals were observed in this trial.<\/span><\/p>","ID":"4d9ce1ab-5e70-480d-aebd-199b5c5810c3","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"A 24-week\r parallel group study was conducted in 125 children with type 1 diabetes\r mellitus aged 2 to 6 years, comparing insulin glargine given once daily in\r the morning to NPH insulin given once or twice daily as basal insulin. Both\r groups received bolus insulin before meals. The primary aim of demonstrating\r non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and\r there was a trend to an increase of hypoglycaemic events with insulin glargine\r [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)]. Glycohaemoglobin\r and glucose variabilities were comparable in both treatment groups. No new\r safety signals were observed in this trial.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","ID":"79a6d9ad-ab96-41f1-ad3a-05d46f97f582","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">5.2     Pharmacokinetic\r properties<\/span><\/b><\/p>","ID":"e7118ca4-b009-496c-afea-8b99bee236da","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"5.2     Pharmacokinetic\r properties","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><\/p>","ID":"b03156e4-c648-4c85-9e93-883c83db0e20","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p>","ID":"6b6a4cff-c14b-43ab-a521-7f0aece99179","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Absorption","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"9195969d-ec9d-469c-8268-eca4c1bd11e8","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In healthy subjects and diabetic patients, insulin serum\r concentrations indicated a slower and much more prolonged absorption and showed\r a lack of a peak after subcutaneous injection of insulin glargine in comparison\r to human NPH insulin. Concentrations were thus consistent with the time profile\r of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the\r activity profiles over time of insulin glargine and NPH insulin. <\/span><\/p>","ID":"e14970ad-9ad0-4458-bb02-dd649d5e10da","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In healthy subjects and diabetic patients, insulin serum\r concentrations indicated a slower and much more prolonged absorption and showed\r a lack of a peak after subcutaneous injection of insulin glargine in comparison\r to human NPH insulin. Concentrations were thus consistent with the time profile\r of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the\r activity profiles over time of insulin glargine and NPH insulin. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1785ed8e-9d25-467f-94ee-e7edbbfd5168","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin glargine injected once daily will reach steady state levels\r in 2-4 days after the first dose. <\/span><\/p>","ID":"6165d338-3b7e-409b-82e9-f8315b6249b2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin glargine injected once daily will reach steady state levels\r in 2-4 days after the first dose. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","ID":"ea48a082-d933-4cde-ba06-b77f843ed67b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":" ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p>","ID":"66dde606-30bd-40b5-9889-6cb94a287dc0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Biotransformation","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1c48f844-6ef9-443c-aa69-0111ad801d5d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">After subcutaneous injection in diabetic patients, insulin glargine\r is rapidly metabolised at the carboxyl terminus of the Beta chain with\r formation of two active metabolites M1 (21A-Gly-insulin) and M2\r (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is\r the metabolite M1. The exposure to M1 increases with the administered dose of insulin\r glargine.<\/span><\/p>","ID":"ccd2d8e6-ea83-4505-acfc-150fdfcf9f05","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"After subcutaneous injection in diabetic patients, insulin glargine\r is rapidly metabolised at the carboxyl terminus of the Beta chain with\r formation of two active metabolites M1 (21A-Gly-insulin) and M2\r (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is\r the metabolite M1. The exposure to M1 increases with the administered dose of insulin\r glargine.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","ID":"6714b37e-fb70-4f03-a3cb-df763371055a","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pharmacokinetic and pharmacodynamic findings indicate that the\r effect of the subcutaneous injection with insulin glargine is principally based\r on exposure to M1. Insulin glargine and the metabolite M2 were not detectable\r in the vast majority of subjects and, when they were detectable their\r concentration was independent of the administered dose of insulin glargine.<\/span><\/p>","ID":"3c4dc7fd-6097-4d7f-8d4e-14ee91f8af4e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The pharmacokinetic and pharmacodynamic findings indicate that the\r effect of the subcutaneous injection with insulin glargine is principally based\r on exposure to M1. Insulin glargine and the metabolite M2 were not detectable\r in the vast majority of subjects and, when they were detectable their\r concentration was independent of the administered dose of insulin glargine.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"7c323a12-76e7-4564-97e7-3d9515f5f2b8","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","ID":"caa74b43-3c1b-456c-8b63-18b7804db69a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Elimination","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"5b2b18f3-4094-4347-8a15-2f0683699038","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">When given intravenously the elimination half-life of insulin\r glargine and human insulin were comparable. <\/span><\/p>","ID":"231edf8b-aa7c-47bd-b1a0-b951355e7629","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"When given intravenously the elimination half-life of insulin\r glargine and human insulin were comparable. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"> <\/p>","ID":"4245a076-dd59-4bad-ab66-cdd4af2b2edb","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":" ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Special populations<\/span><\/u><\/p>","ID":"54e8a05e-b649-4bea-8ca6-7c5aa866ccc9","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Special populations","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><\/p>","ID":"ab4e8287-096a-4b08-9500-f278ae61af98","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In clinical\r studies, subgroup analyses based on age and gender did not indicate any\r difference in safety and efficacy in insulin glargine-treated patients compared\r to the entire study population.<\/span><\/p>","ID":"7bfca194-e31c-4a65-b544-f97c34ff3d6d","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In clinical\r studies, subgroup analyses based on age and gender did not indicate any\r difference in safety and efficacy in insulin glargine-treated patients compared\r to the entire study population.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"2fa357af-be0f-4e01-b2dc-027b12e78c88","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p>","ID":"8b06b12a-7022-4739-8f8d-ad46cf0a90f2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Paediatric population","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"30db2210-9912-4dc9-994f-4574782e8b5b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Pharmacokinetics in children aged 2 to less than 6 years with type 1\r diabetes mellitus was assessed in one clinical study (see section 5.1). Plasma\r trough levels of insulin glargine and its main M1 and M2 metabolites were\r measured in children treated with insulin glargine, revealing plasma\r concentration patterns similar to adults, and providing no evidence for\r accumulation of insulin glargine or its metabolites with chronic dosing.<\/span><\/p>","ID":"c33680d4-1cf6-489c-9101-73186a26018d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Pharmacokinetics in children aged 2 to less than 6 years with type 1\r diabetes mellitus was assessed in one clinical study (see section 5.1). Plasma\r trough levels of insulin glargine and its main M1 and M2 metabolites were\r measured in children treated with insulin glargine, revealing plasma\r concentration patterns similar to adults, and providing no evidence for\r accumulation of insulin glargine or its metabolites with chronic dosing.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","ID":"7db02b86-fd44-442d-a327-fc1220b3f8da","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.3     Preclinical safety data<\/span><\/b><\/p>","ID":"4f44609b-c58b-434b-9cbb-a42787f52b5b","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"5.3     Preclinical safety data","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"6200c8e9-b2f6-454c-b5f8-f0f2dd7c9c19","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Non-clinical data reveal no special hazard for humans based on\r conventional studies of safety pharmacology, repeated dose toxicity,\r genotoxicity, carcinogenic potential, toxicity to reproduction.<\/span><\/p>","ID":"cd709c3e-69cf-4433-8653-0f98dcb3c72f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Non-clinical data reveal no special hazard for humans based on\r conventional studies of safety pharmacology, repeated dose toxicity,\r genotoxicity, carcinogenic potential, toxicity to reproduction.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"f233a735-7226-495d-8b87-0195c7290a35","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b9126a4c-d594-41ef-9b12-1cacc792faca","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/b><\/p>","ID":"d2e3f4d9-ea2e-4c05-bbc8-5a42c9b94f91","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"12c1e56e-5001-4742-a8bc-ea97b7d840e6","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p>","ID":"2da03970-e203-4814-8369-69acba8cd1b7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.1     List of excipients","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"3efcfb61-bc22-48a5-9021-2d3d0ca9c548","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Zinc oxide<\/span><\/p>","ID":"6cfdd65e-f3d1-44f6-bb16-621b7104fac8","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Zinc oxide","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Metacresol<\/span><\/p>","ID":"6bfe8fba-b319-4571-80bb-6ada2b02fdca","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Metacresol","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Glycerol<\/span><\/p>","ID":"0c542757-3d94-43bb-9988-dbfb1afc15f0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Glycerol","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Hydrochloric acid (for pH adjustment)<\/span><\/p>","ID":"6118a597-3a6f-4354-937f-1a96041c2847","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hydrochloric acid (for pH adjustment)","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Sodium hydroxide (for pH adjustment)<\/span><\/p>","ID":"840837d9-ffb1-443f-98a6-1da9a9668675","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Sodium hydroxide (for pH adjustment)","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Water for injections<\/span><\/p>","ID":"97060cf9-330d-4156-997b-3536f18e596b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Water for injections","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"47373957-2ba6-4a62-bf51-8cb1de115486","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p>","ID":"777c5f5d-ebab-4471-a2ac-f8ff217d9e86","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.2     Incompatibilities","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"87d8497c-d6e8-456c-9a01-0c02be031191","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">This medicinal product must not be mixed with other medicinal\r products. <\/span><\/p>","ID":"4d82feac-3c7c-471c-b4d7-0523a7425852","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"This medicinal product must not be mixed with other medicinal\r products. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"fdb7f5b4-ecd3-4b2b-894c-372f47cf30e6","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/b><\/p>","ID":"3a5e25a2-c47a-47a2-81a1-9359a342c27f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.3     Shelf life","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"5418f9f6-2e51-40cf-90e8-32f79c0fc67d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">2 years.<\/span><\/p>","ID":"e8ad0f66-b2cc-471b-a670-b873a3ee95a7","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"2 years.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"3cfcfda4-7af7-4b4d-9094-e9336b780ff3","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Shelf life after first use <\/span><\/u><\/p>","ID":"556eb031-fcd9-44c9-ae11-7a12f5cbb8d6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Shelf life after first use ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"edbe0e1b-3195-4a0e-9b2f-6fc3d9f80289","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The medicinal product may be stored for a maximum of 28 days up\r to 30\u00b0C and away from direct heat or direct light. Pens in use must not be\r stored in the refrigerator. <\/span><\/p>","ID":"55fc0dfa-cf68-4446-b6df-a4ca579bb155","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The medicinal product may be stored for a maximum of 28 days up\r to 30\u00b0C and away from direct heat or direct light. Pens in use must not be\r stored in the refrigerator. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"d118f13c-b795-443a-8fdd-67fe2897e138","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pen cap must be put back on the pen after each injection in\r order to protect from light.<\/span><\/p>","ID":"f9d002e8-53e8-442c-a6f5-ed2e6398e033","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The pen cap must be put back on the pen after each injection in\r order to protect from light.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"588298b7-b245-466c-b9f9-d10fb5dff86e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/b><\/p>","ID":"c7c964df-60d9-4bcd-a58c-5fcfc6d6b7e7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.4     Special precautions for storage","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"35afc9b0-8db4-4959-876b-71cc447b311b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Before use<\/span><\/u><\/p>","ID":"58c0023e-5da9-4076-a808-a3742c47fd07","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Before use","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"0ffbc9da-32b0-48e6-9f7b-3e6b60940308","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C - 8\u00b0C).<\/span><\/p>","ID":"da1e5fa5-03f5-472a-970a-aed5aacb9782","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Store in a refrigerator (2\u00b0C - 8\u00b0C).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"2e0d6acf-2d6c-4a3b-9b06-0c4be5380570","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze.<\/span><\/p>","ID":"b0d94a95-ec1c-4633-9014-f158eb95958b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Do not freeze.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b084cb95-8ec6-450e-8da1-4b2eda6d5424","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not store ABASAGLAR next to the freezer compartment or a freezer\r pack.<\/span><\/p>","ID":"dedc2ee0-de1b-4b80-8950-0d965215a72b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Do not store ABASAGLAR next to the freezer compartment or a freezer\r pack.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"33c1861c-3bda-4d26-b948-3dbe96f3d9ac","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Keep the cartridge in the outer carton in order to protect from\r light.<\/span><\/p>","ID":"fb7ef4c8-6fe1-4bcf-9dd8-173cc96fabc8","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Keep the cartridge in the outer carton in order to protect from\r light.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"52a623b3-5d70-4f06-844a-85c6693d8896","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">In use <\/span><\/u><\/p>","ID":"4c151851-3a77-416f-ac53-feca1ae9a12b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In use ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"2955cb85-7c72-411c-ba5b-3c9e216da6ce","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For storage conditions after first opening of this medicinal\r product, see section 6.3.<\/span><\/p>","ID":"144c2b64-3116-4aa4-a99b-f99a9795aaea","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For storage conditions after first opening of this medicinal\r product, see section 6.3.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"10276c1d-0d63-442b-a392-909eab8baabe","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.5     Nature and contents of container<\/span><\/b><\/p>","ID":"b215db25-3eec-4ae6-a945-2960efc081b1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.5     Nature and contents of container","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><s><span lang=\"EN-GB\"><\/span><\/s><\/b><\/p>","ID":"c8b91f0e-3c16-4be3-babd-29a7d866d8aa","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">3 mL solution in a cartridge (type 1 colourless glass) with a\r plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl\r rubber) with aluminium seal.<\/span><\/p>","ID":"8990f19c-99f4-43d8-87a3-61c7e6f0dfb9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"3 mL solution in a cartridge (type 1 colourless glass) with a\r plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and halobutyl\r rubber) with aluminium seal.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"56a6f22e-f948-43e0-bcee-c09145ece0ec","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Packs of 5 and 10 cartridges. Not all pack sizes may be marketed.<\/span><\/p>","ID":"89e0f8dd-4c16-49c9-9926-d4f60e1fa631","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Packs of 5 and 10 cartridges. Not all pack sizes may be marketed.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"d62b54d7-b6a4-430e-beb3-cee94ed74969","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.6     Special precautions for disposal and other handling<\/span><\/b><\/p>","ID":"42a5ce6a-9916-42d1-9003-2f5cb8d14c21","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.6     Special precautions for disposal and other handling","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"dea5e87f-d1f7-41f2-b888-27c563c821b8","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR must not be mixed with any other insulin or medicinal\r products or diluted. Mixing or diluting can change its time\/action profile and\r mixing can cause precipitation.<\/span><\/p>","ID":"151efc1e-34a1-4639-82bd-c28387433bca","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR must not be mixed with any other insulin or medicinal\r products or diluted. Mixing or diluting can change its time\/action profile and\r mixing can cause precipitation.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"282d9acb-a76c-4418-9edf-0e2b07d9ff30","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Insulin pen<\/span><\/u><\/p>","ID":"2851e127-e380-4f5d-9215-e79d6c410d02","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin pen","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"50088398-e729-40d9-83b9-14a5e8ddde01","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The ABASAGLAR cartridges are to be used only in conjunction with a\r Lilly reusable insulin pen (see section 4.4). <\/span><\/p>","ID":"d884c6f7-41eb-48b2-93f6-3a304aee809a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The ABASAGLAR cartridges are to be used only in conjunction with a\r Lilly reusable insulin pen (see section 4.4). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"228362c4-0b15-4320-bbf5-734a90f1934a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pen should be used as recommended in the information provided with\r the device. <\/span><\/p>","ID":"e3abd564-4591-493c-aa9e-b3badd44ff62","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The pen should be used as recommended in the information provided with\r the device. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"7da370c3-0dce-401d-ad85-f20d00f8ff48","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The instructions for using the pen must be followed carefully for\r loading the cartridge, attaching the needle, and administering the insulin\r injection. <\/span><\/p>","ID":"f0cf0fa4-e173-4ec8-b35d-2a767fcdb188","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The instructions for using the pen must be followed carefully for\r loading the cartridge, attaching the needle, and administering the insulin\r injection. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1c27986f-3d5a-484b-a6f1-c52ac582b9df","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If the insulin pen is damaged or not working properly (due to\r mechanical defects) it has to be discarded, and a new insulin pen has to be\r used. <\/span><\/p>","ID":"3d26e5d1-64c4-4a45-a3c8-b0c05b8fcc0e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"If the insulin pen is damaged or not working properly (due to\r mechanical defects) it has to be discarded, and a new insulin pen has to be\r used. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"36e72df7-32b7-4c49-8e46-ade307484d5d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Cartridge<\/span><\/u><\/p>","ID":"5730bc20-0aae-4aba-9aad-ee0c3f59001f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Cartridge","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"f8cd3af1-5393-44f8-815f-d6d2ad1a7c43","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Inspect the cartridge before use. It must only be used if the\r solution is clear, colourless, with no solid particles visible, and if it is of\r water-like consistency. Since ABASAGLAR is a solution, it does not require\r re-suspension before use. Air bubbles must be removed from the cartridge before\r injection (see instructions for using the pen).<\/span><\/p>","ID":"b9b5bcd5-a4e7-458e-b060-ddb746e8c5e2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Inspect the cartridge before use. It must only be used if the\r solution is clear, colourless, with no solid particles visible, and if it is of\r water-like consistency. Since ABASAGLAR is a solution, it does not require\r re-suspension before use. Air bubbles must be removed from the cartridge before\r injection (see instructions for using the pen).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"af1b4c3e-635c-4a50-aecf-a60751d89d0a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">To prevent the possible transmission of disease, each pen must be\r used by one patient only. <\/span><\/p>","ID":"4171d5af-b6cc-4661-9746-777700e6711d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"To prevent the possible transmission of disease, each pen must be\r used by one patient only. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"2012fdc4-8632-4b96-a816-ef6007d9ff2c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Empty cartridges must not be refilled and must be properly\r discarded. Insulin label must always be checked before each injection to avoid\r medication errors between insulin glargine and other insulins (see section 4.4).<\/span><\/p>","ID":"468d67c8-887a-4947-b8c6-117e58ef247a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Empty cartridges must not be refilled and must be properly\r discarded. Insulin label must always be checked before each injection to avoid\r medication errors between insulin glargine and other insulins (see section 4.4).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"479c6c78-0a6c-4129-a6d0-8e26fa678449","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"e71fa239-7441-4679-8744-e30974f2c092","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><b><span lang=\"EN-GB\">7.       MARKETING\r AUTHORISATION HOLDER<\/span><\/b><\/p>","ID":"cc1e7b89-aad5-4882-8a1a-02a20a38542e","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"7.       MARKETING\r AUTHORISATION HOLDER","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"e7edbec0-2372-4e22-ba2b-cc946140da03","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The\r Netherlands<\/span><\/p>","ID":"3565ac06-2d40-4ca5-b9a2-1a084a38e545","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The\r Netherlands","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"8c99e981-e664-41d4-af01-a5b726ec6f32","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"d2ab3812-f0d5-4b9c-a49c-3bf6aee2207f","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">8.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p>","ID":"5724e2d3-ba62-4077-a823-7a9f1265ceef","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"8.       MARKETING AUTHORISATION NUMBER(S)","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"ea8657b1-06dc-41eb-a973-27d7ca081138","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/14\/944\/003<\/span><\/p>","ID":"47bbc217-4c9b-4852-97a6-638f80243c5b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/14\/944\/003","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/14\/944\/009<\/span><\/p>","ID":"553228fa-c483-46df-9343-97c6a2e819a8","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/14\/944\/009","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"61b71ada-50ef-4451-889a-5792e6670b6b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"df04cd3a-939b-4aed-9350-328624dd2de8","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/p>","ID":"ee9c56ba-ed47-46bd-b7a5-7855088051ea","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"601cc9fe-fa27-4a12-9dcf-6f63edb77b08","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Date of first authorisation: 9 September 2014<\/span><\/p>","ID":"21b54cc2-8b2d-426a-8ae0-17dd4e737cd7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Date of first authorisation: 9 September 2014","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Date of latest renewal: 25 July 2019<\/span><\/p>","ID":"c03e6833-8bc9-4b79-b27d-dae299a8f7ec","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Date of latest renewal: 25 July 2019","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"ab9f194c-c518-4276-98c0-3fd13f852b21","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"ba97d8ea-cb6d-428a-8f22-8e9cb42a9e7e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/b><\/p>","ID":"c312a68f-d49b-4470-8658-772a737f2db2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"9cb8b3f9-6c88-4179-bb9e-ef869f4ddcbc","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Detailed\r information on this medicinal product is available on the website of the\r European Medicines Agency http:\/\/www.ema.europa.eu <br clear=\"all\" style=\"page-break-before:always\"\/> <b>1.       NAME OF <\/b><b>THE MEDICINAL PRODUCT<\/b><\/span><\/p>","ID":"b2c90162-a5a9-456d-8bfb-0016b69ace7e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Detailed\r information on this medicinal product is available on the website of the\r European Medicines Agency http:\/\/www.ema.europa.eu  1.       NAME OF THE MEDICINAL PRODUCT","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"55d993e0-9608-4450-917a-1ad9dbbc2d3e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR<\/span><span lang=\"EN-GB\"> 100 units\/mL KwikPen solution\r for injection in a pre-filled pen<\/span><\/p>","ID":"0e5ebdc6-d303-40b5-9a65-54755cd466d0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR 100 units\/mL KwikPen solution\r for injection in a pre-filled pen","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR<\/span><span lang=\"EN-GB\"> 100 units\/mL Tempo Pen solution\r for injection in a pre-filled pen<\/span><\/p>","ID":"9ba23c19-70c0-49e4-96c5-171468e56709","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR 100 units\/mL Tempo Pen solution\r for injection in a pre-filled pen","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"60cbbdfd-3405-4105-9a53-43543fbb49a5","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"dca600a3-341e-4b94-bd0d-ac6f7d382238","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE COMPOSITION<\/span><\/b><\/p>","ID":"996ecfd2-9f34-4ac6-a255-a100b5803fb9","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"2.       QUALITATIVE AND QUANTITATIVE COMPOSITION","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"f376b80e-474d-4b21-af07-48abdd30b2bf","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Each mL\r contains 100 units insulin glargine* (equivalent to 3.64 mg). <\/span><\/p>","ID":"6c1efeb2-0d9a-464c-8580-d87298c9e20a","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Each mL\r contains 100 units insulin glargine* (equivalent to 3.64 mg). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><\/p>","ID":"1c8e59d8-a614-42ea-b68c-3737ad816e86","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Each pen contains 3 mL of solution for injection, equivalent to\r 300 units. <\/span><\/p>","ID":"19164987-819c-4f1c-85fe-0abb75539292","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Each pen contains 3 mL of solution for injection, equivalent to\r 300 units. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><\/p>","ID":"1dfb9b0b-6760-4814-9b67-05540fcf60ff","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">* produced by recombinant DNA technology in <i>Escherichia coli<\/i>.\r <\/span><\/p>","ID":"80b8a3d6-1e32-40dd-80c3-5bbd4c31e443","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"* produced by recombinant DNA technology in Escherichia coli.\r ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"37c2d77c-8d00-4427-b87d-7fe3753750f3","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For the full list of excipients, see section 6.1.<\/span><\/p>","ID":"0e9de374-b51b-40a2-88d4-4e25d336adcc","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For the full list of excipients, see section 6.1.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"f9cf9702-6952-4a57-9b7d-f3e880170763","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"8637dd2f-d16d-45e5-855a-0aca6ab1b021","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/b><\/p>","ID":"0344c398-45fb-4e75-8a15-2fd6dbe5fdc1","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"3.       PHARMACEUTICAL FORM","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"8276dfc6-3a90-40fb-8d4c-858be6f8fc18","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Solution for\r injection (injection) <\/span><\/p>","ID":"30cd8bc9-b001-47ce-bcf4-132db3f8deee","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Solution for\r injection (injection) ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"1eb5ee64-9bef-4429-8bd8-a0f2c12d5e33","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Clear,\r colourless solution.<\/span><\/p>","ID":"80b17512-4e9d-46b0-a1b5-343fd4bf5550","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Clear,\r colourless solution.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"1a627da4-e549-44bb-abfb-887b8fd76106","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"6393d44b-5150-4cae-91f0-6ee930c6c429","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\" style=\"text-transform:uppercase\">4.       <\/span><\/b><b><span lang=\"EN-GB\">CLINICAL PARTICULARS<\/span><\/b><\/p>","ID":"e4e62750-5b16-4bb3-8d48-471efd277f50","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.       CLINICAL PARTICULARS","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"a5d4e4c7-865a-4ba1-ab9c-94a35c4fde17","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/b><\/p>","ID":"ebdcbafb-1ec6-4435-8d78-71f06d4e6e56","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.1     Therapeutic indications","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"eaa18610-80a1-421b-bf68-f8fd67472d11","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Treatment of diabetes mellitus in adults, adolescents and children\r aged 2 years and above.<\/span><\/p>","ID":"c4c43dcb-2003-4509-9422-b4f1d7339a12","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Treatment of diabetes mellitus in adults, adolescents and children\r aged 2 years and above.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"72c66539-f50b-4595-ba1f-5d39df0a33a7","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">4.2     Posology\r and method of administration<\/span><\/b><\/p>","ID":"80e3a023-cb73-4c36-a835-d21184e6bcf1","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.2     Posology\r and method of administration","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"e6d8543d-3a80-463e-a7f6-73c3aaa537d7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p>","ID":"75d2ff8c-7fa7-4bf1-9744-f854f7e12711","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Posology","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1e9310bd-b6fe-4415-a786-7506cd9d5f04","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR contains insulin glargine, an insulin analogue and has a\r prolonged duration of action. <\/span><\/p>","ID":"06bcd167-e9c2-4415-9521-a895d872ba29","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR contains insulin glargine, an insulin analogue and has a\r prolonged duration of action. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1908d07a-bbfd-488c-830b-eb1c4c816b49","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR should be administered once daily at any time but at the\r same time each day. <\/span><\/p>","ID":"f849a54c-352c-42a6-a9ba-996860ede695","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR should be administered once daily at any time but at the\r same time each day. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"618ee2a2-7cc1-4a8a-94d0-94946b4ab926","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The dose regimen (dose and timing) should be individually adjusted.\r In patients with type 2 diabetes mellitus, ABASAGLAR can also be given\r together with orally active antidiabetic medicinal products. <\/span><\/p>","ID":"973818c9-5232-4a79-8a78-7e6a1b864cae","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The dose regimen (dose and timing) should be individually adjusted.\r In patients with type 2 diabetes mellitus, ABASAGLAR can also be given\r together with orally active antidiabetic medicinal products. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"d9e0628d-f88e-4c1f-b5db-cb56b80e05b4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The potency of this medicinal product is stated in units. These\r units are exclusive to insulin glargine and are not the same as IU or the units\r used to express the potency of other insulin analogues (see section 5.1). <\/span><\/p>","ID":"52fe0a01-0588-46b5-9392-e6537f6b140c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The potency of this medicinal product is stated in units. These\r units are exclusive to insulin glargine and are not the same as IU or the units\r used to express the potency of other insulin analogues (see section 5.1). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"7b4b4b00-5363-49a2-8561-203c68241dc5","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Special populations<\/span><\/u><\/i><\/p>","ID":"583dce31-18d4-4ff0-9304-37c2d0be2243","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Special populations","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"c6fcea19-1ff8-4ef3-9205-9a4db1cb2c73","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Elderly population (\u226565 years old)<\/span><\/i><\/p>","ID":"01416955-a992-499d-a973-f58d4a37f5ea","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Elderly population (\u226565 years old)","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In the elderly, progressive deterioration of renal function may lead\r to a steady decrease in insulin requirements.<\/span><\/p>","ID":"379bc8e6-67d6-4b91-8046-7d0e00544420","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In the elderly, progressive deterioration of renal function may lead\r to a steady decrease in insulin requirements.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"4a50a46d-efc9-432a-8f38-c72799b0f2b2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"e4adcb9e-dc29-4c2a-9b59-c5bc642a0e23","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Renal impairment","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">In patients with renal impairment, insulin requirements\r may be diminished due to reduced insulin metabolism.<\/span><\/p>","ID":"e1f2706a-b5b5-4d25-a5de-a30d808fff3c","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In patients with renal impairment, insulin requirements\r may be diminished due to reduced insulin metabolism.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"a37f07ad-947c-4dcc-9951-5312ef6021c9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p>","ID":"0bcb943e-5391-4828-b532-bcb334619621","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hepatic impairment","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">In patients with hepatic impairment, insulin\r requirements may be diminished due to reduced capacity for gluconeogenesis and\r reduced insulin metabolism.<\/span><\/p>","ID":"6189be8e-7184-4214-970d-8efbf76c828a","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In patients with hepatic impairment, insulin\r requirements may be diminished due to reduced capacity for gluconeogenesis and\r reduced insulin metabolism.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"a44b7ff1-2e77-4342-8068-629ac03e6517","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p>","ID":"ce636eec-8ca2-4a81-a897-bf3ee17e7633","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Paediatric population","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"9954580c-7194-49c4-9bd8-68316c0c44e9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Adolescents and children aged 2 years and older<\/span><\/i><\/p>","ID":"4c39170f-ba3c-4083-8536-b9040be46ab3","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Adolescents and children aged 2 years and older","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The safety and efficacy of insulin glargine have been established in\r adolescents and children aged 2 years and older (see section 5.1). The\r dose regimen (dose and timing) should be individually adjusted.<\/span><\/p>","ID":"a48ff673-b15b-4cac-b4d7-0d5f9e19c6a7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The safety and efficacy of insulin glargine have been established in\r adolescents and children aged 2 years and older (see section 5.1). The\r dose regimen (dose and timing) should be individually adjusted.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"42a0e98f-83eb-42c3-bd8b-70aea0b878b4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><span lang=\"EN-GB\">Children below 2 years of age<\/span><\/i><\/p>","ID":"abc5bed3-7de7-4b6d-8a70-875a965ba6e0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Children below 2 years of age","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The safety and efficacy of insulin glargine have not been\r established. No data are available. <\/span><\/p>","ID":"0b1ae989-b7f6-4619-bf98-665247f920cb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The safety and efficacy of insulin glargine have not been\r established. No data are available. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"9da38695-b99c-4d7a-a75b-ac9146f41bd0","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Switch from other insulins to ABASAGLAR<\/span><\/u><\/i><\/p>","ID":"e440d184-75d1-4f58-a3b7-078825ce3399","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Switch from other insulins to ABASAGLAR","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"e2d11d96-2469-485c-b7d4-fdf801bc3476","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">When switching from\r a treatment regimen with an intermediate or long-acting insulin to a regimen\r with ABASAGLAR, a change of the dose of the basal insulin may be required and\r the concomitant antidiabetic treatment may need to be adjusted (dose and timing\r of additional regular insulins or fast-acting insulin analogues or the dose of\r oral antidiabetic medicinal products). <\/span><\/p>","ID":"5f977c95-82a3-46b0-9d13-bef446ebbcfd","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"When switching from\r a treatment regimen with an intermediate or long-acting insulin to a regimen\r with ABASAGLAR, a change of the dose of the basal insulin may be required and\r the concomitant antidiabetic treatment may need to be adjusted (dose and timing\r of additional regular insulins or fast-acting insulin analogues or the dose of\r oral antidiabetic medicinal products). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"aeffd52e-bc88-4305-9e3b-6ac2a246ff0f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Switch from twice daily NPH insulin to ABASAGLAR<\/span><\/u><\/i><\/p>","ID":"37587eb0-71a5-4e88-9bc1-85e3f0a1318b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Switch from twice daily NPH insulin to ABASAGLAR","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"8d690213-f39f-4c9c-901b-b00de046669d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">To reduce the risk of nocturnal and early morning hypoglycaemia,\r patients who are changing their basal insulin regimen from a twice daily NPH\r insulin to a once daily regimen with ABASAGLAR should reduce their daily dose\r of basal insulin by 20-30 % during the first weeks of treatment.<\/span><\/p>","ID":"5bef2ce1-617e-4697-b61e-1233f3f2dfb7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"To reduce the risk of nocturnal and early morning hypoglycaemia,\r patients who are changing their basal insulin regimen from a twice daily NPH\r insulin to a once daily regimen with ABASAGLAR should reduce their daily dose\r of basal insulin by 20-30 % during the first weeks of treatment.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"30b4ce0a-eb93-44be-9c6e-8333b6a70376","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Switch\r from insulin glargine 300 units\/ml to ABASAGLAR<\/span><\/u><\/i><\/p>","ID":"27daf702-277b-43cf-8a79-9192f63c3beb","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Switch\r from insulin glargine 300 units\/ml to ABASAGLAR","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"6fb0f3c0-d3bc-4593-a4dd-2b71f0c55862","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR and Toujeo\r (insulin glargine 300 units\/ml) are not bioequivalent and are not directly\r interchangeable. To reduce the risk of hypoglycemia, patients who are changing\r their basal insulin regimen from an insulin regimen with once daily insulin\r glargine 300 units\/ml to a once daily regimen with ABASAGLAR should reduce\r their dose by approximately 20%.<\/span><\/p>","ID":"cb00b827-f3fa-4a35-a225-a01a7d1d410d","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR and Toujeo\r (insulin glargine 300 units\/ml) are not bioequivalent and are not directly\r interchangeable. To reduce the risk of hypoglycemia, patients who are changing\r their basal insulin regimen from an insulin regimen with once daily insulin\r glargine 300 units\/ml to a once daily regimen with ABASAGLAR should reduce\r their dose by approximately 20%.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"e3e0cc84-f036-4872-a341-b6507100dee5","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">During the first weeks the reduction should, at least partially, be\r compensated by an increase in mealtime insulin, after this period the regimen\r should be adjusted individually. <\/span><\/p>","ID":"6ef1368f-405e-4e2b-aaae-3d9be9adefc0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"During the first weeks the reduction should, at least partially, be\r compensated by an increase in mealtime insulin, after this period the regimen\r should be adjusted individually. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"f6eb4fd8-ec5c-4212-930c-e710ddd97c59","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Close metabolic monitoring is recommended during the switch and in\r the initial weeks thereafter. <\/span><\/p>","ID":"97b7ac57-9d52-49f0-8208-e4e329cad511","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Close metabolic monitoring is recommended during the switch and in\r the initial weeks thereafter. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">With improved metabolic control and resulting increase in insulin\r sensitivity a further adjustment in dose regimen may become necessary. Dose\r adjustment may also be required, for example, if the patient's weight or\r life-style changes, change of timing of insulin dose or other circumstances\r arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see\r section 4.4). <\/span><\/p>","ID":"a993bdd0-f3e9-44c2-8a12-55fc798e2cf1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"With improved metabolic control and resulting increase in insulin\r sensitivity a further adjustment in dose regimen may become necessary. Dose\r adjustment may also be required, for example, if the patient's weight or\r life-style changes, change of timing of insulin dose or other circumstances\r arise that increase susceptibility to hypoglycaemia or hyperglycaemia (see\r section 4.4). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"b5a00e72-c145-4f27-9b29-7b1ff92050eb","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients with high insulin doses because of antibodies to human\r insulin may experience an improved insulin response with ABASAGLAR.<\/span><\/p>","ID":"e728d72e-6887-4843-9121-3de27688c306","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Patients with high insulin doses because of antibodies to human\r insulin may experience an improved insulin response with ABASAGLAR.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"2c491060-f8e5-4421-ad93-ea302bb92a78","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Method of administration<\/span><\/u><\/p>","ID":"9977e3b9-97b4-4bda-b19e-2a8a57535423","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Method of administration","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"d6ccc009-71e7-46fa-9163-8b99e273dbc4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is administered subcutaneously.<\/span><\/p>","ID":"907acb7a-bc00-41b5-b653-22ae37d1bbfa","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR is administered subcutaneously.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"03c53cb6-fa3f-4c10-914f-9295fb26eafb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR should not be administered intravenously. The prolonged\r duration of action of insulin glargine is dependent on its injection into\r subcutaneous tissue. Intravenous administration of the usual subcutaneous dose\r could result in severe hypoglycaemia.<\/span><\/p>","ID":"34e5d6f5-4e70-4de4-8a74-5406ca19e868","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR should not be administered intravenously. The prolonged\r duration of action of insulin glargine is dependent on its injection into\r subcutaneous tissue. Intravenous administration of the usual subcutaneous dose\r could result in severe hypoglycaemia.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"bfaae5d0-a077-4771-8272-075edd8cf6eb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">There are no clinically relevant differences in serum insulin or\r glucose levels after abdominal, deltoid or thigh administration of insulin\r glargine. <\/span><\/p>","ID":"86a53c04-2ff5-4003-a70d-4e5481f4d64b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"There are no clinically relevant differences in serum insulin or\r glucose levels after abdominal, deltoid or thigh administration of insulin\r glargine. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"24ffe592-4f29-4afe-924f-b6d6af19c6b9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Injection sites should always be rotated within the same region in\r order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see\r section 4.4 and 4.8).<\/span><\/p>","ID":"5c953284-5404-4f0e-bf0b-7410a49c5d81","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Injection sites should always be rotated within the same region in\r order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see\r section 4.4 and 4.8).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"850887b0-9a46-45fe-ae91-49bf49845e53","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR must not be mixed with any other insulin or diluted.\r Mixing or diluting can change its time\/action profile and mixing can cause\r precipitation. <\/span><\/p>","ID":"078167f7-b13e-4379-9b34-ca6ea52fad2e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR must not be mixed with any other insulin or diluted.\r Mixing or diluting can change its time\/action profile and mixing can cause\r precipitation. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"3454f9df-a219-441e-bc52-00f907b7ff86","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For further details on handling, see section 6.6.<\/span><\/p>","ID":"58711e79-f7ce-4db4-ba6f-50c24556ff9e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For further details on handling, see section 6.6.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"12fbd487-5db7-400d-84d9-022df4ea1e71","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Before using ABASAGLAR solution for injection in pre\u2011filled\r pen, the instructions for use included in the package leaflet must be read\r carefully (see section 6.6).<\/span><\/p>","ID":"998275d0-d2fa-4efc-a20d-30e243b65b0a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Before using ABASAGLAR solution for injection in pre\u2011filled\r pen, the instructions for use included in the package leaflet must be read\r carefully (see section 6.6).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"ecb4f91e-47c8-49b7-8aaa-a5a2e3a15cbf","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"Default\"><i><u><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>KwikPen<\/span><\/u><\/i><\/p>","ID":"d424d7ca-e734-4bbe-baf0-1048dd3795e0","Styles":"None","Classes":"['Default']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"KwikPen","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"Default\"><i><u><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><\/span><\/u><\/i><\/p>","ID":"b682eaae-1f2a-4199-9980-20a0ae778ac5","Styles":"None","Classes":"['Default']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"Default\"><a name=\"_Hlk46321788\"><span style='font-size:11.0pt;\r font-family:\"Times New Roman\",serif'>The<\/span><\/a><span style='font-size:11.0pt;\r font-family:\"Times New Roman\",serif'>K<\/span><span lang=\"BG\" style='font-size:\r 11.0pt;font-family:\"Times New Roman\",serif'>wik<\/span><span style='font-size:\r 11.0pt;font-family:\"Times New Roman\",serif'>P<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>en is <\/span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>registered<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'> in two\r presentations. One <a name=\"_Hlk46321308\">delivers 1 \u201360 units<\/a> in\r steps of<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>1 unit\r in a single injection<\/span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\r and the other<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>\r delivers 1 \u2013 <\/span><span style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>8<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>0 units\r in steps of 1 unit in a single injection. The needed dose is dialled in\r units. The number of units is shown in the dose window of the pen<\/span><span lang=\"BG\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'>. <\/span><\/p>","ID":"279e9045-710d-4600-a55b-8eb26fcffff7","Styles":"None","Classes":"['Default']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"TheKwikPen is registered in two\r presentations. One delivers 1 \u201360 units in\r steps of1 unit\r in a single injection\r and the other\r delivers 1 \u2013 80 units\r in steps of 1 unit in a single injection. The needed dose is dialled in\r units. The number of units is shown in the dose window of the pen. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"ca6b27a9-292c-4c09-b73c-b56aca89c919","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Tempo Pen<\/span><\/u><\/i><\/p>","ID":"33b4c5b8-1c10-4a1e-9bcb-70a360b8185a","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Tempo Pen","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"9c22d749-8045-4604-962d-27c366af2673","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><a name=\"_Hlk38964026\"><span lang=\"EN-GB\">The Tempo Pen delivers 1 \u2013 80 units in steps of 1 unit\r in a single injection. The needed dose is dialled in units. The number of units\r is shown in the dose window of the pen.<\/span><\/a><\/p>","ID":"a34597da-6f78-4f58-926e-7c43ddf1cd83","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The Tempo Pen delivers 1 \u2013 80 units in steps of 1 unit\r in a single injection. The needed dose is dialled in units. The number of units\r is shown in the dose window of the pen.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"mdTblEntry\" style=\"line-height:normal\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The Tempo Pen can be used with the optional transfer\r module Tempo Smart Button (see section 6.6).<\/span><\/p>","ID":"0156ba71-14db-4d18-bdd3-692870bc49f7","Styles":"line-height:normal","Classes":"['mdTblEntry']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The Tempo Pen can be used with the optional transfer\r module Tempo Smart Button (see section 6.6).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"mdTblEntry\" style=\"line-height:normal\"><\/p>","ID":"117d1189-aefe-49ea-b38b-63070c5d7dfe","Styles":"line-height:normal","Classes":"['mdTblEntry']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><a name=\"_Hlk32916492\"><span lang=\"EN-GB\">As with any insulin injection,\r when using the Tempo Pen, Smart Button and the mobile application,<\/span><\/a><span lang=\"EN-GB\">the\r patient should be instructed to check their blood sugar levels when considering\r or making decisions about another injection if they are unsure how much they\r have injected.<\/span><\/p>","ID":"b6d05289-4ca1-4ae4-a9d6-ae70fcfbc20a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"As with any insulin injection,\r when using the Tempo Pen, Smart Button and the mobile application,the\r patient should be instructed to check their blood sugar levels when considering\r or making decisions about another injection if they are unsure how much they\r have injected.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"afd8b269-4b8f-4581-b7da-5f810b060e3c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/b><\/p>","ID":"f4886492-4929-4dfe-8b54-03d287fd64c2","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.3     Contraindications","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","ID":"b6a96462-ebe2-4102-8638-ed00bf315fe7","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">Hypersensitivity to the active substance or to any of\r the excipients listed in section 6.1.<\/span><\/p>","ID":"5b3087b6-9d21-4966-831a-f694aa589189","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hypersensitivity to the active substance or to any of\r the excipients listed in section 6.1.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"47492c5c-abf6-45e3-a747-fa8d7d18c9e0","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.4     Special warnings and precautions for use<\/span><\/b><\/p>","ID":"a762b758-2632-4ffc-b451-7e8af2168099","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.4     Special warnings and precautions for use","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"1b267124-7941-4341-84c4-7636713bdcac","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Traceability<\/span><\/u><\/p>","ID":"79bc4105-b97e-4d8a-8f78-b91dd23cb8fc","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Traceability","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"08a4705e-3545-4f1f-a4d2-a3e6330b4dd5","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered medicinal product should be clearly recorded.<\/span><\/p>","ID":"6cc52e48-266b-43ec-a58c-cd43b9640d60","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In order to\r improve the traceability of biological medicinal products, the name and the\r batch number of the administered medicinal product should be clearly recorded.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p>","ID":"5ea8dfbd-9232-45d0-b2f9-dbdc17f31615","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Diabetic ketoacidosis<\/span><\/u><\/p>","ID":"b885427f-6f56-4047-8b80-a35f024ca6bb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Diabetic ketoacidosis","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p>","ID":"61238fb2-83c7-46fd-ad8e-1f2ef7a9ae15","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR is not the insulin of choice for the treatment of diabetic\r ketoacidosis. Instead, regular insulin administered intravenously is\r recommended in such cases. <\/span><\/p>","ID":"2caff13d-57c1-4b72-99d4-e2c77e88c4d9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR is not the insulin of choice for the treatment of diabetic\r ketoacidosis. Instead, regular insulin administered intravenously is\r recommended in such cases. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"e1ff7d0f-de99-46ac-87fc-fc5cfc1ac713","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Insulin requirements and dose adjustments<\/span><\/u><\/p>","ID":"ee02c9fa-65df-4b06-8b86-cc015349235f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin requirements and dose adjustments","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"fd1622a2-cc7e-4451-91e7-0596516acd3f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In case of insufficient glucose control or a tendency to\r hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the\r prescribed treatment regimen, injection sites and proper injection technique\r and all other relevant factors must be reviewed before dose adjustment is\r considered.<\/span><\/p>","ID":"a6ffe2dd-c2a0-4f64-afb9-6253717fdfae","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In case of insufficient glucose control or a tendency to\r hyperglycaemic or hypoglycaemic episodes, the patient's adherence to the\r prescribed treatment regimen, injection sites and proper injection technique\r and all other relevant factors must be reviewed before dose adjustment is\r considered.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"9d92b487-062e-4a1e-b1bb-80eb0d58bdc4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Transferring a patient to another type or brand of insulin should be\r done under strict medical supervision. Changes in strength, brand\r (manufacturer), type (regular, NPH, lente, long\u2011acting, etc.), origin\r (animal, human, human insulin analogue) and\/or method of manufacture may result\r in the need for a change in dose.<\/span><\/p>","ID":"68718bff-30c2-4c5d-8be9-c25192d32b0f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Transferring a patient to another type or brand of insulin should be\r done under strict medical supervision. Changes in strength, brand\r (manufacturer), type (regular, NPH, lente, long\u2011acting, etc.), origin\r (animal, human, human insulin analogue) and\/or method of manufacture may result\r in the need for a change in dose.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"07aa1b41-8136-4067-9b46-d636685baeb1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/u><\/p>","ID":"11b76990-c7b6-4b14-a4cf-859cdaff9b47","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hypoglycaemia","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"e318d732-15b5-43b0-a181-7a7ca0b4f56c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The time of occurrence of hypoglycaemia depends on the action\r profile of the insulins used and may, therefore, change when the treatment\r regimen is changed. Due to more sustained basal insulin supply with insulin\r glargine, less nocturnal but more early morning hypoglycaemia can be expected.<\/span><\/p>","ID":"9b784bcc-fecb-48b1-bb3d-99a1dfa043b7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The time of occurrence of hypoglycaemia depends on the action\r profile of the insulins used and may, therefore, change when the treatment\r regimen is changed. Due to more sustained basal insulin supply with insulin\r glargine, less nocturnal but more early morning hypoglycaemia can be expected.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"5a390dfe-7948-4e21-a1f1-e93595dc7b47","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Particular caution should be exercised, and intensified blood\r glucose monitoring is advisable in patients in whom hypoglycaemic episodes\r might be of particular clinical relevance, such as in patients with significant\r stenoses of the coronary arteries or of the blood vessels supplying the brain\r (risk of cardiac or cerebral complications of hypoglycaemia) as well as in\r patients with proliferative retinopathy, particularly if not treated with\r photocoagulation (risk of transient amaurosis following hypoglycaemia). <\/span><\/p>","ID":"e9bb5841-239e-4b9e-a943-0c1be28c3881","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Particular caution should be exercised, and intensified blood\r glucose monitoring is advisable in patients in whom hypoglycaemic episodes\r might be of particular clinical relevance, such as in patients with significant\r stenoses of the coronary arteries or of the blood vessels supplying the brain\r (risk of cardiac or cerebral complications of hypoglycaemia) as well as in\r patients with proliferative retinopathy, particularly if not treated with\r photocoagulation (risk of transient amaurosis following hypoglycaemia). ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"5afc0990-ac89-43b9-8267-56bf30d77c4b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients should be aware of circumstances where warning symptoms of\r hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be\r changed, be less pronounced or be absent in certain risk groups. These include\r patients:<\/span><\/p>","ID":"834e2878-23e8-4b04-9276-70a5f99f432a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Patients should be aware of circumstances where warning symptoms of\r hypoglycaemia are diminished. The warning symptoms of hypoglycaemia may be\r changed, be less pronounced or be absent in certain risk groups. These include\r patients:","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom glycaemic control\r is markedly improved,<\/span><\/p>","ID":"9cfbcc3a-ec29-4830-af1d-b411677be947","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        in whom glycaemic control\r is markedly improved,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom hypoglycaemia\r develops gradually,<\/span><\/p>","ID":"bece3fc0-9b6b-42cd-a86d-eb7361169a3e","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        in whom hypoglycaemia\r develops gradually,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        who are elderly,<\/span><\/p>","ID":"e745c6bf-848f-499d-8187-366c5dd2c442","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        who are elderly,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        after transfer from\r animal insulin to human insulin,<\/span><\/p>","ID":"9a5d7286-46e5-41d1-a2c8-1546da0fb789","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        after transfer from\r animal insulin to human insulin,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        in whom an autonomic\r neuropathy is present,<\/span><\/p>","ID":"ca7476f4-8e64-482f-93b0-ff5a19943dbe","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        in whom an autonomic\r neuropathy is present,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        with a long history of\r diabetes,<\/span><\/p>","ID":"6634b7d5-aa07-4973-a002-7a6a71d24bc8","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        with a long history of\r diabetes,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        suffering from a\r psychiatric illness,<\/span><\/p>","ID":"c216fbac-07eb-4069-abd3-1ac5f5ff9f3b","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        suffering from a\r psychiatric illness,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        receiving concurrent\r treatment with certain other medicinal products (see section 4.5).<\/span><\/p>","ID":"ac54c8f8-1524-4333-a385-b275ae594f4b","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        receiving concurrent\r treatment with certain other medicinal products (see section 4.5).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"bdd0b0b9-24a0-4f47-bf19-fdc9f921ae63","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Such situations may result in severe hypoglycaemia (and possibly\r loss of consciousness) prior to the patient's awareness of hypoglycaemia.<\/span><\/p>","ID":"f37351a5-3138-411f-b46b-c00f9bc17059","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Such situations may result in severe hypoglycaemia (and possibly\r loss of consciousness) prior to the patient's awareness of hypoglycaemia.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"78134040-3b0b-4916-9588-e42626573ffa","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The prolonged effect of subcutaneous insulin glargine may delay\r recovery from hypoglycaemia.<\/span><\/p>","ID":"bebcc18b-50c9-4678-81ff-cbe3b9065ca0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The prolonged effect of subcutaneous insulin glargine may delay\r recovery from hypoglycaemia.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"f642f9cc-2e63-42ef-abe2-b0374c9e511c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">If normal or decreased values for glycated haemoglobin are noted,\r the possibility of recurrent, unrecognised (especially nocturnal) episodes of\r hypoglycaemia must be considered. <\/span><\/p>","ID":"2a30aefa-1106-4759-be61-b62b67a5ad62","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"If normal or decreased values for glycated haemoglobin are noted,\r the possibility of recurrent, unrecognised (especially nocturnal) episodes of\r hypoglycaemia must be considered. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"7427da0a-9225-46e8-927b-ba52a9542c4f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Adherence of the patient to the dose and dietary regimen, correct\r insulin administration and awareness of hypoglycaemia symptoms are essential to\r reduce the risk of hypoglycaemia. Factors increasing the susceptibility to\r hypoglycaemia require particularly close monitoring and may necessitate dose\r adjustment. These include:<\/span><\/p>","ID":"5b8ee7b5-f819-4ff4-912f-8ae60967c699","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Adherence of the patient to the dose and dietary regimen, correct\r insulin administration and awareness of hypoglycaemia symptoms are essential to\r reduce the risk of hypoglycaemia. Factors increasing the susceptibility to\r hypoglycaemia require particularly close monitoring and may necessitate dose\r adjustment. These include:","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        change in the injection\r area,<\/span><\/p>","ID":"6e87d1a6-9d61-437a-be93-b571c9a94862","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        change in the injection\r area,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        improved insulin\r sensitivity (e.g., by removal of stress factors),<\/span><\/p>","ID":"6f19e910-e98d-4651-b166-8fb93691012a","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        improved insulin\r sensitivity (e.g., by removal of stress factors),","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        unaccustomed, increased\r or prolonged physical activity,<\/span><\/p>","ID":"ab4a677d-82f8-4aae-82df-1357557a5ea9","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        unaccustomed, increased\r or prolonged physical activity,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        intercurrent illness\r (e.g. vomiting, diarrhoea),<\/span><\/p>","ID":"b91c2253-f9a7-4c22-a856-2a2528e33423","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        intercurrent illness\r (e.g. vomiting, diarrhoea),","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        inadequate food intake,<\/span><\/p>","ID":"31fad6c4-5151-4228-9d89-591c415d3686","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        inadequate food intake,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        missed meals,<\/span><\/p>","ID":"0ccb5654-bf50-4ee0-898f-fddc10309dcf","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        missed meals,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        alcohol consumption,<\/span><\/p>","ID":"81989041-3143-4b0e-bfc4-0b4b232aa026","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        alcohol consumption,","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        certain uncompensated\r endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or\r adrenocortical insufficiency),<\/span><\/p>","ID":"4e53b5de-aa61-40bc-aa44-06ef3b9cde22","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        certain uncompensated\r endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or\r adrenocortical insufficiency),","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><span lang=\"EN-GB\">-        concomitant treatment\r with certain other medicinal products.<\/span><\/p>","ID":"dbdc239a-5ae4-44d1-99f5-3edb613348c9","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"-        concomitant treatment\r with certain other medicinal products.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><\/p>","ID":"33d2e3ba-969b-4a80-a145-cd8dd8ad4a62","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Injection\r technique<\/span><\/u><\/p>","ID":"05e44829-0639-4278-b31f-ada370824ec9","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Injection\r technique","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"7f0e3e95-5e95-45cb-bc3a-246568aa4525","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Patients must be instructed to perform\r continuous rotation of the injection site to reduce the risk of developing\r lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed\r insulin absorption and worsened glycaemic control following insulin injections at\r sites with these reactions. A sudden change in the injection site to an\r unaffected area has been reported to result in hypoglycaemia. Blood glucose\r monitoring is recommended after the change in the injection site, and dose\r adjustment of antidiabetic medications may be considered.<\/span><\/p>","ID":"5e81a042-73e1-4cf1-8431-0dd6871e407c","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Patients must be instructed to perform\r continuous rotation of the injection site to reduce the risk of developing\r lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed\r insulin absorption and worsened glycaemic control following insulin injections at\r sites with these reactions. A sudden change in the injection site to an\r unaffected area has been reported to result in hypoglycaemia. Blood glucose\r monitoring is recommended after the change in the injection site, and dose\r adjustment of antidiabetic medications may be considered.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;text-autospace:none\"><\/p>","ID":"8dc7c5a8-a035-424a-b001-13e833ae5879","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"f2a01fe2-bdf2-45b4-b309-b68ed2814ffe","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Intercurrent illness<\/span><\/u><\/p>","ID":"a05714b1-2773-477b-938b-29e195b409d0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Intercurrent illness","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"0ac1f2ab-213e-4cab-8d44-604f9c451019","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Intercurrent illness requires intensified metabolic monitoring. In\r many cases urine tests for ketones are indicated, and often it is necessary to\r adjust the insulin dose. The insulin requirement is often increased. Patients\r with type 1 diabetes must continue to consume at least a small amount of\r carbohydrates on a regular basis, even if they are able to eat only little or\r no food, or are vomiting etc. and they must never omit insulin entirely. <\/span><\/p>","ID":"8788f47c-feb2-4cf8-8a88-57896f5d2df1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Intercurrent illness requires intensified metabolic monitoring. In\r many cases urine tests for ketones are indicated, and often it is necessary to\r adjust the insulin dose. The insulin requirement is often increased. Patients\r with type 1 diabetes must continue to consume at least a small amount of\r carbohydrates on a regular basis, even if they are able to eat only little or\r no food, or are vomiting etc. and they must never omit insulin entirely. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"fe77b0b4-0768-453f-9f3f-8117401ab457","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Insulin antibodies<\/span><\/u><\/p>","ID":"1be89aa5-d9f7-48c7-94b1-587e4a787ebd","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin antibodies","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"593015eb-970d-416a-80a4-f0bb5c0486bb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin administration may cause insulin antibodies to form. In rare\r cases, the presence of such insulin antibodies may necessitate adjustment of\r the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see\r section 5.1).<\/span><\/p>","ID":"bc76209b-0682-4f0c-af55-1c11382777f7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin administration may cause insulin antibodies to form. In rare\r cases, the presence of such insulin antibodies may necessitate adjustment of\r the insulin dose in order to correct a tendency to hyper- or hypoglycaemia (see\r section 5.1).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"a69c208d-001b-4605-ada0-a0c5df09e2aa","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Medication errors<\/span><\/u><\/p>","ID":"8aa878d6-ba00-437d-9838-6a6847b070c4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Medication errors","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"2f3be983-e263-4cac-99fa-615f6bf06b5a","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Medication\r errors have been reported in which other insulins, particularly short\u2011acting\r insulins, have been accidentally administered instead of insulin glargine.\r Insulin label must always be checked before each injection to avoid medication\r errors between ABASAGLAR pre-filled pen as well as other insulins.<\/span><\/p>","ID":"b08c6b45-1ba8-40eb-a847-fc98fa2ef6bf","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Medication\r errors have been reported in which other insulins, particularly short\u2011acting\r insulins, have been accidentally administered instead of insulin glargine.\r Insulin label must always be checked before each injection to avoid medication\r errors between ABASAGLAR pre-filled pen as well as other insulins.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"4c138eb0-d600-4023-be5c-1e0838b7da57","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Combination of ABASAGLAR with pioglitazone<\/span><\/u><\/p>","ID":"3ff598dd-d296-48d5-b418-25ef3303f266","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Combination of ABASAGLAR with pioglitazone","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","ID":"cf913b97-90c9-4856-aaa2-791805edd83f","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><span lang=\"EN-GB\">Cases of cardiac failure have been reported when pioglitazone was\r used in combination with insulin, especially in patients with risk factors for\r development of cardiac heart failure. This should be kept in mind if treatment\r with the combination of pioglitazone and ABASAGLAR is considered. If the\r combination is used, patients should be observed for signs and symptoms of\r heart failure, weight gain and oedema. Pioglitazone should be discontinued if\r any deterioration in cardiac symptoms occurs.<\/span><\/p>","ID":"c2f2b13b-3473-4d70-9bd6-fcf4247ff52d","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Cases of cardiac failure have been reported when pioglitazone was\r used in combination with insulin, especially in patients with risk factors for\r development of cardiac heart failure. This should be kept in mind if treatment\r with the combination of pioglitazone and ABASAGLAR is considered. If the\r combination is used, patients should be observed for signs and symptoms of\r heart failure, weight gain and oedema. Pioglitazone should be discontinued if\r any deterioration in cardiac symptoms occurs.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"7db47555-4b6f-4acc-80ea-82fae76e5680","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Tempo Pen<\/span><\/u><\/p>","ID":"f73c2962-9f7d-4c5e-b501-41db06c408af","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Tempo Pen","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"095be181-c806-41b8-917b-8c998975e327","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The Tempo Pen\r contains a magnet (see section 6.5) that may interfere with the functions of an\r implantable electronic medical device, such as a pacemaker. T<\/span><span lang=\"EN-GB\">he magnetic field extends to approximately 1.5 cm<\/span><span lang=\"EN-GB\">.<\/span><\/p>","ID":"d6db13a9-c6b4-470b-a7ce-81a050ed0844","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The Tempo Pen\r contains a magnet (see section 6.5) that may interfere with the functions of an\r implantable electronic medical device, such as a pacemaker. The magnetic field extends to approximately 1.5 cm.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"eb04483d-63fa-4142-bd74-9c89950575f8","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Sodium\r content<\/span><\/u><\/p>","ID":"7a5d6063-a033-4478-8722-62f8958ec5ad","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Sodium\r content","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"a1f251b9-e74e-45b8-9282-4ac89b10cee6","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">This medicinal product contains less than 1 mmol sodium\r (23 mg) per dose, i.e., essentially \u201csodium\u2011free\u201d.<\/span><\/p>","ID":"c2832bea-96d5-46e2-b3f8-e91918c8a25f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"This medicinal product contains less than 1 mmol sodium\r (23 mg) per dose, i.e., essentially \u201csodium\u2011free\u201d.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"b0fc9595-591a-4f34-8972-236a9fbdec33","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.5     Interaction with other medicinal products\r and other forms of interaction<\/span><\/b><\/p>","ID":"c46b7e2f-aa52-40ac-9d3a-66adeada3d55","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.5     Interaction with other medicinal products\r and other forms of interaction","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"3213c660-e729-42c6-9d1a-d2a641246ca1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A number of substances affect glucose metabolism and may require\r dose adjustment of insulin glargine.<\/span><\/p>","ID":"434c0a0f-3049-41a7-8fde-978435bea0d6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"A number of substances affect glucose metabolism and may require\r dose adjustment of insulin glargine.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"7833993b-fe21-4cca-9e14-f698835fde5a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Substances that may enhance the blood-glucose\u2011lowering effect\r and increase susceptibility to hypoglycaemia include oral antidiabetic\r medicinal products, angiotensin converting enzyme (ACE) inhibitors,\r disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,\r pentoxifylline, propoxyphene, salicylates, somatostatin anologues and\r sulphonamide antibiotics. <\/span><\/p>","ID":"1690e13d-2686-4164-905b-5acdf622093d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Substances that may enhance the blood-glucose\u2011lowering effect\r and increase susceptibility to hypoglycaemia include oral antidiabetic\r medicinal products, angiotensin converting enzyme (ACE) inhibitors,\r disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors,\r pentoxifylline, propoxyphene, salicylates, somatostatin anologues and\r sulphonamide antibiotics. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"63474a39-d4a6-494b-adf3-5cc4a1482ec1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Substances that may reduce the blood-glucose-lowering effect include\r corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid,\r oestrogens, progestogens, phenothiazine derivatives, somatropin,\r sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,\r terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g.\r clozapine and olanzapine) and protease inhibitors. <\/span><\/p>","ID":"9bc22b26-2a0c-4a5d-bce0-187c1542c8f0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Substances that may reduce the blood-glucose-lowering effect include\r corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid,\r oestrogens, progestogens, phenothiazine derivatives, somatropin,\r sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol,\r terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g.\r clozapine and olanzapine) and protease inhibitors. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"2eae74bc-97d5-433f-8e74-d8c65ddefc40","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Beta-blockers, clonidine, lithium salts or alcohol may either\r potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine\r may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. <\/span><\/p>","ID":"8acb819b-debd-4ab9-ad4b-9978050244d8","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Beta-blockers, clonidine, lithium salts or alcohol may either\r potentiate or weaken the blood-glucose lowering effect of insulin. Pentamidine\r may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"6571f06e-2ff0-407f-adbd-27152e353f44","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In addition, under the influence of sympatholytic medicinal products\r such as beta-blockers, clonidine, guanethidine and reserpine, the signs of\r adrenergic counter-regulation may be reduced or absent.<\/span><\/p>","ID":"f1b17e2b-b7a3-4c22-b072-caaec872ccbb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In addition, under the influence of sympatholytic medicinal products\r such as beta-blockers, clonidine, guanethidine and reserpine, the signs of\r adrenergic counter-regulation may be reduced or absent.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"dde9c746-9a91-4b7e-b6c1-f8a692e6ae0b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.6     <\/span><\/b><b><span lang=\"EN-GB\">Fertility, p<\/span><\/b><b><span lang=\"EN-GB\">regnancy and lactation<\/span><\/b><\/p>","ID":"70ed95b0-0a58-4846-8d37-d4aef9909503","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.6     Fertility, pregnancy and lactation","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"c67e12ac-cf43-4d70-b68c-4d452701f543","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p>","ID":"8b25433f-7f9a-4b31-a3ff-71f62264c8af","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Pregnancy","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"612370d2-6e7b-4682-9fd3-6610450b075e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For insulin glargine no clinical data on exposed pregnancies from\r controlled clinical studies are available. A large amount of data on pregnant\r women (more than 1,000 pregnancy outcomes) indicate no specific adverse\r effects of insulin glargine on pregnancy and no specific malformative nor\r feto\/neonatal toxicity of insulin glargine. <\/span><\/p>","ID":"39ed6db0-0a08-4eea-92a2-a897d8fa4510","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For insulin glargine no clinical data on exposed pregnancies from\r controlled clinical studies are available. A large amount of data on pregnant\r women (more than 1,000 pregnancy outcomes) indicate no specific adverse\r effects of insulin glargine on pregnancy and no specific malformative nor\r feto\/neonatal toxicity of insulin glargine. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1f8f1375-cdca-4a49-bc6b-19ccebf004eb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Animal data do not indicate reproductive toxicity. <\/span><\/p>","ID":"5716e14c-e637-4f4e-b394-bc92b63722f4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Animal data do not indicate reproductive toxicity. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"67d84f96-196f-4625-b256-53beb9c8e867","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The use of ABASAGLAR may be considered during pregnancy, if clinically\r needed.<\/span><\/p>","ID":"3363c625-5780-4ccc-ab9d-a73ba0ba7714","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The use of ABASAGLAR may be considered during pregnancy, if clinically\r needed.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"6f5ed0b3-4beb-48a3-9359-e7c733b3a556","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">It is essential for patients with pre-existing or gestational\r diabetes to maintain good metabolic control throughout pregnancy to prevent\r adverse outcomes associated with hyperglycaemia. Insulin requirements may\r decrease during the first trimester and generally increase during the second\r and third trimesters. Immediately after delivery, insulin requirements decline\r rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose\r control is essential. <\/span><\/p>","ID":"57c2b53b-9459-49e9-8155-84da8fbda568","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"It is essential for patients with pre-existing or gestational\r diabetes to maintain good metabolic control throughout pregnancy to prevent\r adverse outcomes associated with hyperglycaemia. Insulin requirements may\r decrease during the first trimester and generally increase during the second\r and third trimesters. Immediately after delivery, insulin requirements decline\r rapidly (increased risk of hypoglycaemia). Careful monitoring of glucose\r control is essential. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"6dfe6137-70ce-4374-b64f-7586827d32f1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p>","ID":"62d6d3db-e9d8-41f6-852f-e7a3327d623c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Breast-feeding","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"3c9df958-3474-4a8e-badd-0cc021d51939","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">It is unknown whether insulin glargine is excreted in human milk. No\r metabolic effects of ingested insulin glargine on the breast\u2011fed\r newborn\/infant are anticipated since insulin glargine as a peptide is digested\r into amino acids in the human gastrointestinal tract. <\/span><\/p>","ID":"17d0ec35-5e32-4189-adbe-69ee9a9aa790","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"It is unknown whether insulin glargine is excreted in human milk. No\r metabolic effects of ingested insulin glargine on the breast\u2011fed\r newborn\/infant are anticipated since insulin glargine as a peptide is digested\r into amino acids in the human gastrointestinal tract. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b582997f-b2e8-494f-a79f-305ae0f87e8b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Breast-feeding women may require adjustments in insulin dose and\r diet. <\/span><\/p>","ID":"7e56b3da-9530-46ff-b7c0-4f75823dcbc1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Breast-feeding women may require adjustments in insulin dose and\r diet. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"e8f3fc1e-fb6d-41ff-a581-b5ae602fb256","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","ID":"fab4f2f2-79f2-476c-af03-bd2496595861","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Fertility","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1a0c9e46-5419-4a83-a103-7d51861259cb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Animal studies do not indicate direct harmful effects with respect\r to fertility.<\/span><\/p>","ID":"27f1470a-8a1e-40df-bad2-d2f6d8f5f57e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Animal studies do not indicate direct harmful effects with respect\r to fertility.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"3fba983c-40f1-4c0f-9cbe-6122d9c75cb3","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.7     Effects on ability to drive and use\r machines<\/span><\/b><\/p>","ID":"bcebb3f3-9dc6-47ca-8bf4-dd61b65ceaae","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.7     Effects on ability to drive and use\r machines","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"0f2b28e2-833e-4ced-a4b2-8ce934926309","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The patient's ability to concentrate and react may be impaired as a\r result of hypoglycaemia or hyperglycaemia or, for example, as a result of\r visual impairment. This may constitute a risk in situations where these\r abilities are of special importance (e.g. driving a car or using machines).<\/span><\/p>","ID":"d4988e4f-b8c0-485e-92ef-0837ea44f1e6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The patient's ability to concentrate and react may be impaired as a\r result of hypoglycaemia or hyperglycaemia or, for example, as a result of\r visual impairment. This may constitute a risk in situations where these\r abilities are of special importance (e.g. driving a car or using machines).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"92d137b8-7a58-4406-b09a-c8822a7a57a0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Patients should be advised to take precautions to avoid\r hypoglycaemia whilst driving. This is particularly important in those who have\r reduced or absent awareness of the warning symptoms of hypoglycaemia or have\r frequent episodes of hypoglycaemia. It should be considered whether it is\r advisable to drive or operate machines in these circumstances.<\/span><\/p>","ID":"8ebc2dba-9d7d-45f6-8708-3cae4dee8671","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Patients should be advised to take precautions to avoid\r hypoglycaemia whilst driving. This is particularly important in those who have\r reduced or absent awareness of the warning symptoms of hypoglycaemia or have\r frequent episodes of hypoglycaemia. It should be considered whether it is\r advisable to drive or operate machines in these circumstances.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"8f1e7270-b770-4144-b472-ea3033dbf573","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">4.8     Undesirable\r effects<\/span><\/b><\/p>","ID":"45873ef7-846a-48fa-be5f-02324c9580c0","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.8     Undesirable\r effects","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"d458d103-1615-4434-8458-94d53475c8e3","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Summary of safety profile<\/span><\/u><\/p>","ID":"e70c54d9-d9a2-4db2-9eef-7ea902405db9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Summary of safety profile","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"4dd94aaa-61be-45d1-a74a-810cc619c22d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Hypoglycaemia (very common), in general the most frequent adverse reaction\r of insulin therapy, may occur if the insulin dose is too high in relation to\r the insulin requirement (see section 4.4).<\/span><\/p>","ID":"ced86bb2-1617-49cc-aad6-a65d62f8f29f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hypoglycaemia (very common), in general the most frequent adverse reaction\r of insulin therapy, may occur if the insulin dose is too high in relation to\r the insulin requirement (see section 4.4).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"d91750b5-9e43-4260-866a-29992491ebd5","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">Tabulated list of adverse reactions<\/span><\/u><\/p>","ID":"96ac62a0-7ca1-42a7-ad7e-ea4feec476ce","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Tabulated list of adverse reactions","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","ID":"5ddf2439-15c8-4e10-b678-e694824ed9fb","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">The following related adverse reactions from clinical\r trials are listed below as MedDRA preferred term by system organ class and in\r order of decreasing incidence (very common: \u22651\/10; common: \u22651\/100\r to &lt;1\/10; uncommon: \u22651\/1,000 to &lt;1\/100; rare: \u22651\/10,000 to\r &lt;1\/1,000; very rare: &lt;1\/10,000 <a name=\"_Hlk23422201\"><span style=\"color:black\">and not known (cannot be estimated from the available data<\/span><\/a>).<\/span><\/p>","ID":"71d13dc0-8252-43ad-ab81-a8a11aaca3fa","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The following related adverse reactions from clinical\r trials are listed below as MedDRA preferred term by system organ class and in\r order of decreasing incidence (very common: \u22651\/10; common: \u22651\/100\r to <1\/10; uncommon: \u22651\/1,000 to <1\/100; rare: \u22651\/10,000 to\r <1\/1,000; very rare: <1\/10,000 and not known (cannot be estimated from the available data).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"0cf8d28e-43f2-454f-8621-b4102cf47967","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Within each frequency grouping, adverse reactions are presented in\r order of decreasing seriousness.<\/span><\/p>","ID":"08079a16-408c-4543-83bc-b64199cced4e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Within each frequency grouping, adverse reactions are presented in\r order of decreasing seriousness.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"4d7a7b35-68fa-4082-ad10-bb76cef452ae","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:12.5pt;border-collapse:collapse;border:none\" width=\"99%\"> <tr style=\"height:16.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">MedDRA system organ classes<\/span><\/b><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Very common<\/span><\/b><\/p> <\/td> <td style=\"width:12.28%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Common<\/span><\/b><\/p> <\/td> <td style=\"width:15.18%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Uncommon<\/span><\/b><\/p> <\/td> <td style=\"width:11.02%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Rare<\/span><\/b><\/p> <\/td> <td style=\"width:11.08%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Very rare<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border:solid windowtext 1.0pt;\r   border-left:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><b><span lang=\"EN-GB\">Not known<\/span><\/b><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Immune system disorders <\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Allergic reactions<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.75pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:16.3pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Nervous system disorders<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:16.3pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:11.0pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Dysgeusia<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:11.0pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Eyes disorders<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:11.0pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Visual impairment <\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Retinopathy<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Lipohypertrophy<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Lipoatrophy<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Cutaneous amyloidosis<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:none;\r   border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Musculoskeletal and connective tissue disorders<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"2\" style=\"width:22.24%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Myalgia<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:12.28%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td colspan=\"8\" style=\"width:87.0%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"87%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">General disorders and administration site conditions<\/span><\/b><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:22.1%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Injection site reactions<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td colspan=\"2\" style=\"width:12.42%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr style=\"height:5.75pt\"> <td style=\"width:22.1%;border:solid windowtext 1.0pt;\r   border-top:none;padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"22%\"> <p class=\"MsoNormal\" style=\"margin-bottom:2.55pt;line-height:normal;page-break-after:\r   avoid\"><span lang=\"EN-GB\">Oedema<\/span><\/p> <\/td> <td colspan=\"2\" style=\"width:15.2%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td colspan=\"2\" style=\"width:12.42%;border-top:none;\r   border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"12%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:15.18%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"15%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:11.02%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><span lang=\"EN-GB\">X<\/span><\/p> <\/td> <td style=\"width:11.08%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"11%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <td style=\"width:13.0%;border-top:none;border-left:\r   none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;\r   padding:0in 5.4pt 0in 5.4pt;height:5.75pt\" valign=\"top\" width=\"13%\"> <p align=\"center\" class=\"MsoNormal\" style=\"text-align:center;line-height:normal;\r   page-break-after:avoid\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"155\"><\/td> <td style=\"border:none\" width=\"1\"><\/td> <td style=\"border:none\" width=\"106\"><\/td> <td style=\"border:none\" width=\"1\"><\/td> <td style=\"border:none\" width=\"86\"><\/td> <td style=\"border:none\" width=\"106\"><\/td> <td style=\"border:none\" width=\"77\"><\/td> <td style=\"border:none\" width=\"78\"><\/td> <td style=\"border:none\" width=\"91\"><\/td> <\/tr> <\/table>","ID":"05b05a61-a416-438a-9311-a3d88c0875a1","Styles":"margin-left:12.5pt;border-collapse:collapse;border:none","Classes":"['MsoNormalTable']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"   MedDRA system organ classes   Very common   Common   Uncommon   Rare   Very rare   Not known     Immune system disorders         Allergic reactions            X           Metabolism and nutrition disorders        Hypoglycaemia   X                    Nervous system disorders        Dysgeusia               X        Eyes disorders        Visual impairment             X           Retinopathy            X           Skin and subcutaneous tissue disorders        Lipohypertrophy      X                 Lipoatrophy         X              Cutaneous amyloidosis                  X     Musculoskeletal and connective tissue disorders        Myalgia               X        General disorders and administration site conditions        Injection site reactions      X                 Oedema            X                    ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"bd9ee7f4-e979-4c73-b5da-6cdd59982b75","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Description of selected adverse reactions<\/span><\/u><\/p>","ID":"678f2aa5-fb47-4d1f-8a5c-30323c3b4081","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Description of selected adverse reactions","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b2d8c02f-ec67-495c-b17d-03b3ed69cd5f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Metabolism and nutrition disorders<\/span><\/u><\/i><\/p>","ID":"70c5cb2f-eff9-43d4-883a-0410da948150","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Metabolism and nutrition disorders","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"b39d819d-9f0a-44b8-8cce-638deae48bed","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Severe hypoglycaemic attacks, especially if recurrent, may lead to\r neurological damage. Prolonged or severe hypoglycaemic episodes may be\r life-threatening. In many patients, the signs and symptoms of neuroglycopenia\r are preceded by signs of adrenergic counter-regulation. Generally, the greater\r and more rapid the decline in blood glucose, the more marked is the phenomenon\r of counter-regulation and its symptoms.<\/span><\/p>","ID":"b1e3591c-c2f4-45bc-a868-607d8dcab618","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Severe hypoglycaemic attacks, especially if recurrent, may lead to\r neurological damage. Prolonged or severe hypoglycaemic episodes may be\r life-threatening. In many patients, the signs and symptoms of neuroglycopenia\r are preceded by signs of adrenergic counter-regulation. Generally, the greater\r and more rapid the decline in blood glucose, the more marked is the phenomenon\r of counter-regulation and its symptoms.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"a39654f1-c729-40f7-baa8-f94692e309b2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Immune system disorders<\/span><\/u><\/i><\/p>","ID":"d59a65ad-3ec1-4a39-99b7-9e96d2b0f323","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Immune system disorders","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"3733ac0b-1c73-4c45-978a-4bb8543164cc","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Immediate-type allergic reactions to insulin are rare. Such\r reactions to insulin (including insulin glargine) or the excipients may, for\r example, be associated with generalised skin reactions, angio-oedema,\r bronchospasm, hypotension and shock, and may be life-threatening.<\/span><\/p>","ID":"fa9cf473-3c11-4986-a1bd-e66a407f9028","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Immediate-type allergic reactions to insulin are rare. Such\r reactions to insulin (including insulin glargine) or the excipients may, for\r example, be associated with generalised skin reactions, angio-oedema,\r bronchospasm, hypotension and shock, and may be life-threatening.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"edc07111-61e1-48d7-bad6-29456ad62b33","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Eyes disorders<\/span><\/u><\/i><\/p>","ID":"c348623d-ab71-4dd3-999c-859305479858","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Eyes disorders","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"20be142e-1243-4407-81de-6e50a9f1be2d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">A marked change in glycaemic control may cause temporary visual\r impairment, due to temporary alteration in the turgidity and refractive index\r of the lens.<\/span><\/p>","ID":"75a06a19-94d3-4472-8790-90f5f194ba88","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"A marked change in glycaemic control may cause temporary visual\r impairment, due to temporary alteration in the turgidity and refractive index\r of the lens.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1d18223f-007b-467c-a39c-cc6fcce86c73","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Long-term improved glycaemic control decreases the risk of progression\r of diabetic retinopathy. However, intensification of insulin therapy with\r abrupt improvement in glycaemic control may be associated with temporary\r worsening of diabetic retinopathy. In patients with proliferative retinopathy,\r particularly if not treated with photocoagulation, severe hypoglycaemic\r episodes may result in transient amaurosis.<\/span><\/p>","ID":"4f527b79-8f93-49dc-9e2b-19b4fc70e91e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Long-term improved glycaemic control decreases the risk of progression\r of diabetic retinopathy. However, intensification of insulin therapy with\r abrupt improvement in glycaemic control may be associated with temporary\r worsening of diabetic retinopathy. In patients with proliferative retinopathy,\r particularly if not treated with photocoagulation, severe hypoglycaemic\r episodes may result in transient amaurosis.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"13f1f159-b8a7-4ff5-9fe7-60aefdb11fa0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Skin and subcutaneous tissue disorders<\/span><\/u><\/i><\/p>","ID":"6b0ca637-1c84-4a99-a854-e07259548a4c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Skin and subcutaneous tissue disorders","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"ee090a66-5cac-4d19-a7ef-004e613d9567","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><span lang=\"EN-GB\">Lipodystrophy and cutaneous amyloidosis may\r occur at the injection site and delay local insulin absorption. Continuous\r rotation of the injection site within the given injection area may help to\r reduce or prevent these reactions (<\/span><span lang=\"EN-GB\">see section 4.4).<\/span><\/p>","ID":"4dcc2da1-37ed-48ff-b447-7462eb418068","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Lipodystrophy and cutaneous amyloidosis may\r occur at the injection site and delay local insulin absorption. Continuous\r rotation of the injection site within the given injection area may help to\r reduce or prevent these reactions (see section 4.4).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"14cf0d8e-f72a-4d2a-a252-9dac969322fc","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><u><span lang=\"EN-GB\">General disorders and administration site\r conditions<\/span><\/u><\/i><\/p>","ID":"abf0878b-498d-4de7-8263-98b019b0a71a","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"General disorders and administration site\r conditions","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"83441822-383a-43ff-9f0b-4d22329fe2ce","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><span lang=\"EN-GB\">Injection site reactions include redness, pain, itching,\r hives, swelling, or inflammation. Most minor reactions to insulins at the\r injection site usually resolve in a few days to a few weeks. <\/span><\/p>","ID":"1838bb30-ee54-40f0-b453-d6e70ee7e913","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Injection site reactions include redness, pain, itching,\r hives, swelling, or inflammation. Most minor reactions to insulins at the\r injection site usually resolve in a few days to a few weeks. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"fc914f67-4a42-4f35-bc36-6a6f69433f13","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Rarely, insulin may cause sodium retention and oedema particularly\r if previously poor metabolic control is improved by intensified insulin therapy.<\/span><\/p>","ID":"28c84c4b-2865-4e44-acd7-1a4ccdb4cdcd","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Rarely, insulin may cause sodium retention and oedema particularly\r if previously poor metabolic control is improved by intensified insulin therapy.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><\/b><\/p>","ID":"54c8b7d6-ce53-4f9a-af4e-12af5628f8cc","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p>","ID":"383cdeea-63f1-45e4-8b4d-c1282d61f590","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Paediatric population","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"77ddaebd-b32c-4f4b-8690-3891c3756b82","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In general, the safety profile for children and adolescents\r (\u2264 18 years of age) is similar to the safety profile for\r adults. The adverse reaction reports received from post marketing surveillance\r included relatively more frequent injection site reactions (injection site\r pain, injection site reaction) and skin reactions (rash, urticaria) in children\r and adolescents (\u2264 18 years of age) than in adults. Clinical\r study safety data are not available for children under 2 years.<\/span><\/p>","ID":"de46ce6c-affd-4d1a-a7d3-70cbf841ace0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In general, the safety profile for children and adolescents\r (\u2264 18 years of age) is similar to the safety profile for\r adults. The adverse reaction reports received from post marketing surveillance\r included relatively more frequent injection site reactions (injection site\r pain, injection site reaction) and skin reactions (rash, urticaria) in children\r and adolescents (\u2264 18 years of age) than in adults. Clinical\r study safety data are not available for children under 2 years.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><\/b><\/p>","ID":"72c1bcf2-dc77-499a-a8b4-11fa5d92b1f2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Reporting of suspected adverse reactions<\/span><\/u><\/p>","ID":"80309105-659e-4f75-b253-032691343593","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Reporting of suspected adverse reactions","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"800b60ee-62f7-4fc7-94b2-77868ca5fdd7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Reporting suspected adverse reactions after authorisation of the\r medicinal product is important. It allows continued monitoring of the\r benefit\/risk balance of the medicinal product. Healthcare professionals are\r asked to report any suspected adverse reactions via <span style=\"background:\r lightgrey\">the national reporting system listed in <\/span><\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Template_or_form\/2013\/03\/WC500139752.doc\"><span style=\"color:windowtext;background:lightgrey\">Appendix V<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p>","ID":"a089b954-c8c9-4586-b3ac-4c9f0a35aba9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Reporting suspected adverse reactions after authorisation of the\r medicinal product is important. It allows continued monitoring of the\r benefit\/risk balance of the medicinal product. Healthcare professionals are\r asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"9fbd32ba-afe8-4bf8-991c-23a36ea55ea7","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">4.9     Overdose<\/span><\/b><\/p>","ID":"0facfe99-7ad4-4c3d-9956-24e1bbf9a734","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"4.9     Overdose","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"a21c6682-8bc6-4699-8029-e16f15833d2d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Symptoms<\/span><\/u><\/p>","ID":"cc5d753c-180a-444a-93e1-a9d953f22569","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Symptoms","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1c1a762e-119a-48e7-89f0-54d396de7be7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin overdose may lead to severe and sometimes long-term and\r life-threatening hypoglycaemia. <\/span><\/p>","ID":"a6cfcf6a-4bde-4294-b337-4c07e2ecc80a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin overdose may lead to severe and sometimes long-term and\r life-threatening hypoglycaemia. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b148e344-6b00-45e5-8ab3-9da5075de371","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Management<\/span><\/u><\/p>","ID":"82b4f409-45ec-48a0-b464-607e0f371f3f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Management","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"9c9854c0-40e2-4f51-a638-66bf5dd3d2a2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Mild episodes of hypoglycaemia can usually be treated with oral\r carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or\r physical activity may be needed. <\/span><\/p>","ID":"14c83cf1-0646-4bf2-89ac-6a44c49d56be","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Mild episodes of hypoglycaemia can usually be treated with oral\r carbohydrates. Adjustments in dose of the medicinal product, meal patterns, or\r physical activity may be needed. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b0d05fc0-825e-4d18-b04d-d4ccb962c67a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">More severe episodes with coma, seizure, or neurologic impairment\r may be treated with intramuscular\/subcutaneous glucagon or concentrated\r intravenous glucose. Sustained carbohydrate intake and observation may be\r necessary because hypoglycaemia may recur after apparent clinical recovery.<\/span><\/p>","ID":"dcf507e5-f014-4af3-b870-e50298e62552","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"More severe episodes with coma, seizure, or neurologic impairment\r may be treated with intramuscular\/subcutaneous glucagon or concentrated\r intravenous glucose. Sustained carbohydrate intake and observation may be\r necessary because hypoglycaemia may recur after apparent clinical recovery.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"31ba0129-7931-4347-a06c-ad67c035ffb7","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"40db0269-3169-42a8-ae0a-6669bce8b3db","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/b><\/p>","ID":"09406fd5-aba5-4a0e-a5a3-7372dfb64147","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"569d1275-1097-4de9-bbdb-3996e5dba652","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><b><span lang=\"EN-GB\">5.1     Pharmacodynamic\r properties<\/span><\/b><\/p>","ID":"3f842f86-18b3-4530-bc7c-2ab13808fe93","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"5.1     Pharmacodynamic\r properties","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"39511024-efa3-4043-9435-53f06559e4b3","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Pharmacotherapeutic\r group: Drugs used in diabetes, insulins and analogues for injection,\r long-acting. ATC Code: A10AE04.<\/span><\/p>","ID":"96dfaea1-7e33-4817-a3c3-5b0879cb5de4","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Pharmacotherapeutic\r group: Drugs used in diabetes, insulins and analogues for injection,\r long-acting. ATC Code: A10AE04.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"05fe3359-a20e-4e9f-b123-a0b0fd22a0c3","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">ABASAGLAR is a\r biosimilar medicinal product. Detailed information is available on the website\r of the European Medicines Agency <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext\">http:\/\/www.ema.europa.eu<\/span><\/a><\/span><span lang=\"EN-GB\">.<\/span><\/p>","ID":"a9958b92-f6f3-4efa-b040-a7f256956ffb","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR is a\r biosimilar medicinal product. Detailed information is available on the website\r of the European Medicines Agency http:\/\/www.ema.europa.eu.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"a1261550-0a7f-4b5b-a838-d650bd0e6a81","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Mechanism of\r action<\/span><\/u><\/p>","ID":"57290cb8-5848-4396-a0fc-e5444a5b8aaf","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Mechanism of\r action","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"0a14aad2-004b-49fb-8c88-bdd04c81a92c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r is a human insulin analogue designed to have a low solubility at neutral pH. It\r is completely soluble at the acidic pH of the ABASAGLAR injection solution\r (pH 4). After injection into the subcutaneous tissue, the acidic solution\r is neutralised leading to formation of micro-precipitates from which small\r amounts of insulin glargine are continuously released, providing a smooth,\r peakless, predictable concentration\/time profile with a prolonged duration of\r action.<\/span><\/p>","ID":"5378b92d-6582-47f7-a3ae-c69879c47c7b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin glargine\r is a human insulin analogue designed to have a low solubility at neutral pH. It\r is completely soluble at the acidic pH of the ABASAGLAR injection solution\r (pH 4). After injection into the subcutaneous tissue, the acidic solution\r is neutralised leading to formation of micro-precipitates from which small\r amounts of insulin glargine are continuously released, providing a smooth,\r peakless, predictable concentration\/time profile with a prolonged duration of\r action.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"a43c5822-4e1f-4a1c-bec6-2300ee708ec9","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r is metabolised into 2 active metabolites M1 and M2 (see section 5.2).<\/span><\/p>","ID":"27c97415-64c6-440e-a6bb-79139eeaf52c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin glargine\r is metabolised into 2 active metabolites M1 and M2 (see section 5.2).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","ID":"06d92c57-1ec9-4cba-a72a-3645baf228c7","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":" ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\">Insulin\r receptor binding<\/span><\/u><\/i><\/p>","ID":"866cc97e-ca58-48a8-8d60-add2ada782df","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin\r receptor binding","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"b2de2b7e-0934-4727-a3f4-e030a27a219c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><i><span lang=\"EN-GB\">In vitro<\/span><\/i><span lang=\"EN-GB\"> studies indicate that the affinity of insulin glargine and its\r metabolites M1 and M2 for the human insulin receptor is similar to the one of\r human insulin.<\/span><\/p>","ID":"7ae6935c-b1cd-4472-b4f6-48264e959229","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In vitro studies indicate that the affinity of insulin glargine and its\r metabolites M1 and M2 for the human insulin receptor is similar to the one of\r human insulin.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"b4dbb34e-f96f-4e61-be2e-a1a15f7c3388","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">IGF-1 receptor\r binding: The affinity of insulin glargine for the human IGF-1 receptor is\r approximately 5 to 8-fold greater than that of human insulin (but approximately\r 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1\r receptor with slightly lower affinity compared to human insulin.<\/span><\/p>","ID":"87696b1f-8dbe-4630-abf9-e3a162c18273","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"IGF-1 receptor\r binding: The affinity of insulin glargine for the human IGF-1 receptor is\r approximately 5 to 8-fold greater than that of human insulin (but approximately\r 70 to 80-fold lower than the one of IGF-1), whereas M1 and M2 bind the IGF-1\r receptor with slightly lower affinity compared to human insulin.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b2717462-81a9-4e64-816d-6346e2da9a28","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The total therapeutic insulin concentration (insulin glargine and\r its metabolites) found in type 1 diabetic patients was markedly lower than\r what would be required for a half maximal occupation of the IGF-1 receptor and\r the subsequent activation of the mitogenic-proliferative pathway initiated by\r the IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may\r activate the mitogenic-proliferative pathway; however, the therapeutic\r concentrations found in insulin therapy, including in ABASAGLAR therapy, are\r considerably lower than the pharmacological concentrations required to activate\r the IGF-1 pathway. <\/span><\/p>","ID":"9a56c78d-d2db-469f-bb2a-02356aafcecf","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The total therapeutic insulin concentration (insulin glargine and\r its metabolites) found in type 1 diabetic patients was markedly lower than\r what would be required for a half maximal occupation of the IGF-1 receptor and\r the subsequent activation of the mitogenic-proliferative pathway initiated by\r the IGF-1 receptor. Physiological concentrations of endogenous IGF-1 may\r activate the mitogenic-proliferative pathway; however, the therapeutic\r concentrations found in insulin therapy, including in ABASAGLAR therapy, are\r considerably lower than the pharmacological concentrations required to activate\r the IGF-1 pathway. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"9e3bc22f-5dbd-4f33-901c-285a6e760b20","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Pharmacodynamic\r effects<\/span><\/u><\/p>","ID":"b93da6fa-6135-44a0-8818-774c6eaabd8d","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Pharmacodynamic\r effects","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"39bcab97-a788-47df-8baf-94fe9ad7f432","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The primary\r activity of insulin, including insulin glargine, is regulation of glucose\r metabolism. Insulin and its analogues lower blood glucose levels by stimulating\r peripheral glucose uptake, especially by skeletal muscle and fat, and by\r inhibiting hepatic glucose production. Insulin inhibits lipolysis in the\r adipocyte, inhibits proteolysis and enhances protein synthesis.<\/span><\/p>","ID":"69898176-02fe-4dd4-9d93-0d0d9a881751","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The primary\r activity of insulin, including insulin glargine, is regulation of glucose\r metabolism. Insulin and its analogues lower blood glucose levels by stimulating\r peripheral glucose uptake, especially by skeletal muscle and fat, and by\r inhibiting hepatic glucose production. Insulin inhibits lipolysis in the\r adipocyte, inhibits proteolysis and enhances protein synthesis.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"6591b8b8-d9d9-4589-9112-8a4ff2e9ae28","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In clinical\r pharmacology studies, intravenous insulin glargine and human insulin have been\r shown to be equipotent when given at the same doses. As with all insulins, the\r time course of action of insulin glargine may be affected by physical activity\r and other variables.<\/span><\/p>","ID":"e6efe4ce-5557-4e5c-91f8-640b93eab192","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In clinical\r pharmacology studies, intravenous insulin glargine and human insulin have been\r shown to be equipotent when given at the same doses. As with all insulins, the\r time course of action of insulin glargine may be affected by physical activity\r and other variables.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"9d420049-9984-43fa-abf5-fd1ad0bf69da","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In euglycaemic\r clamp studies in healthy subjects or in patients with type 1 diabetes, the\r onset of action of subcutaneous insulin glargine was slower than with human NPH\r insulin, its effect profile was smooth and peakless, and the duration of its\r effect was prolonged.<\/span><\/p>","ID":"bf8bdc47-68b3-411f-92d8-d263440a36bc","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In euglycaemic\r clamp studies in healthy subjects or in patients with type 1 diabetes, the\r onset of action of subcutaneous insulin glargine was slower than with human NPH\r insulin, its effect profile was smooth and peakless, and the duration of its\r effect was prolonged.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"e5fa9694-20c3-46da-900f-31601c76bc4a","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The following\r graph shows the results from a study in patients:<\/span><\/p>","ID":"f885e5a7-aa74-4e9e-a520-1f282fff09a7","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The following\r graph shows the results from a study in patients:","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"f084e404-1af6-438b-89ac-1ea817326b8f","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><b><span lang=\"EN-GB\">Figure 1: <\/span><\/b><b>Activity profile in patients with type<\/b><b>1 diabetes<\/b><\/p>","ID":"9c67dde3-2301-4724-aa6c-21371106ff96","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Figure 1: Activity profile in patients with type1 diabetes","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid\"><\/p>","ID":"f7548eb5-4fa3-44aa-bc6d-efddbf2dff75","Styles":"line-height:normal;page-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p align=\"right\" class=\"MsoNormal\" style=\"text-align:right;line-height:normal;\r page-break-after:avoid\"><span style=\"position:absolute;z-index:251686912;\r left:0px;margin-left:-6px;margin-top:15px;width:652px;height:274px\"><img height=\"274\" src=\"data:image\/png;base64,iVBORw0KGgoAAAANSUhEUgAAAowAAAESCAYAAAB3t4R4AAAAAXNSR0ICQMB9xQAAAAlwSFlzAAAOxAAADsQBlSsOGwAAABl0RVh0U29mdHdhcmUATWljcm9zb2Z0IE9mZmljZX\/tNXEAAC5MSURBVHja7d0HuM71\/8dxkU1WSypKkWxKyyZlZFTGL79EkdVUKdvPSjurjMyo7JHMOCIjsik7EVnJpsj77\/W+\/t\/7up2O47Zyzun5vq7Hde7x\/X7v+z51nNf5zET\/+9\/\/EgEALo6lS5cOMLOTRlFxtMaPH\/\/0qS9X8POKc8E3AQAIjBSBESAwAgCBkaIIjCAwAgCBkaIIjCAwAgCBkaIIjCAwAgCBkaIIjCAwAgCBkaIIjCAwAgCBkaIIjCAwAgAIjBSBEQRGAACBkSIwAgRGACAwUgRGgMAIAARGiiIwgsAIAARGiiIwgsAIAARGiiIwgsAIAARGiiIwgsAIAARGiiIwgsAIAARGAiNFYEQCDIyn6op\/M\/5HAEBgpAiMQCyBsVevXgWHDh1a6t+sa9euKfifAQCBkSIwAmcIjD\/99FPUv\/2H5913383G\/wwACIwUgREgMBIYARAYKQIjgREERgIjAAIjRREYQWAkMAIgMFIUgREERgIjAAIjRREYQWAkMAIgMCaAOnnypP31118X\/ZoSlK4ffv98K7jOxbhW9OsSGEFgJDACAIHxDNWrVy8rUKCA7du376Jc7\/jx4\/b+++9bhQoVbP78+f7YfffdZ+3atbvgoDd37ly\/bqdOnS5aaFy0aJHlzp3bvxIYQWAkMAIAgTGGGjlypFWrVs0OHjx42uMxBbJIQ1r\/\/v3tiiuusOHDh\/s5tWrVsp49e\/7t\/LNdL3pr4u7duy1x4sRWtmzZ01oFY7vO2V5z7dq1VqlSJVu1alVE7+9it24SGEFgJDACIDDG6Tp8+LCtXr3aNmzY4AFs3bp1tnjxYvv1119typQpNnPmzFBA+u2332zixIneyrd\/\/34\/ZsmSJfbzzz\/brl27\/Lz169f7scOGDfPAOHbsWNu6das\/rrB37Ngxb8lbuXKlbd682UaNGmXbtm2L8b3t3LnTn9f7+P77793evXs9MFauXDkUJpcvX+7H\/fjjj35fr6H3IkePHrWpU6eGnjv139bGjBljc+bMsQULFtip35\/+2fW5dd6OHTv8vC1btvj71Of9888\/Q+9Jn1nn65zLGRwJjCAwEhgBEBj\/sVKgqlixooc7BTqFId1WIKtXr57fnjZtmp04ccLuueceD18vvPCCjRs3zsOVwluVKlU8MCZJksSKFSvmwTMIjJMmTfLwpeOqVq1qf\/zxh5UsWdKuvPJKa9++vWXLls1y5MjhYS28FAKvvfZa69Onj7Vs2dKSJUvmrZYHDhwIXUuBTV\/V1a3Wy+TJk9t3333nr1GnTh1\/\/ebNm1vatGnt9ddftwEDBli6dOksKirK8uTJY3feeactXLjQunXr5scGnylp0qR22223WevWrf1xvb5eSwGzePHiNmPGDH9ewflyhUYCIwiMBEYABMZ\/tJo2bRoKjMuWLfNApjGIQSB85513PIQpECpcqgXul19+8bGKekxjChWcUqVKZUWLFj0tME6YMMGf03XU7Rt0T+s5nR+8tq4XXgqlelyBVqFO56uVUq19uv3oo4\/6tQoWLOhjML\/++mt\/vHv37v64wqjOHzRokG3fvt3HZ2bMmNHHKur9KVBeffXVflutoDp39OjRfq4+U+nSpf25lClTekjUbXWD58+f31srU6dO7aH6ck2WITCCwEhgBEBg\/EerUaNGocCobljdVmvexo0bPUh17NjRg5Ra4hSmMmTI4N3YCpFqKXzkkUf8+TRp0oTCVRAYv\/zyy1BgDLqRq1ev7s\/puPr16\/ttdWuHl7qhFUAVBD\/44AO75ppr\/P1pnKWuFbymHjv177+1aNHCr9OjRw9\/vFWrVn5fLZVBNWnSxK+jrvDChQt76NR70DhLHavW1SAwakynntN7KFWqlN9Wa6gmB6nFVS2n6o6\/XEVgBIGRwAiAwPiPVtDKp3GJQQujum+DrmQFMrXQaUzhvHnzvFv32WefDQXBIFypS7hEiRJ++4svvvBrTp48OXScuo\/1XM2aNUOBUdfRbY0NDC+d06VLF\/voo4\/s888\/D83g1lddS6FTrY3qztZxGpuox3v37u3nqpta19VElqD0Gi+99JK\/N41NDLqTNf5R54aH2+C9pkiRIhQY1ZV+1VVXefe5jtP3h8AIAiOBEQCB8bzr0KFDHsAuBbWyXayxc0eOHPGuYoUkTSpR96xa2Nq0aeNhT7ebNWvmkzzUTasWO3UpK8TpPagL+uabb\/ZWOrUw5suXz0OdQpzOVYufztXte++910OngpdeTxNf1Oqo2xofGF4KcWrRGzhwoA0ZMsRb9NSiqdfXtRTiNJlGt9UtrS5o3a5bt653dT\/11FN+XY1LDL5XNWrU8C51tZ4qNCr86rmuXbv6uWrJVAhUq6k+15o1a\/y2PpPGTs6ePdu7ovV5Nb5T4yUJjCAwEhgBEBjPqxRCFEw0sUJj5i42hRkFmItRmiWt1jm1LG7atMnDnW6rZU5j9XR7xYoVHlQV8DTpRV+DUjhUy5y6rzXTWN20ekxd1jpX19B1dVvPqZVPoU\/3tZxNcDt6l7QeS58+vYc+UWuhgqoCnc7RtRTK9d41k1utfpqM8sMPP3hgDD6TXiPs90ToesE1P\/30U\/88OlbnKoQG70mfR191rWDJIc2qHjFixGktlwRGEBgJjAAIjOdVCh4KF5eCwlV825nkXEsTbRQQ9Vk1IUYtiJqNfb4tqzpPk3P69u3ry\/hoAo0mseh+XFhXkcAIAiOBEcC\/MDBSF1bqDtZMbU2e0cLimsH8+++\/X9A1v\/rqK+8iV3e6rqkJNfE1eBMYQWAkMAIgMFKXsOJjiyKBEQRGAiMAAiNFERhBYCQwAiAwUhSBEQRGAiMAAiNFERhBYCQwAiAwUhSBEQRGAiMAEBgpAiMIjARGACAwUgRGEBgJjABAYKQIjACBkcAIgMBIERj5eQWBkcAIgMBIUQRGEBgJjAAIjBRFYASBkcAIgMBIUQRGEBgJjAAIjBRFYASBkcAIgMBIUQRGEBgJjABAYKQIjCAwEhgBgMBIERhBYCQwAgCBkSIwAgRGAiMAAiNFYCQwgsBIYARAYKQoAiMIjARGAARGiiIwgsBIYARAYKQoAiMIjARGAARGiiIwIuEExr\/++sv27dtnv\/\/+e4geIzACAIGRIjCCwGjr1q2zwoULW+LEie2KK65wSZMmtU2bNhEYAYDASBEYQWA0a9y4saVOndratm1rXbp0cV27dvVWRgIjABAYKQIjCIzWsWNHq1evnp08efI0CaUIjAAIjBSBEbjAwDh\/\/ny75ZZb7I033rBu3bq5Hj162P79+wmMAEBgpAiMIDCa9e7d21KlSuVjGMNt3LjxrP9jqiVSk2O2bt1qc+fOtXnz5tkvv\/zij8WVVkoCIwACI0VgBC4wMB45csSOHj1qhw4dsj179tgff\/zhrYsnTpyI9Twd16tXL8udO7dPlAmCpm7nypVLQc2vSWAEQGCkKAIj4nlgVM2aNctKlixpt99+uz399NO2d+\/eWI9X62Ht2rUte\/bs9sILL9jw4cNtzpw59u2339qoUaOsefPmlj9\/fnvooYfs+PHjBEYABMZ4WDGNaz\/T\/diOPdtjZ3rdS\/FZwu8TGIFzCIzff\/+9twrmy5fPKlWqZGnTpvWwpxbE2H7wVq5cedZ\/MFavXm1\/\/vkngREAgTGe1a5du+zNN9+0Z555xnr27Bn6d\/3rr7\/2hoLZs2fb+vXrrV27dla\/fn0f+965c2f7+OOP7fDhw7Z7927r16+fNWjQwJo1a2bLli3z4099H\/34t99+2zZv3hzj7xdNxNR1L1ao02dRQ0bTpk39mmvWrLFy5crZihUrCIxApIFRLYqlSpUK3ddyOilTprSZM2dG9D+nuq81DrJVq1YhH330UZz54SEwAiAwnnspWE2YMMGHGiVKlMiGDRvmjx04cMADn4Yz6b6WZlOjQ1RUlAcwHV+sWDEf1jRt2jR\/7v777\/fepvDjFUbPtEFExYoV7bnnnrtogVHXuffee\/1zHDt2zBsz8ubNa999912Ca2kkMOKSBcaGDRt6d3QwUUXd0ZoEo78eI6maNWuGFvtOnjy5e+CBBwiMAAiM8byWLFnivyOSJUvm\/7brvn5PaIx6ELTUEqjfAQsWLPDHChUq5Pe1e5iOV4CsWrVqKBy2b9\/en1dDQ0xhTa2B27dv98YIhcwNGzbYli1b\/L6GPWmsfVB6XMOhNPFSx\/7888\/eaqnx85qAqdsHDx70Y9WDliRJEm\/51PHbtm3zUPvbb7\/5cXq\/muypXrf4HCIJjLhkgVFdy1deeaVPXqlQoYKlSZPG7rrrrojHHmbOnNk+\/PBD78IOXO5uaAIjgLgaGBVmtKqEwo922lIgCu7\/+uuvvtSZbq9du9YDUPCcQtSiRYv89qpVq057TiHrUpS6n3X9QYMGefC79dZbbceOHd5FHQTANm3aeADUccuXL\/dQpu5ePa\/3p+fUKKHWR71vBVA9pq7rmIKZuq0zZcpkpUuX9t8nNWrU8M0ltPSbJlTecccd\/vtJ34syZcp444Z+d2nypt5XihQpvGX0iy++8NuffPKJv45aLfXe1ML4zjvv+DW\/\/PJLD4\/p06e3AgUK2CuvvOLvTZtXxNfQSGDEJQuMwV+Rjz76qN1zzz324osvepdDpKW\/Flu3bu0hUf9AxKUldQiMAOJaYNRYPgUXBbA6depYo0aNQqtMaDiP\/mjX7f\/+97\/+72vwXPfu3e2mm27y2w8++KAHteA6QXfxpQiMY8eODY0rVJjSEKa33nor9HpBYDz1\/fEgNmDAgNAYeLX+6TmNi+\/Tp4\/17dvXw11sgVF11VVXWcGCBf33yUsvveTHn\/p95mMkdVsBOQix+nrqv4v\/Dpo8ebI\/Nm7cOH9Mt4PXUWDUfV1z4sSJfnvkyJH+nG7fd999\/pyGZKlL\/Uzd5QRG\/OsCo5rp1f2sv8o0QFk\/4PrLV3+5qWn+bMvqBPXUU0\/5D7D+ktMPueivSQIjAALj30v\/1m7atMkp+KiLNLivblcFo+A5\/Rsd\/pxaFXVbLZHhzwXdrhe7ZsyYEQpVCmQKVRoHWL58+b8FRrWMRq8gMKpBIji+Q4cOsQZGvU7GjBmtSJEiHtqef\/75UBd30P39ww8\/+O+tu+++2+\/r95B+Z6llUfdPhSZbuHChB0EF1eiBUSFYt0ePHh0KjEG3uQJ7iRIlCIwgMAalWWv6YRs4cKD\/gEUXycLdqsGDB\/tEl1dffdWb80Vd1ARGAATG+F3qZlZrXBDs1H2bLl06n8QSPQAqoEUvTSrRczGNYdQM6pgCox5TYFSPl85Rr5eOV89X8Frqytd7UfeyfvfoMQ2vUsBV+Js+fbotXrzYbwevozGMOk7XDCbzqCUyCIxVqlQJBUa1ohIYQWAM+8tvxIgR\/tesQmOwLaC6PYYMGeJ\/vcVW+msu6H4OuqLpkgZAYEwYpd4nzWRW40L4VrEKWWXLlg1NkqxVq5YHLnU3h\/\/e0CxqjR9Ut7m6l9UqqlU4\/vOf\/\/jxalxQq2H00mQVnZMtWzafkKIxjDpeQ6eeffbZ0G39rmrZsqW3sGrcva6v8Y86t0mTJt5trtsKqOo9K1y4sJ+ryS5aAkjP6Xfezp07\/bZmUev3oW7feeedcWLjCQIj4kRgDP6S04DhYLZaoFOnTv4XXGylHy4NDNZffxkyZDiNBiITGAEQGONvKSRqDOOUKVM8jIWXfj\/od4W6yNWaJ9oAQoEwKN3+5ptv\/Dktr6Mwp1nNuqYeU2tg9OuqFNp0vI5RK6IaN3RbE2rU4qnben1dS62f6jJXaAxKS8L179\/fJw3pWLVyKngGr6tzNWFGt9UqqnN1W+eplVK3dWxMYZbAiH9lYNQPqgZca3cXzZLWX4ny+OOPe7P91KlTY\/2f8tQL2FdffeWDrbVelhZyDWjJBQIjAAIjRREYEc8Doya3KDBqfS0FxJtvvtndcsst\/nikzfExdUnHpbEfBEYABEaKwAicZ2AMSl0Gn3322Rn3Aj1baTyLxpoEi3azcDcAAiNFERiRwAJjsP2TlkbQeootWrSwJ5544rQxIbFV1qxZfcZc+NaAWi6BwAgggQbGv\/4\/NAJxzpdfflmPwIhLEhi1LE74cjqaRXb99ddHPOBXC8hqlnUwO\/pcWygJjADii6FDh1aJiopqB8RVvXr1KsDPKi5JYKxevbo1aNDARo0aZZUrV\/aZcVqfUbPTIqlJkyaFuqG1lZNoc3kCIwAAQAIJjC+\/\/LKvT6UlCLRPqJY60EQYBcFISt3R2k9a62DpOvLkk08SGAEAABJKYNQipoUKFfI1rhT01C2dL1++09bTiq2KFi1qw4cPP+9JMwRGAACAOB4YtW+nwqFCnpbaCRYt1e1I6tQLWd68eX1TeK2\/KEOHDiUwAgAAJJTAqI3Zs2TJYpMnT\/bQqK2dtI\/njz\/+GFEg0zZPKVKk8MkyAbVYEhgBAAASSGDUnpqJEiXyrugBAwZ4i6O294stMCpYrlixwvbs2ROaHa0WSW0Ory2Y4tKWSgRGAACACwyM2ly+ePHi1qVLFw+NDRs29BZHTYKJrTSj+pprrrESJUr42ovB3ptBgCQwAgAAJJDAqMW6NQZR1bt3b+9SVnDcsGFDrOcdOXLEFixYYG+99ZaVL1\/ed3u57rrrvDu6Q4cOBEYAAICEEhi1jI7GMQazm2fPnm01atSwHTt2RBTIwmdG\/\/zzz74Q+Ntvvx1nWhkJjAAAAOcZGFeuXOn7SO\/atcuioqJs7NixTl3LCpFqQYyk3nvvPatTp45Pfqlbt66v69ioUSNr27atX5vACAAAEE8DY9OmTb0rul+\/fqfNcA6crUs6qPr163sXtsY9aktB3c6ZM6fv\/lKyZEkCIwAAQHwNjJqgEqy\/uH379r85ceJERIFM2wC2b98+dP+1116zd955x6+RKlWqiLu2CYwAAABxLDBq2ZwRI0bYsGHDfB\/pcGPGjLFDhw5FFMgyZcrkS\/NodrRoAe9cuXJ5t7ZaGQmMAAAA8TQwtmnTJsau6HPtkm7evLl3QxcoUMC3FNRtzZzOkyePB8fLPfmFwAgAAHCegVELbatL+tdff7WDBw\/+zbkEvY8\/\/tgeeughe\/jhh31bQJ3bq1cvW79+PWMYAQAA4mtgnDdvnk2YMMFOHePL6oTTRBjt2nK2UjBctmxZKFzqq7qlBw0adNmDIoERAADgAgOjlr8pUqSIffrpp5YkSZLTuqO1N7SCZCR13333WbNmzXxLwf79+1uaNGm8a5rACAAAEM8D4+HDh+3o0aO+VuLSpUu9RVH2799vCxcu9OcjqVmzZlnKlCl9KR2FRc2S1jUIjAAAAPE8MP7xxx+2efNma9GihRUtWtRnM8uWLVssa9asvoB3bKWxj2qFVOAcOHCgJUqUyKpWrWp79+61PXv2EBgBAADie2BUqFMw1KxmhT19DahbWjvBxFb33nvvaeeE0wxpAiMAAEA8D4yqJUuW+JZ+uXPntiFDhvg+0PqqLumz1dSpU23cuHE+cWbkyJH2xRdf+JqOusbEiRMJjAAAAPE9MAYLbWsco7qXg\/uRLKejYxo2bOh7SGsZHXVtB+de7nUXCYwAAAAXKTBq+z7t0nLddddZ5syZ\/fYNN9xgpUuXtvnz5581iGmM43PPPWd33XWXX0Pd21qH8c0337TFixcTGAEAAOJ7YBw9erTVrFnzNI899phdc801dvXVV5\/TTGctAq51HbUtYLly5axGjRoERgAAgPgeGM9U2hJQk2CioiI7Va2JM2fOtDlz5th3333nXzW2ccWKFXGie5rACAAAcAGBMRhzGE7L4igwalJLJFWlSpXQzGoJny3dqlUrAiMAAEB8DYza0k9b+IX75JNPrEyZMr7ziybCRFIdOnTwfaQXLFhg3377rY+B\/PDDD322dKpUqS77It4ERgAAgPMMjG+88cZp2wEGtFvLgAEDIg5k2bJl86V1ghZKLctTrFgxb6nUtbQQOIERAAAgHgZG7eqiVsZw69atO+cWwZIlS1qWLFm8VfH999+3a6+91ie9VKtWzVsYtaMMgREAACAeBsaLVVqDsXjx4qEWSs2SVhjVjGttGcgYRgAAgH95YFSpK\/rw4cMu0sW\/CYwAAADxLDCGz5Q+l1q6dKlVrVrVihQp4goWLGhPPPEEgREAACAhBUbNcH7yySetXbt29tVXX\/kaipFWgQIFfKHvBx98MEQ7wBAYAQAAEkhgXLRokSVNmtS3BdTyOE2aNLGMGTPagQMHIgpkefPmtc8\/\/\/xv6zkSGAEAABJIYKxTp45PUNmzZ48HRlWGDBls0qRJEQUyLalzyy232Msvv2wtWrRwvXr1IjACAAAklMCooFe4cGH75ptvfIazuqe1cPfChQsjCmTag1q7uqRIkSKkaNGiBEYAAICEEhi3b99u2bNnD23np6VxNGkl0m7lO+64w3eIiUvd0ARGAACAixgYgxo2bJj169fP5s2bd06BrHPnzj5LesaMGTZ79mynRcAJjAAAAAkkMKplUCFPX6OioqxBgwY2d+7ciAOZwmL07QVz5sxJYAQAAEgogVGTW9QVPX36dEuePLnPkNb2frt37z5r0FStX7\/exz3Onz8\/ZNWqVacdQ2AEAACIx4Gxdu3a9uKLL9qIESMsUaJEHhS1+Pb48ePPeI52c1H39eLFi0M7u4TTY9qX+uOPP2YvaQAAgPgeGOvVq2cNGzb0pXVuvfVW27dvn7cwqns6tmrbtq2lS5fObr\/9dp8p\/eqrr9prr73mATRPnjzeUtmoUaPL3spIYAQAALjAwKjxihp3qG5ptTI2bdrU11WMpGVQ3dHNmze3fPnyeXi86qqrfCHvZs2a2cqVKxnDCAAAkBACo0rdx9OmTfOuZG0L+Ntvv51zMDt+\/LiLa0VgBAAAuAiBUftH33333d5CWK1aNfvll1\/iXPAjMAIAAFymwDhnzhzvji5durTVr1\/fbrrpJl\/I+8iRIwRGAAAAAqPZk08+aeXLlw\/dP3HihKVJk8a7qM9WO3bsCM2MJjACAAAk0MD4\/PPP2z333OPjF2Xz5s2+HuPZdnxRSNQs6FMvZKNHjyYwAgAAJNTAuGHDBm9RzJw5sxUuXNi7p0uVKuXhMbaw2LJlSx\/3mDZtWl+PkcAIAACQQAOj6tRxvhZj2bJlFbDs2LFjZz1ny5YtVqlSJatVq5Z9\/vnnBEYAAICEHBi1jE6w7uLq1asjXh5HWwIGLY5bt261nTt3xrkxjQRGAACACwyMa9as8S7pQYMG+f0bbrjB7r\/\/\/ohD465du6xkyZLeld2uXTurUaOGzZgxg8AIAACQUAKjJq5o7KK2BFStWrXKkiZNarNnz44okFWuXNknzWi2devWre3ZZ5\/1nWI025rACAAAkAACo\/aSLlOmTGiW9N69ey1lypT29ddfRxTIMmXKZIsWLbLx48db586d\/fwUKVLYwYMHCYwAAAAJITAuXbrUWxRvvPFGy5MnjyVJksRnP0cy8UVVvXp1y5Url1WpUsUefPBBe+CBB7zFMa6MYyQwAgAAXGBgVGlpnVdeecVq165t77\/\/\/jmFPbVKKjRq7cZkyZJZ0aJFz2svagIjAABAHA2M27Zt8y7llStX2ooVK3yW9Pz58+3o0aNnDWMKlmPGjLF169b5bYVHzbYeMGBArOs4EhgBAADiUWD84IMPLHHixCGa7SwbN26M9byFCxdaly5dLH369N6qqOt8+OGHVrduXT\/\/8OHDBEYAAICEEBi3b99uc+bMCenatauVK1fOjhw5Eut5Wo4nY8aMoYAZBE5NmGncuDFjGAEAABJKYAwW2g6oK\/nWW289617SKoXKV1991feSjn4dxjACAAAkkMA4adIke+SRR0LuuusubzGMdH9ohUOt2aixjKNGjbLhw4d71zTrMAIAACSQwKh9oO+4444QLanTo0ePiANZs2bNQt3SAe0xTQsjAABAPA+MQfezRO9OPpcu5SxZsljfvn3t8ccf9yV5evXqZXXq1CEwAgAAxPfAqL2jixcv7kqUKHGaUqVK+WSYSCpr1qw2cOBA69Onj6\/jqLGPWpORWdIAAADxPDD279\/fd2QJ3HfffXb\/\/fc77dai9RkjqW7duvne0VqLUTOk1SWtHV+YJQ0AABDPA2PQLR0Eu+hd1JFOeJFgZxctAK4xkTt37mThbgAAgIQQGLUczltvveXhrnTp0r6cTo4cOXy2cyRh8bPPPrNWrVrZsmXLQo\/pmpr0wixpAACAeB4Y1RqYKFEiH8P4559\/+j7QWlJHk1huvvlmfyy20tI5wYLd+qqxi48++qjfrlatGpNeAAAA4ntgbNCggWXOnNn27dtnhw4d8qAXFRXlO7goSC5ZsiTWIFa4cGGrWLGidz8raCpwXnnllda7d28W7gYAAEgIgbFs2bKhlsBjx475cjibNm3ylkUFRi3oHVvlzJnT3njjDb9dvXp1S5cunU98iWtFYAQAADjPwPjiiy\/a9ddf72MNw9dfHDlypLc2btiwIdYglitXLnv++ec9bGoZHo1b1FhI3T9bdzaBEQAAIB4ERgVCrZeYP39+39ll8ODB9tJLL3lYrFmz5lmDWN68ef3YNGnShHZ40W3RWo4ERgAAgHgeGFVz5861fPny+cQVSZIkiTVs2NBbCc9W2tWlfv36vquLxkOKbkv79u0JjAAAAAkhMAalsYurVq2y33\/\/Pc6NQSQwAgAAxIHAmJCLwAgAAEBgJDACAAAQGAmMAAAABEYCIwAAAIGRwAgAAEBgJDACAAAQGAmMAAAABEYCIwAAwL8mMM48lZlO\/psRGAEAAGIJjGPGjHkqKiqq3b9Z+\/bt0\/M\/AwAAwBkCI98EAAAAEBgBAABAYAQAAACBEQAAAARGAAAAEBgBAABAYAQAAACBEQAAAARGAAAAgMAIAAAAAiMAAAAIjAAAACAwAgAAgMAIAAAAAiMAAAAIjAAAACAwAgAAgMAIAAAAEBgBAABAYAQAAACBEQAAAARGAAAAEBgBAABAYAQAAACBEQAAAARGAAAAEBgBAAAAAiMAAAAIjAAAACAwAgAAgMAIAAAAAiMAAAAIjAAAACAwAgAAgMAIAAAAAiMAAABAYAQAAACBEQAAAARGAAAAEBgBAABAYAQAAACBEQAAAARGAAAAEBgBAABAYAQAAAAIjAAAACAwAgAAgMAIAAAAAiMAAAAIjAAAACAwAgAAgMAIAAAAAiMAAAAIjAAAAACBEQAAAARGAAAAEBgBAABAYAQAAACBEQAAAARGAAAAEBgBAABAYAQAAACBEQAAACAwAgDwT\/2CTZToCjMD4j0CIwAAl8hnn31WddasWf8D4rtToTExP9QAAFwCS5cuHXDqF+1Jo6j4X0n5oQYAgMBIUQRGAAAIjBRFYAQAgMBIUQRGAAAIjBRFYAQAgMBIUQRGAAAIjBRFYAQAgMB4joHx5MmTMTqf0nl\/\/fWX\/fnnn+edEHSNX375xU6cOHFO70PH\/vHHH3E+Ael9Hj9+nChIYAQAIO4HRoW6b775xjp37mwdOnSwt956y95++233xhtvWFRU1DkFNgW8MWPG2D333GOzZs06r9C5f\/9+69+\/v7377rt2xx132IgRIyK6zrfffmulSpXyc8837P5Tpe\/r9ddfb5s2bSIOEhgBAIjbgVHB6tChQ3bbbbdZjhw5bMmSJXbqXP\/65ptv2uuvv35O4Usti8uWLbPEiRPblClTziu4NW3a1AOszu3UqZOd+jwRXWf79u2WNm1aD7txLTDq\/YSHw82bN\/tn3LdvH3GQwAgAQNwOjEE9+OCDVqZMGQ984bVo0aJQ+Ar\/GlMgC+\/KTpcunU2aNOmMwe1M3d66ny1bNhs+fPjf3ksk56tFUoFR557p+uf6ePTnz3RM9GuF19SpU61Vq1beAnum887lfRAYAQDAPx4YS5cubWXLlj0taP3888\/+nMYELliwwLt6d+\/e7S1jLVu29K7j8ECjruMePXrYgAEDLGPGjGdsYdRjY8eOtZ49e3oX+K5du\/zx3377zQYOHOithA0aNLAhQ4bYwYMH\/3b+4cOH7dNPP7Xu3bvbRx99dNpYyZw5c\/p7GDdunLdUTps2LfQe1JrXp08f6927tx\/z66+\/+uP6zF999ZV169bN6Xoyb948fw8rVqzwz6tr6Vx9vo0bN\/q5usagQYNs5cqV\/jrqFtfnUvf+4sWL\/bHZs2fbtddea8WKFbPBgwf7Z9LxvXr1st9\/\/z30PVm9erW\/v65du9r06dP9fcny5cv9dXfs2OHnvPrqq7Zt2zYCIwAA+GcD48MPP2z58uWziRMnesvg+++\/H+oW3rNnj9WtW9euvPJKD0MKalmyZPHHglbAl19+2Z577jkPUjpXXdIzZ86MMTA2atTIunTp4l20rVu3tptuusm7k48cOeItmpkyZfJuaAWu6BNYFBYrV67s4VTnV61a1YoXLx46rkCBAvbQQw95a56e0\/tQa6Xex9NPP+3BUN3BlSpVCo3PVNe7bisMKzjr\/L1799qTTz5pyZMn925xfW90nWeeecavGQRZBT5dV6F3woQJduONN9q6des82F111VX+vdP7vPfee\/19f\/\/9936OxofqOvrcKn2v9N9AoVHh\/JprrvHv9bFjx6xNmzZ+rIKkrnvXXXf5Zw5vrSQwAgCASx4YK1SoYLly5bJPPvnEWxIVABXmgsA3fvx472ZWYFN98MEH3nWswKgQpBZFBT6VQk7q1KljbGFUa9vVV199WnfzDTfc4KEreEyTQT7\/\/PMYw+Z7771nhQoVCh2rVs4kSZJ4q5+O1zhMtQYGzz\/xxBOWPXt2D1d6Tt3Vuq3ztm7d6gFNYfCzzz6zoUOHequkrqfnFS71OTTGMyi17Ck463Po9b7++msbPXq039Z71phPXV\/jQJMmTWqrVq3y5\/T9ffbZZ0PvS2NEdW21Gqr0HhQQg+cVDINgunbtWg+uCqK6lt6XWmGD\/xYERgAA8I8ERrWsaRxjeJDT5JUgtCkMqVs1aNVSK+Ott97qx7dt29ZbHINzFXIULidPnvy30NeiRQsPhOGv89RTT9ktt9xyWmBU121MgVGzoBW+ws\/XuMVatWr5YwqFauEMzg1Cn7qY1XqaIUMGD8ZqDdQx\/fr1s4IFC\/pnVYj78ccfPRRqyRt1R+tzRW\/Jq1ixopUrV84fVwDduXNnqFtZSwGpu1stpHrdIDCq1TI8FKu7O02aNN7aqK5yhVCF8uB9K8gquC5cuNDWrFnj1wq60PWZ0qdPf9qQAAIjAAC45IFRE14UxqJPNFH4UzAZNWqUd5MG4wU\/\/PBDb7nT8epeVfgJgpVavhQYY2ph7Nixo7eWqRUyKI1XLFy4cGj85HXXXedhLabAqLCYP3\/+00KcWufUHa7zb7\/9dnvnnXdC5yoYZs2a1d+3HlO4a9asmbfeKaApfKnFM3xNRB2n4zVOMnPmzH8LjAp7aj3UOMnwJXw0xlGhWyFRXdHhgVEBU93Z0QOjur71PVZg1PjF4FpqTdRjGzZs8PCoaymMqr788ksPjDGN7yQwAgCASxYYNeFFrYzBQtkBjd9TqFHw0tjCIDypyzRoYdR6i2oNU3e27qubVaFQwSZ6AFULno5VAA1eQ+Px1B0b3FeAUxdxTIFx5MiRfr7GBQbH630ogOm2WifVwhiEz8aNG3vXuu5rQk3wuMZRPvbYY3bgwAEPZuq6VpgUhWF1r+s9qlU1pgW2tc6k3qe6tYMqWrSo1axZ04+fM2eOJUuWzAOjvmf63tarV89vKyyrNTNlypShSS8K7Grp1Ll6f1rLUuMxdbwm3aRIkSI0OUgzrjU+8kIWRicwAgCAiAOjAolm7KpbV5NPFLY0U1hjFKtXr2516tTxCSWaRKJWLs3YVcjSWD+NW1QAVGnMo4Lc448\/7l3U6vp9\/vnnPWxGL11fs5k1U1oh85VXXgkFKU0+UZBSi6Emp8RUCnsKZ2odVItleBd0kyZN7IEHHvBrq1tbXeB6\/3peAax9+\/beVa7wpvGHelwtiQqNel11VyuUqpVULad6TMdFD2dqDVQ3c3ggVtDU90Bd7Oqy17nqhj569Ki3eipwN2\/e3CfX6HMrVGuCkT67Wg\/z5MnjYyD1mFoj1R2t964Z0gqfarFVq6JmluvampH9L1lih8AIAMDlDIxq0VLoUyuWqGVMEzpErXYKKApyCpXqGtUsaAVG3VfrWfhi1Ao46qbV8jh6LrZJGepy1bGaERyEHr2OAukPP\/zgYwp\/+umnM57\/3Xffeaun3lP00muru1nvJ7i2Qtn69ettxowZ3vIZdO8GtWXLFg+g6gJWaaKLvh+6vt5T9MCozxa0+IWXvm\/aOUevqxnfwfWCCTL6\/um2rq3PKUGrbTDOUoE2aHlUYNT3WsdpLKPeV\/h9AiMAALjkgZGiCIwAABAYKYrACAAACIwUgREAABAYKQIjAAAgMFIUgREAgH9FYIy+9mKkFayrSFEERgAAEnBg1ILUWiNRy9ScS2lJHa1\/qC3+tm\/fTkSiCIwAACTUwKh1C7Xgd7DvcaSlxa21B7O27Iu+RiJFYOSHGgCAOBQYY+sWjq27OPy5mI4723VFi1xrB5Pw7fYoisAIAMBlDowKato\/WbuTqFt4+PDhvo9z+P7JOmbu3Lm+hZ52MtF9jVPULi\/acUXdzzpHu59olxftaLJ\/\/\/7Q+dq1RHsjDxo0KLTTSfi1p02bZsOGDbMhQ4ZY+vTpCYwUgREAgLgUGLXXc+PGjS1NmjS+B3SFChV8X+Vy5cqFtsNTV7G2q9NWdzly5LCuXbv6OMOyZcta1qxZrWXLlpY2bVqbOnWqdejQwa644orQGMa1a9datWrVPBSOGjXKbrjhBg+PQaviCy+84Ps9a0tCdWVrf2XGMFIERgAA4lBgVGl\/5WTJknlroULc4sWLfSyhAqD2ZS5WrJhFRUV5K+Sjjz7qz6mF8b333rN06dJ5a6JaERUwda5C37Zt2\/zaCpXt2rULtSqeem\/e7axjtadz9uzZQ7Oq58+fb0mTJmUMI0VgBAAgrgXGKVOmeFewuqSDyp07t7cW9u3b10qUKOHhbuLEiTZ9+nQPjgp5nTp1srx58562jM73339vqVKlsl27dtmRI0e8tVIti0Fg1KQYBc6VK1da7dq1rXz58qHzT71nS506NV3SFIERAIC4GhgPHDgQekwh8d1337Xu3btboUKF7MSJE6Hngu7kjh072p133hljYNy9e7cdPHjQkiRJYv379w8FRo17VGBUcHz44YetePHiofPVOqlzCYwUgREAgDgWGNX1rDGMQQujwl2ePHl8TcXly5d76OvTp4+HRhk8eLCHvLffftuPCw+MOj5oYVQVKFDAypQpEwqcGqt40003+f3WrVuHltHRay5cuNBSpEjhk3AoisAIAEAcCowzZ870MYzdunWzFStWeMths2bNQq2CmhSjYJczZ04rUqSIffHFFz4j+umnn\/aAp4ktKoXAoUOHesDUmEcFyWXLllmmTJn82upyrlevni\/QrWurFVItlNdff72HR02A0bk6VusyUhSBEQCAONTCePXVV9u4ceNswIABNmHChL+tmajxi507d7ZZs2aFwt6kSZNs7NixNm\/ePH9MLZSaQDN+\/HhvSQyW5lEXs2Zaq2VSXdHhtW\/fPg+IPXv2tB9\/\/NHfgybMsEUgRWAEACAOBUZNZNFs5\/BxihRFYAQAgMDopVZBjU9UV7Ba\/8LHI1IUgREAAAKj7\/msZW969+7tXdOMHaQIjAAAEBgpisAIAAAIjBSBEQAAEBgpAiMAALgQS5Ys6X\/qF+1f\/x8agfiMwAgAwKUwdOjQKlFRUe2A+O5UYEzMDzUAAABi9X+aZNT0jiGhIAAAAABJRU5ErkJggg==\" width=\"652\"\/><\/span><span style=\"position:absolute;z-index:251684864;left:0px;margin-left:161px;\r margin-top:233px;width:159px;height:39px\"><img alt=\"Time (h) after s.c injection\" height=\"39\" src=\"data:image\/png;base64,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\" width=\"159\"\/><\/span><span lang=\"EN-GB\"><img border=\"0\" height=\"286\" id=\"Picture 2\" src=\"data:image\/jpg;base64,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\" width=\"590\"\/><\/span><\/p>","ID":"4db61d20-437d-4cfe-b199-5a0ef18a898c","Styles":"text-align:right;line-height:normal;\r\npage-break-after:avoid","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"a782b82c-8550-428d-98de-c9ca309a4702","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">* Determined as\r amount of glucose infused to maintain constant plasma glucose levels (hourly\r mean values)<\/span><\/p>","ID":"2036ff4c-75a0-4644-a967-91efec6819e5","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"* Determined as\r amount of glucose infused to maintain constant plasma glucose levels (hourly\r mean values)","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"62649ca9-6a8d-41dc-bdd1-5a33f37fdfac","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The longer\r duration of action of subcutaneous insulin glargine is directly related to its\r slower rate of absorption and supports once daily administration. The time\r course of action of insulin and insulin analogues such as insulin glargine may\r vary considerably in different individuals or within the same individual<\/span><\/p>","ID":"7b61cab8-b9c1-4f65-b951-f629cce18181","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The longer\r duration of action of subcutaneous insulin glargine is directly related to its\r slower rate of absorption and supports once daily administration. The time\r course of action of insulin and insulin analogues such as insulin glargine may\r vary considerably in different individuals or within the same individual","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"e1b62474-777f-4426-9d29-d1e09b93374b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a clinical\r study, symptoms of hypoglycaemia or counter-regulatory hormone responses were\r similar after intravenous insulin glargine and human insulin both in healthy\r volunteers and patients with type 1 diabetes.<\/span><\/p>","ID":"5d1d12f5-77af-4907-bcb3-081efafe1408","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In a clinical\r study, symptoms of hypoglycaemia or counter-regulatory hormone responses were\r similar after intravenous insulin glargine and human insulin both in healthy\r volunteers and patients with type 1 diabetes.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","ID":"55c50550-4870-4fc3-8de0-0fd8c723a2bd","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Clinical safety and efficacy<\/span><\/u><\/p>","ID":"64cf10eb-96a9-4dc7-ab13-5d195f70f0bd","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Clinical safety and efficacy","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"10602e13-b7bb-46d9-bc34-6b5a79681f2f","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In clinical\r studies, antibodies that cross-react with human insulin and insulin glargine\r were observed with the same frequency in both NPH-insulin and insulin glargine\r treatment groups.<\/span><\/p>","ID":"5b2d7f5c-42ba-43f0-bd51-5a472cceec55","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In clinical\r studies, antibodies that cross-react with human insulin and insulin glargine\r were observed with the same frequency in both NPH-insulin and insulin glargine\r treatment groups.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"776770e2-7833-424a-a906-6c9d97527872","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Effects of\r insulin glargine (once daily) on diabetic retinopathy were evaluated in an\r open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2\r diabetic patients in which progression of retinopathy by 3 or more steps on the\r Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by\r fundus photography. No significant difference was seen in the progression of\r diabetic retinopathy when insulin glargine was compared to NPH insulin.<\/span><\/p>","ID":"c27d3150-7bec-4c01-a79b-bf47e8d58380","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Effects of\r insulin glargine (once daily) on diabetic retinopathy were evaluated in an\r open-label 5 year NPH-controlled study (NPH given bid) in 1024 type 2\r diabetic patients in which progression of retinopathy by 3 or more steps on the\r Early Treatment Diabetic Retinopathy Study (ETDRS) scale was investigated by\r fundus photography. No significant difference was seen in the progression of\r diabetic retinopathy when insulin glargine was compared to NPH insulin.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"5ca7a588-34d6-4aaf-bdc3-2b3030b25f1e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The ORIGIN\r (Outcome Reduction with Initial Glargine INtervention) study was a multicenter,\r randomised, 2x2 factorial design study conducted in 12,537 participants at high\r cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired\r glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus\r treated with \u22641 antidiabetic oral agent (88% of participants).\r Participants were randomised (1:1) to receive insulin glargine (n=6,264),\r titrated to reach FPG \u226495 mg\/dL (5.3 mM), or standard care (n=6,273).<\/span><\/p>","ID":"a1c2ba00-9b75-4f7a-aecf-81b7fc7713bb","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The ORIGIN\r (Outcome Reduction with Initial Glargine INtervention) study was a multicenter,\r randomised, 2x2 factorial design study conducted in 12,537 participants at high\r cardiovascular (CV) risk with impaired fasting glucose (IFG) or impaired\r glucose tolerance (IGT) (12% of participants) or type 2 diabetes mellitus\r treated with \u22641 antidiabetic oral agent (88% of participants).\r Participants were randomised (1:1) to receive insulin glargine (n=6,264),\r titrated to reach FPG \u226495 mg\/dL (5.3 mM), or standard care (n=6,273).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"ccc66360-2a80-467a-862c-e6e3ac92acc9","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">The first\r co-primary efficacy outcome was the time to the first occurrence of CV death,\r nonfatal myocardial infarction (MI), or nonfatal stroke, and the second\r co-primary efficacy outcome was the time to the first occurrence of any of the\r first co-primary events, or revascularisation procedure (coronary, carotid, or\r peripheral), or hospitalisation for heart failure.<\/span><\/p>","ID":"9c745edd-160e-4626-997f-136479e63b06","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The first\r co-primary efficacy outcome was the time to the first occurrence of CV death,\r nonfatal myocardial infarction (MI), or nonfatal stroke, and the second\r co-primary efficacy outcome was the time to the first occurrence of any of the\r first co-primary events, or revascularisation procedure (coronary, carotid, or\r peripheral), or hospitalisation for heart failure.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"9816d158-69c7-4e7f-a2cf-37921a439e08","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Secondary\r endpoints included all-cause mortality and a composite microvascular outcome.<\/span><\/p>","ID":"b95fb354-df46-418e-9327-26cace1b1ae2","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Secondary\r endpoints included all-cause mortality and a composite microvascular outcome.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"f4c37a83-fe6b-4206-b476-00cde481c0a1","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Insulin glargine\r did not alter the relative risk for CV disease and CV mortality when compared\r to standard of care. There were no differences between insulin glargine and\r standard care for the two co-primary outcomes; for any component endpoint\r comprising these outcomes; for all-cause mortality; or for the composite\r microvascular outcome.<\/span><\/p>","ID":"cccfd0c6-1320-4539-8f5b-e557090cf747","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin glargine\r did not alter the relative risk for CV disease and CV mortality when compared\r to standard of care. There were no differences between insulin glargine and\r standard care for the two co-primary outcomes; for any component endpoint\r comprising these outcomes; for all-cause mortality; or for the composite\r microvascular outcome.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"a7d2c80b-4236-49fa-aba8-733655516324","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Mean dose of\r insulin glargine by study end was 0.42 U\/kg. At baseline, participants had a\r median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9\r to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care\r group throughout the duration of follow-up. The rates of severe hypoglycaemia\r (affected participants per 100 participant years of exposure) were 1.05 for\r insulin glargine and 0.30 for standard care group and the rates of confirmed\r non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard\r care group. Over the course of this 6-year study, 42% of the insulin glargine\r group did not experience any hypoglycaemia. <\/span><\/p>","ID":"989e740d-0fb4-42e7-b52e-8dc6f9675208","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Mean dose of\r insulin glargine by study end was 0.42 U\/kg. At baseline, participants had a\r median HbA1c value of 6.4% and median on-treatment HbA1c values ranged from 5.9\r to 6.4% in the insulin glargine group, and 6.2% to 6.6% in the standard care\r group throughout the duration of follow-up. The rates of severe hypoglycaemia\r (affected participants per 100 participant years of exposure) were 1.05 for\r insulin glargine and 0.30 for standard care group and the rates of confirmed\r non-severe hypoglycaemia were 7.71 for insulin glargine and 2.44 for standard\r care group. Over the course of this 6-year study, 42% of the insulin glargine\r group did not experience any hypoglycaemia. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"ca194128-925f-4a7d-a340-df32bf515a8c","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">At the last\r on-treatment visit, there was a mean increase in body weight from baseline of\r 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the\r standard care group.<\/span><\/p>","ID":"30f3e491-f179-4d93-8dc0-97dc446a548a","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"At the last\r on-treatment visit, there was a mean increase in body weight from baseline of\r 1.4 kg in the insulin glargine group and a mean decrease of 0.8 kg in the\r standard care group.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","ID":"e50972d8-1ca3-4b1c-a46f-8efa81318465","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"8f5fe50a-21bf-4408-96a5-c4938e7fefd1","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Paediatric\r population","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"a3ffe035-4e36-4981-92f9-5b3aac8f30ab","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">In a randomised,\r controlled clinical study, paediatric patients (age range 6 to 15 years)\r with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus\r insulin regimen where regular human insulin was used before each meal. Insulin\r glargine was administered once daily at bedtime and NPH human insulin was\r administered once or twice daily. Similar effects on glycohaemoglobin and the\r incidence of symptomatic hypoglycaemia were observed in both treatment groups,\r however fasting plasma glucose decreased more from baseline in the insulin\r glargine group than in the NPH group. There was less severe hypoglycaemia in\r the insulin glargine group as well. One hundred forty three of the patients\r treated with insulin glargine in this study continued treatment with insulin\r glargine in an uncontrolled extension study with mean duration of follow-up of\r 2 years. No new safety signals were seen during this extended treatment\r with insulin glargine.<\/span><\/p>","ID":"c7cc7c06-b946-42c8-a278-3352a1722af8","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In a randomised,\r controlled clinical study, paediatric patients (age range 6 to 15 years)\r with type 1 diabetes (n=349) were treated for 28 weeks with a basal-bolus\r insulin regimen where regular human insulin was used before each meal. Insulin\r glargine was administered once daily at bedtime and NPH human insulin was\r administered once or twice daily. Similar effects on glycohaemoglobin and the\r incidence of symptomatic hypoglycaemia were observed in both treatment groups,\r however fasting plasma glucose decreased more from baseline in the insulin\r glargine group than in the NPH group. There was less severe hypoglycaemia in\r the insulin glargine group as well. One hundred forty three of the patients\r treated with insulin glargine in this study continued treatment with insulin\r glargine in an uncontrolled extension study with mean duration of follow-up of\r 2 years. No new safety signals were seen during this extended treatment\r with insulin glargine.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"d6148777-afaf-4153-87b4-de5fdcb4acc2","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A crossover\r study comparing insulin glargine plus lispro insulin to NPH plus regular human\r insulin (each treatment administered for 16 weeks in random order) in 26\r adolescent type 1 diabetic patients aged 12 to 18 years was also\r performed. As in the paediatric study described above, fasting plasma glucose\r reduction from baseline was greater in the insulin glargine group than in the\r NPH group. HbA<sub>1c<\/sub> changes from baseline were similar between\r treatment groups; however blood glucose values recorded overnight were\r significantly higher in the insulin glargine\/ lispro group than the NPH\/regular\r group, with a mean nadir of 5.4 mM vs. 4.1 mM. Correspondingly, the\r incidences of nocturnal hypoglycaemia were 32 % in the insulin glargine \/\r lispro group vs. 52 % in the NPH \/ regular group.<\/span><\/p>","ID":"a0b050f1-2b85-4fbb-ba38-e7469b8ccf2b","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"A crossover\r study comparing insulin glargine plus lispro insulin to NPH plus regular human\r insulin (each treatment administered for 16 weeks in random order) in 26\r adolescent type 1 diabetic patients aged 12 to 18 years was also\r performed. As in the paediatric study described above, fasting plasma glucose\r reduction from baseline was greater in the insulin glargine group than in the\r NPH group. HbA1c changes from baseline were similar between\r treatment groups; however blood glucose values recorded overnight were\r significantly higher in the insulin glargine\/ lispro group than the NPH\/regular\r group, with a mean nadir of 5.4 mM vs. 4.1 mM. Correspondingly, the\r incidences of nocturnal hypoglycaemia were 32 % in the insulin glargine \/\r lispro group vs. 52 % in the NPH \/ regular group.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"9e40d8a9-4988-4f0a-9a03-62a4e683e144","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">A 24-week\r parallel group study was conducted in 125 children with type 1 diabetes\r mellitus aged 2 to 6 years, comparing insulin glargine given once daily in\r the morning to NPH insulin given once or twice daily as basal insulin. Both\r groups received bolus insulin before meals. The primary aim of demonstrating\r non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and\r there was a trend to an increase of hypoglycaemic events with insulin glargine\r [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)].\r Glycohaemoglobin and glucose variabilities were comparable in both treatment\r groups. No new safety signals were observed in this trial.<\/span><\/p>","ID":"968e5e95-9c3e-44d2-8f6e-ea00278f3cc1","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"A 24-week\r parallel group study was conducted in 125 children with type 1 diabetes\r mellitus aged 2 to 6 years, comparing insulin glargine given once daily in\r the morning to NPH insulin given once or twice daily as basal insulin. Both\r groups received bolus insulin before meals. The primary aim of demonstrating\r non-inferiority of insulin glargine to NPH in all hypoglycaemia was not met and\r there was a trend to an increase of hypoglycaemic events with insulin glargine\r [insulin glargine: NPH rate ratio (95% CI) = 1.18 (0.97-1.44)].\r Glycohaemoglobin and glucose variabilities were comparable in both treatment\r groups. No new safety signals were observed in this trial.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","ID":"950ce2f2-bd0e-4675-847f-279b2e6f46d6","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/b><\/p>","ID":"46749172-180a-47d0-82ae-56ee02f47b6a","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"5.2     Pharmacokinetic properties","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><\/p>","ID":"4dfd8434-db7f-403a-8723-4e00512e8137","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p>","ID":"8912638d-0217-41c0-893f-4c5abfc9af87","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Absorption","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"287406f2-9fde-40ec-844e-258cfb1266d1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">In healthy subjects and diabetic patients, insulin serum\r concentrations indicated a slower and much more prolonged absorption and showed\r a lack of a peak after subcutaneous injection of insulin glargine in comparison\r to human NPH insulin. Concentrations were thus consistent with the time profile\r of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the\r activity profiles over time of insulin glargine and NPH insulin. <\/span><\/p>","ID":"52c0ee01-0bf2-4d2e-b768-0301b7238d15","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In healthy subjects and diabetic patients, insulin serum\r concentrations indicated a slower and much more prolonged absorption and showed\r a lack of a peak after subcutaneous injection of insulin glargine in comparison\r to human NPH insulin. Concentrations were thus consistent with the time profile\r of the pharmacodynamic activity of insulin glargine. Figure 1 above shows the\r activity profiles over time of insulin glargine and NPH insulin. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"4fb48278-3a0a-4c12-bf88-d393ea43a6bb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin glargine injected once daily will reach steady state levels\r in 2-4 days after the first dose. <\/span><\/p>","ID":"cb833092-66a3-4319-851c-7d49ead2e51a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin glargine injected once daily will reach steady state levels\r in 2-4 days after the first dose. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"> <\/p>","ID":"3d7cf371-1305-434b-86ad-9069ad60a38d","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":" ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p>","ID":"abbeaf4f-d986-42a7-964f-177aab16d754","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Biotransformation","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"21bdba2f-9d1c-4d9d-99ec-86253d006988","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">After subcutaneous injection in diabetic patients, insulin glargine\r is rapidly metabolised at the carboxyl terminus of the Beta chain with\r formation of two active metabolites M1 (21A-Gly-insulin) and M2\r (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is\r the metabolite M1. The exposure to M1 increases with the administered dose of\r insulin glargine.<\/span><\/p>","ID":"bd3035a0-7033-4445-84d5-7b1669c7addf","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"After subcutaneous injection in diabetic patients, insulin glargine\r is rapidly metabolised at the carboxyl terminus of the Beta chain with\r formation of two active metabolites M1 (21A-Gly-insulin) and M2\r (21A-Gly-des-30B-Thr-insulin). In plasma, the principal circulating compound is\r the metabolite M1. The exposure to M1 increases with the administered dose of\r insulin glargine.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","ID":"b1d6d7ea-2acc-408e-b8ce-f73148d4485e","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pharmacokinetic and pharmacodynamic findings indicate that the effect\r of the subcutaneous injection with insulin glargine is principally based on\r exposure to M1. Insulin glargine and the metabolite M2 were not detectable in\r the vast majority of subjects and, when they were detectable their\r concentration was independent of the administered dose of insulin glargine.<\/span><\/p>","ID":"b12c48c8-6826-48f4-8327-5edc45a5ee22","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The pharmacokinetic and pharmacodynamic findings indicate that the effect\r of the subcutaneous injection with insulin glargine is principally based on\r exposure to M1. Insulin glargine and the metabolite M2 were not detectable in\r the vast majority of subjects and, when they were detectable their\r concentration was independent of the administered dose of insulin glargine.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"32796986-b0ec-42aa-b4a6-26b4a7f0de19","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","ID":"efef4119-b496-4121-9ea8-d706a5aaacc1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Elimination","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"617914bc-2576-48ab-9983-23b420a47cd4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">When given intravenously the elimination half-life of insulin\r glargine and human insulin were comparable. <\/span><\/p>","ID":"7b4d1d0f-80ba-489f-8a2b-f444f1d690b7","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"When given intravenously the elimination half-life of insulin\r glargine and human insulin were comparable. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"> <\/p>","ID":"a0744248-7f88-4983-b2bf-8da211469532","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":" ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><u><span lang=\"EN-GB\" style=\"font-size:11.0pt\">Special\r populations<\/span><\/u><\/p>","ID":"d36f25cb-79f5-4f3e-a4b0-94a42b40155c","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Special\r populations","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><\/p>","ID":"271a897f-ba6f-4011-b27a-4d4e613db06a","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">In clinical\r studies, subgroup analyses based on age and gender did not indicate any\r difference in safety and efficacy in insulin glargine-treated patients compared\r to the entire study population.<\/span><\/p>","ID":"a6e47884-c607-4f2c-967f-32e40e1d8d14","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In clinical\r studies, subgroup analyses based on age and gender did not indicate any\r difference in safety and efficacy in insulin glargine-treated patients compared\r to the entire study population.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"a19c97e1-08c1-40c3-b119-864ff54b9afd","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/i><\/p>","ID":"167e1d78-39e5-4e9c-9d18-da6fe99c6d2e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Paediatric population","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"719a6e29-f6fc-4733-9f75-5ef68ae94459","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Pharmacokinetics in children aged 2 to less than 6 years with\r type 1 diabetes mellitus was assessed in one clinical study (see section\r 5.1). Plasma trough levels of insulin glargine and its main M1 and M2\r metabolites were measured in children treated with insulin glargine, revealing\r plasma concentration patterns similar to adults, and providing no evidence for\r accumulation of insulin glargine or its metabolites with chronic dosing.<\/span><\/p>","ID":"7ea35859-b5f2-439d-b0aa-642e782c4974","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Pharmacokinetics in children aged 2 to less than 6 years with\r type 1 diabetes mellitus was assessed in one clinical study (see section\r 5.1). Plasma trough levels of insulin glargine and its main M1 and M2\r metabolites were measured in children treated with insulin glargine, revealing\r plasma concentration patterns similar to adults, and providing no evidence for\r accumulation of insulin glargine or its metabolites with chronic dosing.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-right:-.1pt;line-height:normal\"><\/p>","ID":"50ae7989-f931-4e05-a6db-33d6dba2cafd","Styles":"margin-right:-.1pt;line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">5.3     Preclinical safety data<\/span><\/b><\/p>","ID":"48a7a759-8c49-4040-a29c-f4fe76ff0a24","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"5.3     Preclinical safety data","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"f08facad-7cd6-4dfc-9a87-1341ea619c96","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Non-clinical data reveal no special hazard for humans based on\r conventional studies of safety pharmacology, repeated dose toxicity,\r genotoxicity, carcinogenic potential, toxicity to reproduction.<\/span><\/p>","ID":"9c4dc0a8-c557-40b7-b214-55b07a3896ba","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Non-clinical data reveal no special hazard for humans based on\r conventional studies of safety pharmacology, repeated dose toxicity,\r genotoxicity, carcinogenic potential, toxicity to reproduction.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"09958b6f-6326-4139-8a66-7494151956ce","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"c8657b49-700d-4814-820e-80c836ef2817","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal\"><b><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/b><\/p>","ID":"20872425-5a48-43d6-8134-fbb3831250cf","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"d7286c37-3625-452f-8188-fd9a5fdefbbb","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/b><\/p>","ID":"7cbdb8db-29be-43ba-8519-a5a5793a4df5","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.1     List of excipients","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"aae06825-a243-4097-8c40-2b2211402310","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Zinc oxide<\/span><\/p>","ID":"8dd4c942-b701-4898-9dc9-f6658a3ec7dc","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Zinc oxide","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Metacresol<\/span><\/p>","ID":"01afdf47-a0e3-4800-876d-b8333dd5fb28","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Metacresol","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Glycerol<\/span><\/p>","ID":"df9b6f4a-ce75-4b9b-82e9-fedafe97ad23","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Glycerol","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Hydrochloric acid (for pH adjustment)<\/span><\/p>","ID":"d27c3384-3428-4d84-8420-91bb543156aa","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Hydrochloric acid (for pH adjustment)","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Sodium hydroxide (for pH adjustment)<\/span><\/p>","ID":"5e6b1536-b331-4836-8f4c-14f7ca088263","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Sodium hydroxide (for pH adjustment)","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Water for injections<\/span><\/p>","ID":"d76e4c11-ccac-4a23-af79-168adbdb0965","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Water for injections","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"e7fd4eeb-bd8d-4e3f-ac35-124c9f46f212","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/b><\/p>","ID":"8c1110ee-0955-44f6-a6de-770762afcdd4","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.2     Incompatibilities","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"01572e3f-4680-45ed-8564-3c379299ebd0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">This medicinal product must not be mixed with other medicinal\r products. <\/span><\/p>","ID":"75c88daf-b2dc-439c-aa72-cc817b4400fb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"This medicinal product must not be mixed with other medicinal\r products. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"d4ed77e9-b734-4b7c-bb11-3df7060bd128","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/b><\/p>","ID":"2fa1e0a5-86c6-424c-b542-a1517a8fef8e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.3     Shelf life","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"f1c1d7be-a31a-4741-b084-e91fc1f81a3e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p style=\"margin:0in\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">2 years.<\/span><\/p>","ID":"9db4fc12-cbbe-4f3a-a724-6fbe26fe0218","Styles":"margin:0in","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"2 years.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"df449523-51c9-46ff-abbd-dbb69828356a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Shelf life after first use <\/span><\/u><\/p>","ID":"f20ddbc1-dc0f-461f-9531-03825190eeec","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Shelf life after first use ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"bdf10d70-fe91-4378-bb2e-21538676a6cb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The medicinal product may be stored for a maximum of 28 days up\r to 30\u00b0C and away from direct heat or direct light. Pens in use must not be\r stored in the refrigerator. <\/span><\/p>","ID":"76605f1c-9999-4d54-b270-a233ea80c7a2","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The medicinal product may be stored for a maximum of 28 days up\r to 30\u00b0C and away from direct heat or direct light. Pens in use must not be\r stored in the refrigerator. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"c07b7fb9-b056-4096-ac38-7229fb58f257","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The pen cap must be put back on the pen after each injection in\r order to protect from light.<\/span><\/p>","ID":"ab87871f-70d6-4794-a286-de1b54d3d882","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The pen cap must be put back on the pen after each injection in\r order to protect from light.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"d1870248-af2d-4582-a92a-2a3c78c18da1","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/b><\/p>","ID":"50c1bb60-31aa-4508-a3c7-d6d859c47d86","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.4     Special precautions for storage","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"846580ed-1e63-41c7-b1fb-6c35f9cff16e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">Before use<\/span><\/u><\/p>","ID":"f85c2849-ef80-46a7-868a-fc65d9973e02","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Before use","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"97ed0554-7d7d-4136-afe9-745f7c0f7fef","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Store in a refrigerator (2\u00b0C - 8\u00b0C).<\/span><\/p>","ID":"41c3c9e6-c67a-49c2-bb91-23a4adb74b2d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Store in a refrigerator (2\u00b0C - 8\u00b0C).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"37b8135a-40b8-4066-90b8-0f5ab89dcf5c","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not freeze.<\/span><\/p>","ID":"97d47bac-60aa-4465-850b-08c322d3b4bb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Do not freeze.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"c5f4ec6c-9d27-40c9-a87a-76a266fd5f89","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Do not store ABASAGLAR next to the freezer compartment or a freezer\r pack.<\/span><\/p>","ID":"ba549880-4148-4a7e-9a83-d5a55de36369","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Do not store ABASAGLAR next to the freezer compartment or a freezer\r pack.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"a8dc8765-5fd0-4620-92df-dcf89f462f6d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Keep the pre-filled pen in the outer carton in order to protect from\r light.<\/span><\/p>","ID":"9a852209-854e-4841-a9dd-22b2825b240b","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Keep the pre-filled pen in the outer carton in order to protect from\r light.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"fc558423-fb72-4215-80cc-7fbbf2ef8b72","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><u><span lang=\"EN-GB\">In use <\/span><\/u><\/p>","ID":"ea2d2eee-dfe5-4d7e-9762-7b4700afe7b3","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"In use ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1082fa31-5eaa-4412-83b2-85901297d82e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">For storage conditions after first opening of this medicinal\r product, see section 6.3.<\/span><\/p>","ID":"7b7d087a-07e9-4ad2-a1bd-ee6163ead355","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"For storage conditions after first opening of this medicinal\r product, see section 6.3.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"0372ec8d-92a9-4d68-acb7-6c906ecd784e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><b><span lang=\"EN-GB\">6.5     Nature and contents of container<\/span><\/b><\/p>","ID":"78511a9c-1c76-43d4-943e-d41a425fed47","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.5     Nature and contents of container","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><b><s><span lang=\"EN-GB\"><\/span><\/s><\/b><\/p>","ID":"e11aa1e6-73cd-4317-b3c8-a578036d6254","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><u><span lang=\"EN-GB\">KwikPen<\/span><\/u><\/p>","ID":"8c2e99ab-0555-4c03-a2f0-b13b3d070fb3","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"KwikPen","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","ID":"2433cfd4-fbc9-44d0-9224-e3e728666de5","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">3 mL solution in a cartridge (type 1 colourless glass) with a\r plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and\r halobutyl rubber) with aluminium seal. <\/span><\/p>","ID":"a154586f-ef80-4829-a0e5-9b3c3db86136","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"3 mL solution in a cartridge (type 1 colourless glass) with a\r plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and\r halobutyl rubber) with aluminium seal. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"d4087a1d-4375-40b6-89bb-6d49599b5e9e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The cartridge is sealed in a disposable pen injector. <\/span><\/p>","ID":"f6a66b51-6ca5-414a-91a6-8841058932cf","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The cartridge is sealed in a disposable pen injector. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"e9197b79-72d3-4438-bfba-5e155ec00401","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><span lang=\"EN-GB\">Packs of 5 pre-filled\r pens and multipacks containing 10 (2 packs of 5) pre-filled pens. <\/span><\/p>","ID":"bc4f8f99-2cac-4700-b96c-6cf50cbe7f61","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Packs of 5 pre-filled\r pens and multipacks containing 10 (2 packs of 5) pre-filled pens. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><\/p>","ID":"6295b6e1-a1ac-4f76-a96a-f36ad5dd019c","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\">Tempo Pen<\/span><\/u><\/p>","ID":"27e2812b-815d-4655-9c5f-089b412533e3","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Tempo Pen","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"573cc8ef-3ac1-4783-92d6-5b2bad901020","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">3 mL solution in a cartridge (type 1 colourless glass) with a\r plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and\r halobutyl rubber) with aluminium seal. The cartridge is sealed in a disposable\r pen injector. The Tempo Pen contains a magnet (see section 4.4).<\/span><\/p>","ID":"ba3f0496-e349-4888-8748-59b941bb7b39","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"3 mL solution in a cartridge (type 1 colourless glass) with a\r plunger (halobutyl rubber) and a disc seal (laminate of polyisoprene and\r halobutyl rubber) with aluminium seal. The cartridge is sealed in a disposable\r pen injector. The Tempo Pen contains a magnet (see section 4.4).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"text-autospace:none\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"576338a9-3306-4d81-974d-31ffde90729b","Styles":"text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Packs of 5 <a name=\"_Hlk44087754\">pre-filled pens<\/a> and\r multipacks containing 10 (2 packs of 5) pre-filled pens<\/span><span lang=\"EN-GB\">.<\/span><\/p>","ID":"a1f1103c-7ffd-45b6-83ef-4b740d067e58","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Packs of 5 pre-filled pens and\r multipacks containing 10 (2 packs of 5) pre-filled pens.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"5cac2892-7edf-4c2a-8a1f-4409eb4bb91a","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"e5b15ab3-c15d-46fd-be2b-40c036286f00","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Not all pack sizes may be marketed.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"4c7ab444-b59f-46e1-a179-880b45e363bd","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">Needles are not\r included in the pack.<\/span><\/p>","ID":"b4353dc5-ffe7-4c32-a68f-f9dc9008853e","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Needles are not\r included in the pack.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"d3d5beb5-dbb2-46c9-a6e9-1df2e69ba2ce","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">6.6     Special precautions for disposal and other handling<\/span><\/b><\/p>","ID":"764bc8d1-b28d-42e6-9863-9210c8428825","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"6.6     Special precautions for disposal and other handling","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"4c7f287d-ef94-4a99-afee-9b77d257ae5e","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR must not be mixed with any other insulin or medicinal\r products or diluted. Mixing or diluting can change its time\/action profile and\r mixing can cause precipitation.<\/span><\/p>","ID":"9c758e48-d033-44e1-83fb-d2d5c8a699b9","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR must not be mixed with any other insulin or medicinal\r products or diluted. Mixing or diluting can change its time\/action profile and\r mixing can cause precipitation.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"1ff8d990-d383-4d10-9f84-a19db18055d0","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Inspect the cartridge before use. It must only be used if the\r solution is clear, colourless, with no solid particles visible, and if it is of\r water-like consistency. Since ABASAGLAR is a solution, it does not require\r re-suspension before use. <\/span><\/p>","ID":"0da16825-728a-4302-ac32-33f8e875320d","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Inspect the cartridge before use. It must only be used if the\r solution is clear, colourless, with no solid particles visible, and if it is of\r water-like consistency. Since ABASAGLAR is a solution, it does not require\r re-suspension before use. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"11840dd7-ba12-479d-843a-652868e55cdb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">ABASAGLAR must not be mixed with any other insulin or diluted.\r Mixing or diluting can change its time\/action profile and mixing can cause\r precipitation.<\/span><\/p>","ID":"c10eab22-e68b-4889-beb3-d2369ba4a6c3","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"ABASAGLAR must not be mixed with any other insulin or diluted.\r Mixing or diluting can change its time\/action profile and mixing can cause\r precipitation.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"78a6d07d-dddc-4045-aa03-b5b6118281ae","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Empty pens must never be reused and must be properly discarded. <\/span><\/p>","ID":"a9f3ce26-4c60-4ff4-8650-4788d71e5504","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Empty pens must never be reused and must be properly discarded. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"63259442-20d7-4a97-9daa-6e502e9d742f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">To prevent the possible transmission of disease, each pen must be\r used by one patient only. <\/span><\/p>","ID":"6de0b50b-edf6-415b-ae88-4aaf0953e3fb","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"To prevent the possible transmission of disease, each pen must be\r used by one patient only. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"f518b178-1f79-4a45-9191-2eb411e755df","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Insulin label must always be checked before each injection to avoid\r medication errors between insulin glargine and other insulins (see section\r 4.4).<\/span><\/p>","ID":"7620720e-ec95-46b1-b96d-b8c2040c48bd","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Insulin label must always be checked before each injection to avoid\r medication errors between insulin glargine and other insulins (see section\r 4.4).","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"039b7c46-e649-4f4f-a7a3-98f539cffa49","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">The patient should be advised to read the instructions for use\r included in the package leaflet carefully before using ABASAGLAR solution for\r injection in pre\u2011filled pen.<\/span><\/p>","ID":"f1c33016-8ddb-459a-89f4-c184694e4cbf","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The patient should be advised to read the instructions for use\r included in the package leaflet carefully before using ABASAGLAR solution for\r injection in pre\u2011filled pen.","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"55951f9f-131f-43c0-969f-895dc9d69541","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><a name=\"_Hlk20390276\"><u><span lang=\"EN-GB\">Tempo Pen<\/span><\/u><\/a><\/p>","ID":"546bdf34-b84a-4e94-87f9-6f728183b517","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Tempo Pen","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"72b4ed97-a9ea-455b-a8aa-dbaf769148b4","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"mdTblEntry\" style=\"line-height:normal\"><a name=\"_Hlk38978858\"><\/a><a name=\"_Hlk45820494\"><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The Tempo Pen is\r designed to work with the Tempo Smart Button. <\/span><\/a><span lang=\"EN-GB\" style=\"font-size:11.0pt\">The Tempo Smart Button is an optional product that can\r be attached to the Tempo Pen dose knob and aids in transmitting Abasaglar dose\r information from the Tempo Pen to a compatible mobile application. The Tempo\r Pen injects insulin with or without the Tempo Smart Button attached. To\r transmit data to the mobile application, follow the instructions provided with\r the Tempo Smart Button and the instructions with the mobile application. <\/span><\/p>","ID":"a53b3f15-6a01-4f0c-b61a-3ade62d54666","Styles":"line-height:normal","Classes":"['mdTblEntry']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"The Tempo Pen is\r designed to work with the Tempo Smart Button. The Tempo Smart Button is an optional product that can\r be attached to the Tempo Pen dose knob and aids in transmitting Abasaglar dose\r information from the Tempo Pen to a compatible mobile application. The Tempo\r Pen injects insulin with or without the Tempo Smart Button attached. To\r transmit data to the mobile application, follow the instructions provided with\r the Tempo Smart Button and the instructions with the mobile application. ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"9603c168-8d3f-4b02-81df-e040b74c0535","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"c5d50e29-b36c-4eb3-9372-145e7ab88535","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r normal;page-break-after:avoid;text-autospace:none\"><b><span lang=\"EN-GB\">7.       MARKETING\r AUTHORISATION HOLDER<\/span><\/b><\/p>","ID":"101d4b04-6588-4ffb-947e-1fcea928b95f","Styles":"margin-left:28.35pt;text-indent:-28.35pt;line-height:\r\nnormal;page-break-after:avoid;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"7.       MARKETING\r AUTHORISATION HOLDER","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;page-break-after:avoid;text-autospace:\r none\"><\/p>","ID":"37b222ba-34f5-47f7-b175-c19dd219cd22","Styles":"line-height:normal;page-break-after:avoid;text-autospace:\r\nnone","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The\r Netherlands<\/span><\/p>","ID":"72b991c4-7948-45e4-b732-1022ef19539f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The\r Netherlands","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"218e18e3-2480-44c0-baac-7dd6cfcfcf63","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"dae28b09-48fd-4705-9bd4-2a006dc8d2e2","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">8.       MARKETING AUTHORISATION NUMBER(S)<\/span><\/b><\/p>","ID":"b5e32948-def1-46e5-ba33-cec68d4a9bbc","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"8.       MARKETING AUTHORISATION NUMBER(S)","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"30cd07f3-dadb-4918-af9a-c84a4c42fba3","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"EN-GB\">EU\/1\/14\/944\/007<\/span><\/p>","ID":"2a12b670-65ac-4f97-a783-ed2ebf923c8d","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/14\/944\/007","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ES-TRAD\">EU\/1\/14\/944\/008<\/span><\/p>","ID":"1429094a-07c6-499c-8e5b-415576e78992","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/14\/944\/008","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ES-TRAD\">EU\/1\/14\/944\/012<\/span><\/p>","ID":"19481445-ac07-439a-8cd8-d85b8ef6b368","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/14\/944\/012","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><span lang=\"ES-TRAD\">EU\/1\/14\/944\/013<\/span><\/p>","ID":"b2809ec7-f4da-445f-bf30-127a1b593a89","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/14\/944\/013","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><span lang=\"ES-TRAD\" style=\"color:black\">EU\/1\/14\/944\/014<\/span><\/p>","ID":"da0ddd0a-f75f-4f3b-bad2-72a83aa006fd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/14\/944\/014","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\"><span lang=\"ES\" style=\"color:black\">EU\/1\/14\/944\/015<\/span><\/p>","ID":"607d1f99-3d4d-4660-bd4f-bf2edbf1a282","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"EU\/1\/14\/944\/015","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"485e85c6-004d-418d-8d59-aaa02f862af7","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"0e585855-ceb1-4059-bd3b-e2a26414515f","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION<\/span><\/b><\/p>","ID":"0a43af15-404d-4ef2-b971-0a9b7c6b07a6","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"9.       DATE OF FIRST AUTHORISATION\/RENEWAL OF THE AUTHORISATION","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"96be6768-d05c-4d12-8df4-4a3208c3bdef","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Date of first authorisation: 9 September 2014<\/span><\/p>","ID":"a2e5e3ee-4536-4390-b042-3b9c46ce5b00","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Date of first authorisation: 9 September 2014","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Date of latest renewal: 25 July 2019<\/span><\/p>","ID":"2bb9d8f4-4fb6-4e75-84e5-d2980dd6760f","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Date of latest renewal: 25 July 2019","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"ed25527e-44ab-47f7-9366-9ffe0e26f991","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal\"><\/p>","ID":"fb67216a-327d-4025-9d5f-b04bbd1bc7d1","Styles":"line-height:normal","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><b><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/b><\/p>","ID":"633ab2aa-5752-4b0b-bd99-d1eeff578123","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><\/p>","ID":"b7d7429f-d5fd-4b74-80f5-f39fecc99d18","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<p class=\"MsoNormal\" style=\"line-height:normal;text-autospace:none\"><span lang=\"EN-GB\">Detailed information on this medicinal product is available on the\r website of the European Medicines Agency <\/span><span lang=\"EN-GB\"><a href=\"http:\/\/www.ema.europa.eu\"><span style=\"color:windowtext\">http:\/\/www.ema.europa.eu<\/span><\/a><\/span><\/p>","ID":"b09c242e-1fa4-4944-a96a-d1ecd9081e85","Styles":"line-height:normal;text-autospace:none","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":"Detailed information on this medicinal product is available on the\r website of the European Medicines Agency http:\/\/www.ema.europa.eu","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"8c3b103f-03fb-4bf9-afc3-a949edfd1b80","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"Text":" ","ParentId":"c3fea244-c576-484b-8378-4d1a65545a06"}]